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Abstract 
 
 
Nanoparticles (NPs) are progressively being investigated for use in biomedical 
applications, including biological agents delivery like gene delivery, drug and protein 
delivery. Activation of complement pathways and interactions with immune recognition 
subcomponents can modulate the clearance of the NPs and subsequent inflammatory 
response. Such modulation could affect the intended translational applications either in 
the development as tissue-specific drug delivery platform or in the treatment of 
pulmonary diseases such as tuberculosis and lung cancer thus, poses challenges to 
develop them for in vivo applications. Here, we set out to study the interaction between 
innate immune components such as properdin, a small fragment of properdin, TSR4+5, 
a key lung pattern recognition molecule, surfactant protein D (SP-D), and carbon 
nanotubes (CNTs), and potential downstream effects on the immune response via 
macrophages. We report, that human properdin, an up-regulator of the complement 
alternative pathway and stabilizer of C3 convertase can opsonize CNTs via its 
thrombospondin type I repeat (TSR) 4 and 5. Uptake of properdin bound CNTs was 
enhanced by a macrophage cell line, THP-1, surging a robust pro-inflammatory immune 
response. In addition, recombinant TSR4+5 on CNTs, inhibited complement 
consumption, suggesting that TSR4+5, can be potentially used as a complement 
inhibitor in a number of pathological circumstances arising due to unintentional 
complement activation. Similarly, a recombinant fragment of human SP-D (rfhSP-D) 
bound to CNTs via its C-type lectin domain and augmented phagocytosis by THP-1 
monocytic cell lines, together with an increased pro-inflammatory response. 
Furthermore, rfhSP-D opsozined CNTs continued to activate complement pathway via 
the classical pathway. Complement deposition on the rfhSP-D opsonised CNTs led to 
dampening of the pro-inflammatory immune response. Furthermore, like CNTs, Iron 
oxide nanoparticles are also recognized by complement pathway, but mainly by 
alternative complement pathway. Complement deposition enhanced their uptake by 
activated THP-1 macrophages and dampened the pro-inflammatory responses. These 
studies emphasise the significance of understanding the interaction between innate 
immune humoral factors including complement in developing nanoparticle-based drug 
delivery strategies. 
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Review of literature: Complement activation by 
nanoparticles and implications 
Chapter I 
 2 
1.1 Nanomedicine 
Delivering biological or therapeutic agents to the desired site with precision is a major 
problem in the treatment of many diseases. Problems such as limited effectiveness and 
lack of specificity with rapid clearance and undesired side effects have rendered the 
conventional use of drugs ineffective. Thus, strategies should be implemented to device 
a controlled drug delivery system to overcome these limitations.  Such delivery systems 
not only provide protection against rapid drug degradation or clearance from the system 
but also lower the doses of drug required by enhancing drug concentration in targeted 
organ or tissues. Targeting cells or specific tissues by means of designed carriers for 
drugs or any other bioactive compounds is more a fundamental and successful approach 
that forms the basis of nanotechnology. This concept dates back to 1900s when Paul 
Ehrlich postulated the term “Magic Bullet” in which the drug is precisely targeted to the 
site of interest at the right time (Ehrlich and Sachs, 1902). Nanoparticles have a great 
potential to be used as drug carriers; in fact, nanotechnology is not far away from the 
model termed by Paul Ehrlich. It is aimed at enhancing release, reducing toxicity, 
enhancing solubility and bioavailability of drugs. In 2005, European science foundation 
(ESF) has embrace disciplines such as analytical tools, nano-imaging, nanomaterials 
and nano-devices, novel drug delivery system, clinical regulatory and toxicological 
issues to improve human health.  
The use of nanotechnology in various sectors of therapeutics has revolutionized the 
field of medicine by designing biomedical tools for therapeutics and diagnosis. 
Designed nanostructures have possibilities to offer better pharmacokinetic properties, 
controlled and sustained release targeting a specific part of the body. Such targeted 
delivery system can decrease drug resistance by reducing dose needed (Lee et al., 2006; 
Dutta and Jain, 2007), decrease toxicity by increasing the stability of drug and 
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formulation(Brewer, Coleman and Lowman, 2011), enhance solubility and 
bioavailability (Farokhzad and Langer, 2006). Such advantages have led to the 
revolutionisation of the drug development process and have changed the landscape of 
the pharmaceutical industry.  
1.2 Nanoparticles 
Nanoparticles (NPs) are ultrafine-engineered materials having the dimension in the 
order of 100
th
 of nm or less. They are engineered in different sizes, shapes, composition 
based on requirement or functionality (Figure 1.1-1). NPs used in biomedicine can be 
divided into different categories: hard and solid particles; soft particles and others 
(Bhatia, 2016). Hard and solid particles include metal and ceramic NPs such as gold 
particles, iron oxides, and carbon nanotubes. They have a defined core size though 
overall size and shape may vary based on functionalization. The second categories, soft 
particles, typically include polymers like micelles, vesicles, liposomes, core-shell 
structure, polymer-drug conjugates, and gels. Their shape and size heavily vary based 
on environmental factors like pH, ionic strength, and temperature. In a third category, 
others, antibody-drug conjugates, albumin particles and composite NPs have been 
considered as (Bhatia, 2016).  
Chapter I 
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Figure 1.1-1 Examples of commonly used NPs in biomedical applications. 
Organic NPs includes Dendrimers, polymers, liposomes, ferritin, micelles etc. Inorganic 
NPs included metallic NPs like iron oxides, gold, quantum, silica etc. and carbon-
basedNPs like carbon nanotubes, fullerenes etc. 
 
Furthermore, based on the chemical composition of nanoparticle core, NPs can be 
divided into organic and inorganic NPs (Xing et al., 2014). Organic NPs consist of 
Dendrimers  (Abbasi et al., 2014), micelles  (La et al., 1996), liposomes  (Akbarzadeh 
et al., 2013), ferritin (Drysdale, 1976), hybrid and compact polymeric NPs (Lipid 
polymers, lipid-PEG shells)  (Wang et al., 2017b) etc. whereas gold NPs (Liang, Wang 
and Liu, 2009), quantum dots (Juzenas et al., 2008), silica (Liberman et al., 2014), iron 
oxides NPs (Woo et al., 2004), carbon based NPs (fullerenes, carbon NPs, graphene)  
(Cha et al., 2013) etc. are considered as inorganic NPs. 
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1.2.1 Characteristics of NPs 
NPs surface to volume ratio increases with decreasing their size and for the small 
particle size; their properties are no longer dominated by the bulk of the materials. Thus, 
NPs properties behave differently than their larger counterparts in terms of their size, 
diameter and charge, which influence the in vivo behaviour of NPs and their physical 
stability in the biological environment. Features like in vivo performance, drug release 
profile and stability are affected by the surface charge of the NPs. 
Various other properties are considered in the design of NPs for biomedical use. 
Properties like Carrier-drug interaction, charge determination, chemical analysis of 
surface, drug stability, NPs dispersion stability, particle size and distribution, release 
profile, surface hydrophobicity is highly considered (Rodzinski et al., 2016). These 
factors also influence rapid clearance from the system during systemic delivery (Alexis 
et al., 2008) 
1.2.2 Magnetic NPs 
Magnetic NPs or iron oxide NPs (IONP) are developed with a view to targeting specific 
sites of the body using an external magnetic field (Child et al., 2011). Metallic magnetic 
particles are composed of magnetic elements such as cobalt, nickel, iron. Magnetite, 
maghemite, cobalt ferrite and chromium dioxide, oxide form of metals, are used in 
biomedicine (Bao et al., 2016). Magnetic NPs on their own are poorly biocompatible, 
non-biodegradable and chemically unstable in a physiological environment. They need 
to be functionalized to attain colloidal stability, longer circulation life and lower toxicity 
(Fratila et al., 2014). Due to the large surface area to volume ratio, NPs tend to 
aggregate. Functionalization prevents from undesirable aggregation by reducing surface 
energyand provides uniformity in the solution. Functionalization can be achieved by 
ligand addition or ligand exchange. Ligand addition involves adsorption of polymers 
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such as dextran(Easo and Mohanan, 2013), chitosan (Kostevsek et al., 2016), 
polyethylene glycol (PEG) (Lak et al., 2013), polyvinylpyrrolidone (PVP) (Merrifield et 
al., 2013) etc to the surface by electrostatic or hydrogen bonding. In ligand exchange, 
the native surface is replaced with functional groups such as amines, carboxylic acids, 
thiols etc.  Such functional groups assist in covalently linking of proteins, enzymes, 
receptors, oligonucleotides, and peptides for specific cell target  (Lin et al., 2008). 
However, the choice of the coating is reliant on the intended biomedical application. 
Figure 1-1-2 shows the sketch and transmission electron microscopy (TEM) figure of 
starched functionalized magnetite (Iron oxide NPs) used in this study.  
 
Figure 1-1-2 Structure of starch functionalized magnetic nanoparticle used in this 
study. 
A) TEM image of magnetic NPs. An aqueous suspension of IONPs was adsorbed on 
carbon grid and micrographs were recorded using a JEOL 2100 FEG-TEM operating at 
80Kv, and the images were processed using Gatan microscopy suite software (Gatan, 
Inc). B) Sketch of starch functionalized iron oxide nanoparticle. Iron oxide core is 
covalently functionalized with lipophilic fluorescence dye and polysaccharide matrix, 
starch for uniform suspension in aqueous solution.  
 
Magnetic NPs have been widely used as contrast agent (Wei et al., 2017) or iron 
supplement (Balakrishnan et al., 2009). Some of the approved magnetic NPs are 
Feridex, Peraheme, Resovist, Ferristene, Ferumoxsil, ferumoxytol (Schutz et al., 2013). 
However, Feridex has been discontinued due to complement activation and 
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hypersensitivity (Banda et al., 2014). IONPs have also been studied as potential cancer 
therapy inducing hyperthermia (Lee et al., 2011). Magnetic particles (magnetite cationic 
liposomes) are injected into a tissue and exposed to external magnetic field allowing 
heat generation up to the range of 42-45
0
C, thus irreversibly damaging the cancer 
tissues by causing necrosis  (Tanaka et al., 2005). 
1.2.3 Carbon NPs 
Carbon nanotubes (CNTs) are tubular structures of carbon, first reported in 1991 by 
Iijima (Iijima, 1991). Each carbon atom is connected to another 3 carbon atom in 
hexagonal networks or honeycomb attics arranged in a graphite sheet rolled up into a 
cylinder (Figure 1-1-3). One or both ends are closed by a buckyball. Based on the 
rolling orientation of graphene sheet, CNTs are classified as an armchair, zigzag and 
chiral nanotubes. Depending on the number of concentric carbon tubes, they can be 
divided into single-walled nanotubes (SWNTs) (Iijima and Ichihashi, 1993), double-
walled (DWNTs) or multi-walled nanotubes (MWNTs) (Iijima, 1991). DWNTs have 
been studied in this work. Apart from carbon nanotubes, other allotropic carbon NPs 
have been described including graphene (graphene oxide and reduced graphene oxides) 
(Novoselov et al., 2004), nanodiamonds (Kurbatov et al., 2010), fullerene (Kroto et al., 
1985; Krätschmer et al., 1990) and nano-onions(Ugarte, 1992). Graphene isthe 2D 
structure of a thin layer of trigonally bonded sp
2
carbon atoms together in a hexagonal 
honeycomb lattice (Figure 1-1-3). Oxidised and reduced version of graphene, graphene 
oxides (GO) and reduced graphene oxides (rGO) consists of partly tetrahedrally bonded 
sp
3 
carbon atoms (Schniepp et al., 2006). Unlike graphene, nanodiamonds (ND) are 
crystal in structure with 2-8 nanometers in diameter consisting of two closely packed 
interchangeable graphite (sp
2
) and diamond (sp
3
) bonds (Kurbatov et al., 2010) (Figure 
1-1-3). An interchangeable bond provides ND with a very special property of flexibility. 
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Similarly, fullerenes are 3D in structure, stable and smallest known nanostructure 
consisting 20(C20) or 60 (C60) or 70 (C70) sp
2
 carbon atoms arranged in hexagons and 
pentagons to form a spherical structure (Krätschmer et al., 1990) (Figure 1-1-3). 
Concentric fullerenes of different carbon atoms arranged in a multilayer resembling that 
of an onion like shape are called carbon nano-onions (Figure 1-1-3).They are often 
called as multi-layered fullerenes (Ugarte, 1992). Like in multi-walled CNTs, each 
concentric closed layers are held together by van der Waals force. Carbon nano-onions 
can be of several layered, however, the stable configuration exists with inner layered 
fullerenes with carbon 60 (C60) followed by fullerenes with carbon 240 (C240), 540 
(C540) and 960 following the sequence: (C960) (C60 @ C240 @ C540 @ C960…..C60n2) 
(n=1, 2, 3, 4, …..n) (Yoshida and Ōsawa, 1993). 
The characteristics of CNTs are their unique size, geometry, atomic structure, ultra-
lightweight, high electrical conductivity, high surface area to volume ratio, high 
mechanical strength, metallic or semi-metallic behaviour, collectively making them 
versatile carriers for biological active ingredients like drugs and genetic material. 
Despite showing promising results in vitro and in vivo in biomedical use like cell 
specificity, gene delivery, drug efficacy, gene silencing, and diagnosis, to date, none of 
the carbon-based drug delivery has been approved. Some of the preclinical phase carbon 
nanotubes based cancer drug conjugates are listed in Table 1-1 
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Figure 1-1-3 Sketch of carbon-based nanoparticles used in biomedicine. 
Carbon-based nanoparticles cover a broad range of shape and size. Carbon nanotubes 
are hallowed tubes like structure with (DWNT and MWNT) or without (SWNT) 
concentric tubes. Fullerenes are caged-like fused-ring structure. Several concentric 
fullerenes give a structure of carbon nano-onions. Nanodiamonds are crystal structure 
fused with graphite and diamond bonds.   
 
1.3 Delivery of nanoparticle: tumour-targeting mechanism 
Use of NPs in drug delivery of cancer therapeutics is continuously growing. 
Furthermore, anti-cancer drugs are usually toxic to the human body and making them 
into systemic administrations is often associated with serious side effects. Nanoparticle-
based anti-cancer drug delivery has become particularly attractive. Ideally, drug-loaded 
NPs should reach the targeted part without affecting the tissues and organ en route, 
minimal loss of their volume in blood circulation, and release of the drug after reaching 
the target. After releasing the drug, NPs should make their way to elimination from the 
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body. Targeting in tumour microenvironment can be achieved through passive or non-
specific strategy and active or specific strategy 
Table 1-1:Preclinical staged carbon-based NPs for drug delivery in cancer 
Agent 
delivered 
Status Details of study References 
Cisplatin Preclinical Cisplatin loaded carbon nanohorn 
enhanced efficacy in murine lung 
cancer in vivo  
 (Ajima et al., 
2008) 
Paclitaxel Preclinical Paclitaxel-loaded CNTs enhanced 
circulation life, tumour killing in 4T1 
murine breast cancer 
 (Liu et al., 
2008) 
Doxorubicin Preclinical Enhanced tumour cytotoxicity, blood 
circulation half-life and increase 
survival rate in chemo-resistant 
breast and liver cancer in mouse 
 (Chow et al., 
2011) 
Epirubicin Preclinical Tumour regression in a mouse model 
of human triple negative breast 
cancer targeting EGFR. 
 (Moore et al., 
2013) 
SiRNA Preclinical siRNA delivery using MWNTs in 
mice inhibited tumour growth. 
 (Podesta et 
al., 2009) 
Melittin 
peptide 
Preclinical Perfluorocarbon NPs enhanced 
therapeutic efficacy against human 
breast and skin cancer mouse 
xenograft tumour 
 (Soman et al., 
2009) 
Radionuclide Preclinical Radio metal ion conjugated 
effectively targeted in vivo in murine 
xenograft lymphoma model 
 (McDevitt et 
al., 2007) 
1.3.1 Passive targeting 
A tumour needs a continuous supply of nutrients and oxygen to grow and spread. For 
that purpose, the development of new blood vessels is inevitable. Development of new 
blood vessels is called angiogenesis and are often very rapid, vigorous and irregular 
(Folkman, 1971b), resulting in impaired and leaky blood vessels in a tumour where 
drugs or nanoparticles leak into tumour tissue through permeable vessels and retain in 
the tumour microenvironment. Such phenomenon is known as enhanced permeability 
and retention effect (EPR) first described by Maeda and Matsumura (Matsumura and 
Maeda, 1986; Maeda and Matsumura, 1989). EPR is now becoming the gold standard in 
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the passive targeting of cancer. Most of the NPs for drug delivery (nanocarriers) use the 
EPR effect to deliver the drug (Figure 1-1-4). It has been reported that within 1-2 days, 
10-50 fold higher concentrations of drug-loaded NPs can be seen in tumour sites than in 
normal tissues  (Iyer et al., 2006). However, the concentration of NPs in tumour site 
depends upon the size of NPs. To this end, ideal nanocarrier size is suggested to be 
between 10 and 100nm for efficient extravasation in the leaky vasculature and to avoid 
filtration by kidney glomerular wall-sized 4-6nm. The charge of the particles should be 
as neutral as possible and must be hidden from the reticulo-endothelial system to avoid 
any opsonization and phagocytosis (Gullotti and Yeo, 2009). Apart from the surface 
charge, nanocarrier should be hydrophilic to escape possible macrophage engulfment. 
Hydrophilic functionalization can be achieved by coating the surface with a hydrophilic 
polymer like polyethylene glycol (PEG) and polyethylene oxide (PEO). PEG and PEO 
prevent opsonisation (Jeon et al., 1991; Peracchia et al., 1999) and thus providing 
longer blood circulation life (Kwon et al., 1994).  Passive targeting is restricted to use 
only when the vessels are permeable unlike a hypovascular tumour such as (Unezaki et 
al., 1996) prostate and pancreatic cancer  (Unezaki et al., 1996; Maeda, Bharate and 
Daruwalla, 2009).  
Table 1-2:  Passively tumour-targeted NPs in cancer therapy 
Drug Name Target References 
Albumin-
Paclitaxel 
Abraxane® Metastatic breast cancer (Abraxane, 2017) 
Doxorubicin 
paclitaxel 
Livatag® Hepatocarcinoma  (Trochon-joseph et al., 
2016) 
Liposomes-
doxorubicin 
Doxil® Ovarian 
Metastatic breast cancer 
Kaposi sarcoma 
 
(Janssen, 2015) 
Liposomes-
doxorubicin 
Myocet® Breast cancer  (Harris et al., 2002) 
Liposomes-
Daunorubicin 
DaunoXome® Kaposi sarcoma  (Rosenthal et al., 
2002) 
Liposomes-
Vincristine 
Onco-TCS® Non-Hodgkin lymphoma (INEX, 2004) 
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1.3.2 Active targeting 
In active targeting, antibodies, peptides, and ligands are coupled to the nanocarrier to 
act as receptors to the target site (Figure 1-1-4). Use of magnetic NPs is considered as 
active targeting because the external magnetic field is created to guide them to the site 
of interest. Such approach is revolutionizing the use of nanomedicine in cancer 
treatment.  Though it is highly selective, versatile and less likely to cause side effects, it 
has to overcome some barriers before interacting with receptors on tumour and release 
the conjugated drug. As the main principle behind active targeting is to facilitate 
receptor-ligand interactions, unavailability of receptor on cells or saturation of receptors 
by endogenous ligand should be overcome for successful delivery of drug to the target 
site. Drug conjugated nanoparticles should not be immunogenic because ligand for 
receptor conjugated on nanoparticles could activate the immune system causing the 
rapid clearance of by macrophages  (Tolcher et al., 1999). In some cases, receptors may 
not be expressed on the surface rather they might reside inside the cells or are 
internalized making them very hard to reach. So there should be an abundant and 
homogenous expression of receptors on the target cells or a tumour(Capone, Papsidero 
and Chu, 1984). Receptors could be already bound with ligand resulting in difficulties 
of binding of NPs.  
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Figure 1-1-4 Nanoparticle drug delivery methods. 
Nanocarriers reach tumour site by using either passive targeting or active targeting. A) 
Passively targeted delivery. Nanocarriers reach target sites by extravasation via leaky 
vessels. Nanocarriers are accumulated in the extracellular environment, not within 
tumour cells.  B) Actively targeted delivery: Antibody decorated on NPs is targeted 
against tumour cells. NPs extravagate through leaky blood vessels and accumulate on 
tumour cell membranes and enter the cells. (Danhier, Feron and Preat, 2010) 
In the active targeting approach, tumours are targeted via two methods; targeting 
the cancer cell and targeting the tumoural endothelium.  Cancer cells over express 
numerous receptors on their surface. The aim of tumour cancer cells based target 
strategy is to improve the cellular uptake of the nanocarriers upon binding of the ligand 
on the NPs to a receptor on the cell surface (Kirpotin et al., 2006). Internalised NPs 
release the drug inside the cells thus causing cell death. Such approach is highly 
efficient in case of delivery of DNA, RNA, siRNA or protein.  The popular receptors 
targeted strategy includes transferrin receptor  (Daniels et al., 2006; Dixit et al., 2015), 
folate receptor  (Muralidharan et al., 2016), glycoproteins  (Punfa et al., 2014; 
Iangcharoen et al., 2011), epidermal growth factor receptors (EGFR) (Acharya, 
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Dilnawaz and Sahoo, 2009) and human epidermal receptor-2 (HER-2)  (Yao et al., 
2016). These receptors are expressed by up to 100 fold compared to expression in 
normal cells making them available for interaction with the conjugated ligand on NPs. 
Tumours are highly vascularized. Targeting the tumoural endothelium and the 
associated marker looks promising by causing blockage in oxygen and nutrient supply. 
In fact, the idea of killing cancer cells by cutting off their nutrient supply dates back to 
1971 (Folkman, 1971a). The main targets of the tumoural endothelium includes 
vascular endothelial growth factor (VEGF)  (Shi et al., 2015), αvβ3 integrin 
(Desgrosellier and Cheresh, 2010), vascular cell adhesion molecule-1 (VCAM-1)  
(Gosk et al., 2008) and matrix metalloproteinase (MMPs)  (Hatakeyama et al., 2007) 
Passive target based nanocarriers have already been approved and active target 
strategy looks more specific and versatile. However, as of now only a median of 0.7% 
administered are found to be localized within a solid tumour (Wilhelm et al., 2016). In 
this scenario, to increase the efficiency, we need to increase the amount of administered 
dose. As more than 99% of administered NPs end up residing in the off-target site, high 
nanoparticle doses may increase the risk of toxicity. This brings several questions to 
light regarding the fate of administration and other players in nanoparticles-based drug 
delivery system, which could influence their efficacy. 
1.4 Nanoparticle clearance 
Immune system strongly influences the effectiveness of intravenously administered 
NPs. Innate immune components recognize, sequester, degrade and eliminate foreign 
particles like viruses, fungi, parasites, and bacteria. The innate immune system is the 
first line of defence and is non-specificwhereasthe adaptive immune system is more 
specific and comprises of B cells and T cells.  Both systems work in efficient removals 
of foreign particles in circulation. In brief, recognition of foreign particles starts with 
Chapter I 
 15 
opsonisation of foreign particles by complement components and other abundantly 
available proteins like albumin, antibodies and collectins. Opsonisation helps in 
recognition of particles, which results in activation of macrophages, dendritic cells, and 
leukocytes. Phagocytosis occurs by professional phagocytic cells like macrophages, 
neutrophils. Fragments of the foreign particle are presented on the cell surface by 
antigen presenting cells (APC) such as dendritic cells, macrophages, B-lymphocytes for 
recognition by T-lymphocytes. Recognition of antigen presented on the APC results in 
activation of the acquired immune system. Activation of B-cells of the acquired immune 
system produces antibodies against those foreign particles further assisting in 
phagocytosis and degradation of particles. During the activation of both immune 
systems, several cytokines and chemokines are also produced. These small signalling 
molecules regulate the process to give a balanced immune response (Lanzavecchia, 
1985; Clark and Kupper, 2005).  
Apart from the immune system, mononuclear phagocytic cells in bone marrow, 
skin, lymph nodes, liver, and spleen sequester administered NPs. Most of the systemic 
NPs are sequestered by liver and spleen where degradation occurs for final elimination. 
Liver includes kupffer cells expressing scavenger receptors, which recognizes the 
opsonins on the NPs and trap them (Gustafson et al., 2015). Similarly, macrophages 
residing in the white and red compartment of spleen known as splenic macrophages, 
engulf NPs and eliminate them (Bronte and Pittet, 2013).  
Another system competing with tumours for circulating NPs is the renal system  
(Liu et al., 2013). The epithelial lining of kidney glomeruli contains filtration slits of 4-
6nm in width (Venkatachalam and Rennke, 1978). Any NPs with a cut-off size smaller 
than filter slit can pass through the epithelial lining and get collected into the proximal 
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convoluted tubule. Some NPs are endocytosed by the cells whereas the rest is passed to 
the bladder and eliminated (Nair et al., 2015).  
1.5 Immune system 
Nanoparticles interact with the body either by accidental exposure such as 
industrial or environmental or deliberate exposure such as therapeutics through 
vaccination or drug delivery. Nanoparticles may enter the body through the various 
route of entry like inhalation, ingestion, systemic injection or direct contact. Thus, the 
interaction of nanoparticles with either blood or tissue or lung is unavoidable. 
Therefore, it is essential to study and understand the interactions between nanoparticles 
and all immune components. Here, the interaction of nanoparticles, mainly carbon 
nanotubes and magnetic nanoparticles, with the innate immune system has been studied. 
The two wings of the immune system, innate and adaptive immune system 
(Figure 1-5), comprised of highly specialized immune cells, proteins and various other 
components which are very effective in recognition and clearance of foreign or altered 
self-agents as rapidly and safely as possible. Both systems get activated when foreign 
materials invade the body and undesirable activation of the immune response may lead 
to harmful consequences and may affect the fate of drug-laden NPs. 
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Figure 1-5 Nanoparticles interaction with the immune system 
The immune system can be divided into two interacting parts, the innate immunity and 
adaptive immunity. Innate immunity is fast with broader specificity and comprises of 
various immune cells like a dendritic cell, macrophages, neutrophils, mast cells, NK-
cells and soluble components like complement components. Adaptive immunity is 
rather slow but very specific and comprises of T-cells and B cells and antibodies. 
(Adapted from (Luo, Chang and Lin, 2015) 
1.5.1 Innate immunity 
Innate immunity is a broad-specific, rapid and first line defence system, which relies on 
pattern recognition receptors (PRRs) for the recognition of molecular pattern associated 
with pathogens known as pathogen-associated molecular patterns (PAMPs) and 
damage-associated molecular patterns (DAMPs) (Janeway and Medzhitov, 2002; 
Matzinger, 1994). The main components of innate immune systems include physical 
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epithelial barriers (skin, tracts and secretions), antigen presenting cells such as dendritic 
cells; macrophages, monocytes, neutrophils, basophils, mast cells, eosinophils, natural 
killer (NK) cells and complement components.  Phagocytes such as macrophages, 
monocytes, neutrophils and epithelial cells express PRRs on their surfaces (membrane-
bound) or in the cytoplasm (Mogensen, 2009). These receptors are a key element in 
sensing and the clearance of altered self or non-self materials (eg. Nanoparticles and 
microbes) and trigger downstream effector function to eliminate the danger. These 
receptors include pattern classical pattern recognition receptors such as toll-like 
receptors (TLRs), C-type lectin receptors (CLRs), nucleotide-binding oligomerization 
domain-like receptors (NLRs), retinoid acid-inducible gene I (RIG-I)-like receptors 
(RLRs) (Brubaker et al., 2015). PRRs bind to PAMPs such as microbial nucleic acids, 
lipoproteins, membrane components [peptidoglycans, Lipopolysaccharides (LPS)] and 
DAMPs such as nucleic acids, heparin sulphate, uric acid, ATP and intracellular 
organelles; mitochondria. Binding of PRR to the ligands leads to activation of 
phagocytes and transmit the signals to release signalling molecules such as cytokines, 
chemokines, growth factors etc. Recently, molecular docking studies showed that TLR4 
directly interacts and binds with both CNTs, pristine and carboxylated CNTs with its 
side-walls and tip region and the binding mode is hydrophobic for pristine and 
electrostatics interactions for carboxylated CNTs  (Mukherjee et al., 2018a). 
Furthermore, it has also been shown that TLR2/4 sensed SWNTs resulting in MyD88 
dependent activation of NF-kB leading to secretion of CCL5 in human macrophages. 
This finding shows that nanoparticle have a unique molecular pattern, termed as 
nanoparticle-associated molecular patterns (NAMPs), can be recognized by PRR on the 
surface of phagocytic cells (Fadeel, 2012). The activation of PRR stimulated immune 
cells to phagocytes, direct killing of pathogens, migration of cell to inflammatory sites, 
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the release of inflammatory cytokines and anti-microbial peptides (Takeda, Kaisho and 
Akira, 2003). Professional phagocytes when stimulated by PRR, phagocytes via either 
receptor-mediated endocytosis process such as involving complement receptors (CR), 
scavenger receptors (SR) (Section 1.6.7.3) or non-receptor mediated phagocytosis 
(Figure 1-7). Internalised foreign agents fuses with lysosomes containing degrading 
enzymes such as proteases, nucleases, hydrolytic enzymes, lipases and break into 
certain small products in low pH (3.8-5.0) condition (Turk et al., 2002). 
Biodegradability of carbon nanotubes is not fully understood despite tremendous 
applications but studies carried out intracellular biodegradation show similar 
mechanism involving reactive oxygen-mediated degradation. Studies have shown that 
functionalized MWCNTs and iron oxide hybrids with CNTs are degraded by 
macrophages via Nrf2 signalling pathway by producing reactive oxygen species such as 
O2*, H2O2, and OH* (Elgrabli et al., 2017). CNTs length and functionalization 
(oxidisation) also influence in their biodegradation inside macrophages where short 
pristine CNTs are more prone to degradation than long CNTs (pristine or 
functionalized) compared to short functionalized. Degradation is intracellular pH-
dependent  (Landry et al., 2016) and mediated by respiratory burst initiated by 
activation of NOX (NADPH Oxidase) (Hou et al., 2016). Some reports have 
demonstrated that animal peroxidases such as myeloperoxidase (MPO) (Shvedova et 
al., 2012), plant peroxidise (horseradish peroxidase) (Allen et al., 2009) and eosinophil 
peroxidase (EPO) (Andon et al., 2013) can degrade carbon-based nanoparticles. 
Antigen-presenting cells (APC) such as dendritic cells, monocytes/macrophages, B cells 
process these digested and fragmented foreign agents and presents on the cell surface 
via major histocompatibility complex class II (MHC II) to be recognized by Helper T 
lymphocytes (CD4
+
 T cells). Cytotoxic T lymphocytes (CD8
+
 T cells) recognizes the 
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processed antigen only via MHC I which is present in all nucleated cells and platelets 
except red blood cells (Gruen and Weissman, 1997).  Neutrophils though are 
professional phagocytes, do not express MHC II and directly play role in CD4
+
T cells 
activation. However, upon activation by GM-CSF, IFN-, neutrophil express surface 
MHC-II and costimulatory molecules but does not enable them to function as antigen-
presenting cells to CD4
+
 T cells (Gosselin et al., 1993). Recently, neutrophils stimulated 
with cytomegalovirus pp65 and influenza hemagglutinin was able to express MHC-II 
molecules and co-stimulatory molecules activate memory CD4
+
 T cells (Vono et al., 
2017) The concept of antigen presentation to either CD4
+
T cells or CD8
+ 
T cells have 
been exploited in nanoparticles based antigen delivery for vaccination. Carbon-polymer 
composite conjugated with T cells growth factor IL-2, MHC class I and co-stimulatory 
ligand for CD8
+
 T cells (anti-CD28) acted as APC and showed greater expansion of 
human CD8
+
 T cells and expanded lymphocytes significantly delaying tumour growth 
in murine melanoma model (Fadel et al., 2014). Similarly, nanoparticles, (polylactic-co-
glycolic acid) (PLGA), loaded with a tumour associated antigen were efficiently 
internalised by DCs and enhanced the presentation of murine MHC -I and MHC II 
thereby, enhancing the production of IFN- by CD8 T cells and proliferation of CD4 T 
cells respectively (Ma et al., 2011), thus providing a promising strategy for tumour 
immunotherapy. Antigen presentation by APCs, stimulation of T lymphocytes (helper T 
cells and cytotoxic T cells) and subsequent release of small signalling molecules like 
cytokines, chemokines and growth factors leads to adaptive immunity where APCs 
especially DC acts as a bridge between innate immunity and adaptive immunity due to 
their ability to activate naïve T cells by processing and presenting antigen via both 
MHC I and MHC II molecules to both CD8 and CD4 T cells (Rescigno et al., 1998).  
DCs develop in bone marrow and mature upon exposure to PAMP (eg. LPS), 
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inflammatory cytokines (eg. IL-2, IL-7, IL-13, hepatocyte growth factor) and cell 
surface receptors (eg.CD40) and viral products (eg. Double-stranded RNA) and up-
regulates co-stimulatory molecules, B7 (CD80/CD86) (de Saint-Vis et al., 1998). 
1.5.2 Adaptive immunity 
The adaptive immunity is mediated by two cellular elements, T and B-lymphocytes. 
Both B and T cells can recognize any antigen due to this ability to create novel and 
unique antigen receptors by the process known as VDJ (variable, diversity, joining) 
recombination (Grawunder, West and Lieber, 1998), unlike cells in an innate immune 
system where cells have fixed inherited receptors. B cells bind to antigen via B-cell 
receptors (BCR) also known as membrane-bound immunoglobulin. Binding of antigen 
via BCR results in secretion of antibodies specific to bound antigen by differentiated B 
cells, the plasma cells (Treanor, 2012). T cell receptors (TCR), on the other hand, differ 
from BCR in several ways. BCR can be secreted as immunoglobulin unlike TCR, which 
is always cell surface bound. BCR binds to the native tertiary structure of antigen where 
TCR binds to the primary structure of antigen only presented via MHC II and I 
molecules (Griesser and Mak, 1994). Crosstalk between B cells and T cells is prominent 
in the adaptive immune system. CD4
+
 T cells stimulate naïve B cells to proliferate and 
differentiate to memory cells and plasma cells by recognizing antigen presentation by B 
cells via MHC II molecules to T cells and secretion of a cytokine such as IL-4, IL-5 and 
IL-6 (Flynn et al., 1998). T cells can be functionally divided into CD4
+
 helper T cells 
and CD8
+
 T cells (cytotoxic T cells, Tc cells, CTL). T cells are developed in bone 
marrow and maturation takes place in the thymus. Activation of CTL and CD4
+
 T cells 
and differentiation into effector cell takes place by a combination of signal 1 and signal 
2. TCR binding to MHC I (for CTL) and MHC II (for CD4 T cells) generate signal 1. 
Signal 2 is provided by costimulatory proteins, B7 proteins recognize the co-receptor 
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protein CD28 on the surface of T cells. Thus activated T cells produce IL-2 and binding 
of IL-2 on their receptors induces differentiation and proliferation of T cells. Activated 
CTL provides cell-mediated immunity by recognizing foreign antigen expressed on the 
cell surface, virally infected cells and even protecting against spontaneous malignant 
tumours (Castelli et al., 2000). Activation of CTL is tightly regulated and inhibited by 
the inhibitory receptor, CTLA-4 regulating self-tolerance and T cell activation (Lohr et 
al., 2003). Signal 1 and signal 2 on CD4
+
T helper cells to polarize them into TH1, TH2 
and Treg (TH-regulatory) cells. Polarization is mainly dependent upon cytokine signal 
from DCs. Th1-polarising factor (IL-12. IL-27), TH2 polarizing factor (CCL2) and 
Treg-polarizing factor (IL-10, TGB-) from DCs polarizes CD4+T helper cells into 
TH1, TH2 and Treg cells respectively. TH1 cells secrete Th1 cytokines (IFN-, TNF-) 
and stimulate Tc cells inducing cell-mediated immunity. Th2 T cells secrete Th2 
cytokines (IL-4. IL-5 and IL-13) and stimulate B cells. Treg cells secrete IL-19 and 
TGF- and suppress the response of other T cells (Bilsborough et al., 2003). Thus, T 
cells polarization helps to tune and regulate the adaptive immune response directly 
though, the signal comes from innate immune system intermediate cells, APCs.  
1.5.2.1 Interaction of NPs with T and B cells 
B and T lymphocytes, as a model for circulating cells, have been used to analyse the 
toxicity and the stimulatory effect of functionalized and non-functionalized CNTs. 
Amphotericin B, an antifungal drug, conjugated CNTs have shown less cytotoxicity to 
T cells than equal concentration of amphotericin in soluble form (Jurkat cell line) and 
result showed that amphotericin B conjugated CNTs can provide an antifungal activity 
better than amphotericin B alone (Benincasa et al., 2011).  Functionalized CNTs 
(oxidized-CNTs) have been studied as an immunotherapy by stimulating T cells. Anti-
CD3 (T-cell stimulating antibody) and anti-CD28 (Co-stimulatory ligand) conjugated 
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with SWNTs revealed better T cells stimulation than similar concentration of soluble 
anti-CD3 and anti-CD28 in mouse splenocytes (Fadel et al., 2008) and considerably 
more stimulation was observed in functionalized CNTs than their non-functionalized 
counterparts (Fadel et al., 2010). Furthermore, a genotoxicity study showed that 
functionalized (amidation) CNTs did not affect in T cells proliferation contrast to non-
functionalized CNTs (Cveticanin et al., 2010). Functionalized (Oxidised and 
ammonium functionalized) MWNTs showed no cytotoxicity to peripheral blood 
monocytes (PBMCs) derived from healthy donors and none of these MWNTs induced T 
cells stimulation and expansion (Cveticanin et al., 2010) contrast to earlier study which 
reported that oxidised MWNTs induces apoptosis of Jurkat T cells (Bottini et al., 2006).  
MWNTs and SWNTs exposure to B cells have shown significant cytotoxicity and 
SWNTs were more severe cytotoxic than MWNTs as SWNTs caused cell membrane 
penetration as revealed by TEM images and further revealed that lymphocytes are more 
sensitive to CNTs than skin (HaCat) and lung (MSTO-211H) cell lines (Hu et al., 
2010). However, cytotoxicity was not observed in lymphocytes co-incubated with 
breast cancer cells line (MCF-7) with carboxylate MWNTs rather cytotoxicity was 
observed in MCF-7 cells and was T lymphocytes mediated by up regulating NF-B 
expression and subsequent IFN- and TNF- secretion (Sun et al., 2011).  One of the 
properties of CNTs, needling effect, has been exploited in the delivery of short 
interfering RNA (siRNA) inside CD4
+
T cells to silent HIV-specific cell-surface 
receptor (CD4) and co-receptors (CXCR4/CCR5). PEGylated NPs were shown to 
interact with splenic B cells to secret anti-PEG-IgM in T cell-independent manner 
(Ichihara et al., 2010; Ishida et al., 2007). This raise an alert in the safe use of 
functionalized nanoparticles as functionalization have been considered less 
immunogenic and safe to immune cells due to less-toxic, more biodegradable and bio-
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tolerable (Bourdiol et al., 2013). A recent study showed that B cells actively uptake 
CMC functionalized CNTs (and augments pro-inflammatory cytokine secretion (TNF-
, IL-1). Down-regulation of proinflammatory cytokines and upregulation of anti-
inflammatory cytokines, IL-10 was observed by complement deposition on them 
(Pondman et al., 2016). Similar, immune modulation was observed in T cells (Jurkat 
cells) however; uptake was much lesser than that of B cells (Pondman et al., 2016).  
1.6 NPs interaction with innate immune components 
1.6.1 Human plasma proteins 
Blood plasma contains 1,000 different proteins in various concentrations. Therefore, 
intravenously administrated NPs see competition between various biological molecules 
to adsorb on its surface. At first, smaller molecular weight and abundant protein 
(albumin and fibrinogen) get adsorbed and other proteins may later displace these 
proteins with a higher affinity towards the particle surface. This effect is known as 
Vroman‟effect (Vroman, 1962). The layers of bound or adsorbed proteins around the 
particles are known as protein corona. Protein adsorbed with high-affinity form a “hard 
corona” where as proteins with low-affinity form the “soft corona”. The bound 
molecule forms a corona that alters the size and interfacial composition of nanoparticles 
like effective size, surface charge, physicochemical properties. This gives a new identity 
to the nanoparticles, which is seen by immune cells differently as surface proteins or 
lipids provide different recognition patterns, alter the interaction with the immune 
components and modulate the immune response (Maiorano et al., 2010). Corona, 
however, does not completely mask the native nanomaterial or functional group 
suggesting that the nanoparticles surface is exposed enough for receptor recognition by 
immune cells (Simberg et al., 2009). 
Chapter I 
 25 
In a study on dextran functionalized magnetic particles, the formation of protein 
corona did not significantly modulate the nanoparticles circulation lifetime.  In another 
study, adsorption of more serum proteins have been observed in negative and neutral 
surface charged super paramagnetic iron oxide nanoparticles (SPION) coated with 
polyvinyl alcohol polymer than dextran coated SPION (Sakulkhu et al., 2014). 
Similarly, more protein adsorption was observed in negatively charged oxidized CNTs 
(Shannahan et al., 2013; Rybak-Smith et al., 2011). However, the adsorption of some 
abundant proteins such as serum albumin and low abundance proteins such as 
serotransferrin, α-fetoprotein and kininogen-1 are found to be non-specific to 
nanomaterial or the surface charge. Simberg et al have demonstrated the existence of 
IONP core binding proteins such as a histidine-proline rich glycoprotein, kininogen-1 
and dextran binding protein such as mannose-binding lectins A and C (Simberg et al., 
2009). Serum albumin was found to be the most abundant protein on CNTs unlike on 
metallic nanoparticles (Deng et al., 2009). Irrespective of functionalisation, CNTs were 
observed to bind serum albumin, apolipoprotein types, titin, keratin, α-S1-casein, α2-
HS-glycoprotein and α1-antiproteinase (Shannahan et al., 2013). Thus, protein corona is 
very multifaceted and different coronas exist for all nanoparticles of different size, 
surface charge, and coating. Thus, the composition of the proteincorona is exclusive to 
the nanomaterial and varies in many parameters. 
1.6.2 Neutrophils 
Neutrophils play a key role in the defence during acute inflammation via several 
strategies such as actively engulfment and degradation, degranulation and secretion of 
myeloperoxidase (MPO) and neutrophil extracellular traps (NETs) for the non-
phagocytic killing of microbes (Papayannopoulos and Zychlinsky, 2009). They migrate 
first to an inflammatory site and produce inflammatory mediators including chemokines 
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such as IL-8, GRO, MIG, IP-10, I-TAC, MCP-1, MIP-1, MIP-1 to attract other 
immune cells such as DCs, monocytes, NK cells, T-lymphocytes (Scapini et al., 2000). 
Nanoparticles, gold and graphene oxides (GO), were found to trigger NETs release in 
primary human neutrophils (Bartneck et al., 2010; Mukherjee, Bottini and Fadeel, 
2017). More NETs release was observed in response to micrometre-sized GO and also 
induced disruption of lipid rafts in neutrophils (Mukherjee, Bottini and Fadeel, 2017). 
Recently, GO was found to undergo degradation by MPO and degraded GO was non-
toxic to human lung cells (Mukherjee et al., 2018b). MPO mediated intracellular 
degradation of carbon nanotubes by neutrophils have been reported. Like GO, 
biodegraded CNTs showed no pulmonary inflammation when aspirated into the mice 
lungs (Kagan et al., 2010). In an inflammatory condition such as acute lung injury and 
ischemic tissue injury, where neutrophils are adhered on to the lining of vascular 
endothelium, piceatannol-loaded albumin nanoparticles have prevented vascular 
inflammation by internalization of drug-loaded nanoparticle and signalling to 2 
integrin to detach, thereby detaching and dampening pro-inflammatory function (Wang 
et al., 2014). Such therapeutic approaches are promising in the treatment of 
inflammatory diseases caused by neutrophil sequestration and unwanted activation. 
1.6.3 Basophil 
Basophil and eosinophil are bone marrow-derived cells that contribute to the 
inflammation associated with allergic diseases, asthma and helminth infections. They 
share the common phenotypic features in terms of their involvement in adhesion and 
migration via beta 1 and 2 integrins and stimulation and differentiation by common 
cytokines such as IL-3, GM-CSF and IL-5 (Valent et al., 1989). Interaction of these 
cells with nanoparticles has not been studied efficiently despite the wide range of 
nanomaterials proposed in the potential development of nanomedicine. Using the blood 
Chapter I 
 27 
of healthy and allergic volunteers, SWNTs triggered significant basophil activation and 
development of allergic reaction observed by cell-surface CD63 expression (Kiss-Toth 
Dojcsak et al., 2014). However, another carbon-based nanoparticle, fullerenes, showed 
anti-allergic properties in vitro and in vivo (Ryan et al., 2007). Fullerenes showed no 
cytotoxicity to human basophils and dampened the release of basophil mediators such 
as histamine and proteoglycans. Furthermore, it inhibited basophil allergic responses by 
reducing antigen-induced cytoplasmic ROS levels and anaphylaxis in IgE- sensitized 
mice.  Complement activation by fullerenes has not been reported. However, the 
presence of anti-IgGisotype-specific to fullerene in mouse indicates them as 
complement activating nanoparticles (Chen et al., 1998). Complement activation and 
subsequent release of anaphylatoxins such as C3a and C5a would potentially stimulate 
basophils through their C3aR and C5aR receptors. Thus, further study is necessary to 
understand the allergic properties of NPs.  
1.6.4 Eosinophils 
Studies have shown that SWCNTs and MWCNTs promote the stimulation and 
infiltration of eosinophils in the lung, bronchoalveolar fluid and blood and promoting 
allergic immune responses in mice (Erdely et al., 2011). Like neutrophils, eosinophil 
express peroxidase known as eosinophil peroxidase (EPO) is mainly responsible for 
destroying invading parasites including helminths. Reports suggest that eosinophil 
triggers the release of EPO in response to CNTs in mice lungs (Girtsman et al., 2014) 
and EPO in vitro and ex vivo by activated eosinophils has shown to degrade oxidised 
SWNTs (Andon et al., 2013). Other than CNTs, metallic NPs like nickel oxide has been 
shown to recruit eosinophils and neutrophil and involves the release of chemokines, 
eotaxin (Lee et al., 2016).  
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1.6.5 Mast cells 
Mast cells are non-phagocytic cells and play a vital role in allergic reactions, like 
basophils and eosinophils. They release inflammatory mediators such as histamine, 
proteases, cytokines/chemokines (IL-4, IL-13, and TNF-), lipid mediators 
(leukotrienes, prostaglandins) (Borish and Joseph, 1992). During an allergic reaction, B-
cells release IgE and IgE binds to mast cells surface via FcR1 receptors. Binding of 
IgE triggers mast cells to degranulation. Degranulation is also induced by external 
toxins and endogenous cationic proteins secreted by eosinophils and neutrophils (Hogan 
and Schwartz, 1997). A recent study demonstrates that differentially functionalized 
CNTs can inhibit the cell viability, degranulation and histamine release in mast cell line 
model (Ede et al., 2018).  Pristine CNTs not only significantly reduce the cell viability 
but also inhibited IgE-FCR1 mediated degranulation compared to carboxylated CNTs. 
Furthermore; SWNTs exposure resulted in a concomitant reduction in MAPK/ERK 
activation (Ede et al., 2018). This indicates that pristine SWNTs can interact with IgE 
receptors on the mast cell surface preventing the binding of IgE. Suppression of mast 
cell pro-inflammatory degranulation function by SWNTs has previously been reported 
by Umemoto et al. (Umemoto et al., 2014). SWNTs induce membrane rearrangement 
and subsequent suppression of receptor-mediated signalling pathway involving FCR1 
receptor. Similar effects were also observed with fullerenes in a mouse model (Ryan et 
al., 2007).  These reports suggested that carbon-based NPs area negative regulator of 
allergic mediator in mast cells. Similar effects were observed with different kind of 
NPs, polymeric NPs (PLGA NPs), in a mouse model in which NPs administration 
suppressed the antigen-induced systemic allergic response and inhibited histamine 
release (Tahara et al., 2012). However, in contrast to these reports, Chen et al, 
demonstrated that metallic NPs (TiO2) increase histamine release in rat mast cells. 
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These conflicting results indicate that systemic circulation of NPs may suppress or 
promote degranulation depending upon nanomaterials. 
1.6.6 Natural Killer (NK) cells 
NK cells are lymphocytes of innate immune system sharing the common lymphoid 
progenitor with B and T cells. They are associated with recognition and killing of 
virally infected cells and neoplastic cells via secretion of membrane-disrupting protein, 
perforin, granzymes and initiation of caspase-dependent apoptosis involving association 
of death receptors (Fas/CD95) on the target cells with ligands such as FasL and TRIAL 
on NK cells (Zamai et al., 1998). NPs have been shown to affect NK cells activity and 
stimulation. NK function has been significantly suppressed in mice upon inhalation of 
MWNTs as shown by the loss of target cell lysis function (Mitchell et al., 2007) 
However, human NK cells have demonstrated an increase in their activity and 
stimulated upon exposure (Delogu et al., 2012). Recently, Loss of NK cells activity to 
kill target cell upon exposure to SWNTS and functionalized SWNTs have also been 
reported (Alam and Saxena, 2017).  Alam and Saxena extensively studied two types of 
CNTs, pristine SWNTs and functionalized SWNTs. They reported that functionalized 
SWNTs induced inhibition of cellular proliferation, increased apoptosis, decreased 
degranulation, lowered ligand-death receptor interaction and lowered inflammatory 
cytokine (IFN-, TNF-) release in NK cells. These results suggest that CNTs possibly 
have a negative effect on NK cells normal functions.   
1.6.7 Complement pathway 
A key component of the immune system that plays an important role in seeing and 
sensing foreign particles, their handling and eventually elimination through a series of 
the enzymatic reactions is the complement system. Complement recognizes foreign 
invades primarily through pattern recognition. It consists of at least 30 soluble and 
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membrane-bound proteins working in conjunction to maintain host defence, balanced 
inflammatory response, homeostatic and immune reactions (Ricklin et al., 2010). There 
are three established pathways of complement activation: classical pathway, lectin 
pathway and alternative pathway (Figure 1-6). Pathways are initiated by the binding of 
initial complement components; Antibody and C1q in classical pathway, mannose-
binding lectin and ficolin in lectin pathway and C3b and properdin in alternative 
pathway.  
 
Figure 1-6 The three complement pathways: Classical, Lectin and Alternate 
pathways with different recognition strategies. 
The classical pathway initiates by recognition and binding of antigen-
antibodycomplexes via C1q, lectin pathway with the binding of mannose or 
carbohydrates moieties with MBL. Classical and lectin pathway converge in common 
C3 convertase (C4b2a). The alternative pathway is initiated with spontaneous 
hydrolysis of C3 to C3b. All pathways converge at the formation of C5 convertase and 
results in the formation of membrane attack complex (MAC) leading to cell lysis. 
Potent anaphylatoxins; C4a, C3a and C5a are generated which enhance the 
inflammation. 
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C1q, a charge pattern recognition protein consists of 18 homologous polypeptide chains 
6 each of A, B and C domain. Each of the chains consists of a short N-terminal region, 
the collagen-like domain at the middle followed by C-terminal globular head domain 
(Reid, Bentley and Wood, 1984; Sellar, Blake and Reid, 1991). The globular head 
domain recognizes the PAMPs and binds to charge clusters or hydrophobic patches on 
the targets (Kishore et al., 2003; Kishore et al., 2004). Binding of C1q to its targets 
results in activation of C1r and C1s of C1 complex, which in turn cleaves C4 and C2 
forming C3 convertase (C4bC2a). In lectin pathway, MBL binds to mannose or 
carbohydrate moieties activating membrane-associated serine proteases (MASPs), 
which cleave C4 and C2 forming common C3 convertase (C4bC2a). C3 convertase 
cleaves C3 into C3b and C3a. C3b opsonizes the targets and binds to complement 
receptors expressed on macrophages for phagocytosis. C3b also binds to C3b 
convertase forming C5 convertase (C4bC2aC3b) and cleaves C5 into C5a and C5b. C5b 
forms a complex with C6, C7, C8 and C9 forming membrane attack complex (MAC). 
MAC disrupts the lipid bilayer of cells (Ricklin et al., 2010).  
The alternative pathway involves the slow hydrolysis of inactive C3 into C3 (H2O), 
altering its conformation and exposing new binding sites facilitating binding of factor 
B. Factor D cleaves factor B and forms C3 convertase (C3bBb). Properdin (factor P) 
stabilizes C3bBb to C3bBbP (Fearon and Austen, 1975). C3bBbP in turns cleaves C3 
leading to amplification of C3b formation and C5 convertase (C3bBbC3b). C3 
convertase is stabilized by properdin while Factor H acts as an antagonist. Factor H 
inactivates C3b to form inactive iC3b. C5 convertase cleaves C5 forming C5b, which 
combines with C6, C7, C8 and C9 to form membrane attack complex (MAC) leading to 
cell lysis.  
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1.6.7.1 Complement activation by nanoparticles 
One of the liposomal doxorubicin formulated nanomedicines, DOXIL highlight the 
importance of complement activation. DOXIL is infused at a very low rate to avoid 
complement activation and subsequent hypersensitivity. Even administration at a very 
slow rate induces serious cardiopulmonary distress with anaphylactic shock in 10% of 
patients (Szebeni et al., 2002). Another example of nanomedicine, which was approved 
for contrast agent and later discontinued, is Feridex due to alternative pathway 
activation (Szebeni et al., 2011). In addition to these two drugs, a diverse range of 
nanomaterials including Poly (lactic-co-glycolic acid (PLGA) nanoparticles 
(Fornaguera et al., 2015) and CNTs activate complement via either alternative or 
classical pathway (Pondman et al., 2014). C1q has been shown to crystallize on pristine 
and functionalized CNTs in a confirmation that does not promote classical pathway 
(Ling et al., 2011). However, another study (Pondman et al., 2015) reported a high-
affinity direct binding of C1q to CNTs involving hydrophobic interactions that led to 
complement activation. The ways other complement components assemble on 
nanoparticle surface have still remained unclear. Recently, it has been shown that non-
specifically adsorbed serum and plasma protein on the dextran functionalized IONP 
forms a covalent link with C3 thus initiating alternative pathway rather than 
conventional direct binding of C3 to dextran shell of IONP via thioester bond (Chen et 
al., 2017). Such surface bound proteins accelerate the assembly of the complement 
components in complement activation thus poses a challenge in the reduction of 
complement consumption by nanomedicine.  
1.6.7.2 Strategy to dampen complement activation 
C4a, C3a and C5a generated during complement activation act as anaphylatoxins. These 
peptides cause the release of histamine, enhance vascular permeability and smooth 
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muscle contraction (van Lookeren Campagne, Wiesmann and Brown, 2007) eventually 
causing a host complement-activation related pseudoallergy (CARPA) (Szebeni et al., 
2012). Liberated C5a results in recruitment of regulatory T cells, immunosuppressive 
monocytes into malignant tumours and thus affecting the prognosis of cancer 
(Markiewski et al., 2008; Moghimi and Farhangrazi, 2014). 
Complement activation, therefore, is a thoughtful concern for the successful 
development of intravenous nano-based drug delivery. In order to dampen the inevitable 
complement activation on NPs surface, modified sugar alcohols of surface 
polysaccharides, dextran with alkylating, acetylating, or crosslinking agents have been 
used but these modifications have failed to inhibit complement activation and C3 
opsonisation (Wang et al., 2016). In separate studies, Kishore and colleagues 
extensively investigated the complement deactivation using recombinant individual 
globular head modules of C1q molecules and factor H (Pondman et al., 2014; Pondman 
et al., 2015). The recombinant globular head module of C1q (ghA, ghB and ghC) and 
factor H dampened the complement activation when adsorbed on CNTs. It has also been 
shown that individual globular heads bind to CNTs via hydrophobic interaction through 
the globular head, ligand recognition domain of C1q. Pre-coating with globular heads 
inhibited the direct interaction of C1q with CNTs possibly by occupying same binding 
pattern on the surface and thus inhibiting stable binding of C1q resulting in inhibition of 
classical pathway activation (Pondman et al., 2016). Adsorption of Factor H on 
graphene oxide and reduced graphene oxide has also been shown to inhibit complement 
activation to naturally occurring levels (Belling et al., 2016). Surface adsorption of 
soluble complement regulators such as globular heads of C1q and factor H have offered 
a novel way of controlling complement pathway activation and also down-regulation of 
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inflammation caused by nanoparticles, important factors in the design of immune-safe 
nanomedicine.  
Besides complement components, polymers like PEG and its derivatives have 
also been extensively studied in inhibition of complement activation. It has been 
considered to provide a shielding or masking of the surface of the nanomaterial from 
complement recognition (Moghimi and Szebeni, 2003). On the contrary, recent 
biochemical and immunological studies have shown that such polymeric derivatives 
also trigger complement, in spite of their protective PEG armour (Hamad et al., 2008). 
Mechanisms of PEG-mediated complement activation are still a matter of debate. 
Various factors such as PEG chain length, surface density and molecular weight may 
affect the degree of complement activation. However, some studies have suggested that 
the immune system can produce PEG-specific antibodies after intravenous 
administration of PEG-liposomes (Ishida et al., 2007), which further give an insight into 
one of the various mechanisms of PEG-mediated complement activation (Taguchi et al., 
2009). 
1.6.7.3 Complement/receptor-mediated endocytosis of NPs 
Complement activation and opsonisation of NPs with C3b follows the interactions with 
complement receptors: CR1, CR2, CR3, CR4 (Zipfel and Skerka, 2009). C3b upon 
degradation by inhibitory factor I is converted into iC3b. iC3b, though, retains the 
capacity to act as an opsonins, it no longer acts as C3b in the amplification of 
complement alternative pathway. Further cleavage of iC3b by factor I results in the 
formation of C3d. C3b, iC3b and C3d have an affinity toward different complement 
receptors present on the membrane of host immune cells and may signal for different 
functions. CR1 binds to C3b, iC3b and C4b and mediates the clearance of immune 
complex and enhances phagocytosis (Medof et al., 1982). CR1 is abundant 
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onerythrocytes (Nielsen et al., 1997) and follicular dendritic cells (Reynes et al., 1985). 
iC3b has a lower affinity toward CR1 but higher affinity towards CR3 and CR4, 
commonly found on professional phagocytic cells (Helmy et al., 2006). Thus, C3b 
decorated particles bound to erythrocytes via CR1 are transferred into the liver for 
clearance. CR2 is abundantly present on B cells. Both CR1 and CR2 act as co-receptors 
for surface-bound immunoglobulin and regulate B cell differentiation and maturation 
(Zipfel, 2009). CR2 on B cells binds to C3d and instructs them to respond to C3d-
coupled foreign antigens thus linking innate and adaptive immune system.   
Complement activating nanoparticles are readily endocytosed and cleared by 
macrophages (U937) and B cells (Raji) in vitro (Pondman et al., 2017b; Pondman et al., 
2015; Pondman et al., 2014). B cells are known to present the highest number of CR2 
and CR1 complement receptors on their surface. Macrophages, also express abundant 
CR1, CR3 and CR4 receptors. Thus, rapid endocytosis of complement deposited 
nanoparticles by macrophages and B cells is an indicator of the involvement of 
complement receptors. Interestingly, no difference was observed in the uptake of 
complement deposited and untreated CNTs by Jurkat cells (T-cell line), which are 
known to lack complement receptors. These evidences further advocate the role of 
complement receptors in endocytosis and clearance of complement activating 
nanoparticles.  Pre-coating of CNTs with recombinant globular heads of human C1q 
and factor H increased and decreased phagocytosis respectively by macrophages 
(Pondman et al., 2015). 
Besides, CR, macrophages and dendritic cells are equipped with other receptors 
like Toll-like receptors (TLR), scavenger receptors (SR), integrins, lectin-like receptors 
and Fc receptors to recognize, bind and phagocyte foreign particles. Antigen-presenting 
cells like monocytes/macrophages, dendritic and B cells bind and either phagocyte 
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(macrophages and dendritic cells) or receptor-mediated endocytose (B cells) foreign 
agents and process them into peptide fragments (epitope) and then display them on their 
plasma membrane through class II and class II MHC molecules (Kambayashi and 
Laufer, 2014) for T lymphocyte recognition through TCR (T cell receptor). Thus, 
bridging innate and acquired immunity. Other phagocytic receptors such as scavenger 
(SR) and mannose receptors are also involved in clearance of nanoparticles in a 
complement-independent manner. Non-opsonized NPs were shown to be taken up via 
sugar receptor-mediated processes involving mannose receptors (Artursson, Johansson 
and Sjoholm, 1988). Furthermore, it has been shown that complement receptor-
mediated phagocytosis overrides the sugar receptor-mediated process in the case of 
phagocytosis of the particles that have a tendency to adsorbed significant amounts of 
serum proteins. Involvement of SR-A mediated endocytosis has also been reported in 
macrophage uptake of SPION, ferumoxides and ferumoxtran-10 contrast agents (Raynal 
et al., 2004). Involvement of TLRs in phagocytosis is still not clear. However, TLR 4 
has been shown to enhance the phagocytosis of titanium dioxide nanoparticles in TLR-
transfected human epithelial cell lines independent of its co-receptor, CD14 (NCI-
H292) (Mano, Kanehira and Taniguchi, 2013). However, the mechanism of 
phagocytosis is not well defined but it has been shown that titanium dioxide stimulates 
TLR4 expression and increases the phagocytic activity and p38 MAPK signalling 
pathway in sea urchin immune cells (Pinsino et al., 2015). Furthermore, TLR4 
stimulants, such as alginates, are required to enhance the uptake of gold nanoparticles 
by murine macrophages (Bi et al., 2017). Aliginate was shown to upregulate TLR4 
expression and the activation of Akt/NF-kB and p38 MAPK signalling pathways. These 
findings show that TLR4 may not bind to nanoparticles directly but stimulation of 
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TLR4 enhances uptake through other routes for example by upregulating SR expression 
(Bi et al., 2017) 
1.6.7.4 Non-complement dependent endocytosis of NPs 
The latest information on cellular uptake of nanoparticles suggests the involvement of 
phagocytosis, pinocytosis, caveolae-dependent and clathrin-mediated endocytosis in 
their uptake (Figure 1-7). These pathways are highly dependent on a particle‟s 
physicochemical properties, experimental conditions and the cell type (phagocytic or 
non-phagocytic cells) (Kettler et al., 2014). Endocytosis processes are energy dependent 
and highly conserved in eukaryotes. Foreign objects greater than 750 nm are 
engulfed and transported into the cells via phagocytosis. Smaller particles of size around 
100 nm are mostly internalized by pinocytosis or macropinocytosis. Clathrin-mediated 
endocytosis or receptor-mediated endocytosis is probably the best-characterized 
mechanisms for nanoparticle internalization in which particles are deposited in small 
endocytic vesicles which later fuse with early endosomes (Zhao et al., 2011). Organic 
molecule coated particles take a different route of internalisation compared to their 
uncoated counterpart. Pristine gold nanoparticles are endocytosed via macropinocytosis 
and clathrin-mediated endocytosis whereas PEG-coated gold nanoparticles mostly enter 
cells via clathrin-mediated endocytosis, not by macropinocytosis (Brandenberger et al., 
2010). However, there was no difference in their intracellular distribution after 
endocytosis. Similar intracellular localization patterns were observed with both 
uncoated liposomes and hyaluronic acid coated liposomes though they entered via two 
different pathways; fusion with the plasma membrane and receptor-mediated 
internalization (Nazarenus et al., 2014).  
Moreover, a combination of three pathways has been reported in the uptake of 
CNTs; clathrin-mediated, caveolae mediate and macropinocytosis (Maruyama et al., 
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2015). Furthermore, very recently Cui et al also suggested the involvement of multiple 
pathways simultaneously but in an orderly fashion; with macropinocytosis being the 
preferred entry pathway then caveolae-mediated and clathrin-dependent endocytosis as 
a rare pathway in CNT uptake (Cui et al., 2017). Long CNTs (630±171nm) have been 
shown to be internalized by direct penetration or needling through plasma membrane 
(Cui et al., 2014). After NPs uptake by macrophages, NPs could localise in the 
cytoplasm or within the endo-lysosomal system (Kang et al., 2008; Cui et al., 2014; 
Osman et al., 2012). Nuclear localisation of NPs is very rare but in some cases, 
endosomal escape and nuclear translocation have been observed (Mu, Broughton and 
Yan, 2009). Some studies have suggested that silica NPs can accumulate in lysosomes 
(Lesniak et al., 2012) and SWCNTs can reside in intracellular vacuoles in Hela cells 
(Yehia et al., 2007). This differential localisation of NPs is dependent on ligand coating 
(Gao et al., 2013). The uptake of IL-13 peptide linked PEG-PCL NPs was higher and 
the endocytosed particles were distributed throughout the cell compared to PEG-PCL 
NPs and PEG-PCL NPs which co-localised with endosomes (Gao et al., 2013). 
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Phagocytosis 
Phagocytosis is a common endocytic process widely observed in cells types such as 
epithelial cells, professional immune cells (monocytes, neutrophils, macrophages, 
basophils, eosinophil, mast cells, NK cells) and fibroblasts (Aderem and Underhill, 
1999). Foreign particles, cells and infectious microorganisms are engulfed and 
disabled by the cells‟ plasma membrane protrusions as a response to innate and 
adaptive immunity.  The process of phagocytosis occurs through the interaction of 
cell surface receptors with foreign agents. Receptors like Fc receptor family for IgG 
(FcΥRI, FcΥRIIA, FcΥRIIB2, FcεRI. FcαRI) and complement receptors (CR1, CR3 
and CR4) and α5β1 integrin (Underhill and Goodridge, 2012) stimulate uptake. Large 
particles (>250nm) are endocytosed through this process and form phagosomes. The 
phagosome matures by fusion with lysosomes and engulfed agents are degraded by 
hydrolytic enzymes in the low pH environment of the phagolysosome (Figure 1-7), 
Degradation of the foreign agents leads to detection of epitopes inside the cells, which 
stimulates signalling to the nucleus to trigger an inflammatory response and 
presentation of peptides derived from the foreign agent to other immune cells via 
MHC class II.  
Macropinocytosis 
It is an actin-driven endocytic process in which solute molecules; nutrients and 
antigens are internalized forming vesicles called macropinosomes. It is a route of 
uptake of viruses, bacteria and apoptotic cells and in dendritic cells material taken up 
by macropinocytosis is processed and subsequently presented by MHC II. After 
formation, macropinosomes undergo a maturation process during which they shrink 
and the content is concentrated. Macropinosomes ultimately fuse with the endo-
lysosome system where loading of MHCII molecules takes place for the subsequent 
presentation of the antigen to T cells (Racoosin and Swanson, 1993)(Figure 1-7).  
Clathrin-mediated endocytosis (CME) 
CME is a complex endocytosis process in eukaryotic cells in which cargo is packed in 
vesicles containing a clathrin coat.  The vesicle forms with the participation of a series 
of protein modules (Complexes) starting with the induction of curvature in the 
membrane and addition of adaptor protein complex (AP2) forming a spherical 
clathrin-coated pit (Figure 1-7)(McMahon and Boucrot, 2011). Once the vesicles are 
Chapter I 
 40 
 
formed, the GTPase dynamin is assembled around the neck of the vesicle and initiates 
its release from the plasma membrane. Released vesicles lose their clathrin coat by 
the action of auxilin and heat shock protein 70 (HSC70) (McMahon and Boucrot, 
2011). The vesicles are then trafficked to endosomes and where their content is sorted 
to either recycle back to the plasma membrane or to be digested in the lysosome.  
CME is also called receptor-mediated endocytosis. 
Clathrin-independent endocytosis (CIE) 
Unlike CME, CIE does not require coat proteins for vesicle formation and 
invagination. CIE pathway uses actin and actin-associated small GTPases like Arf-6, 
RhoA and Cdc42 for vesicle formation (Ferreira and Boucrot, 2017). The formed 
vesicles are delivered to the early endosomes and later to late endosomes (Figure 1-7) 
which subsequently fuse with lysosomes for degradation. Cargo may be also 
trafficked to the trans-Golgi network or recycled to plasma membrane similar to what 
is observed with CME (Grant and Donaldson, 2009) 
Caveolae 
Caveolae are small (60-80nm) plasma membrane invaginations abundantly observed 
in fibroblasts, adipocytes, endothelial cells but absent in neurons and leukocytes. 
Caveolae are coated with caveolin proteins (CAV1, CAV2 and CAV3). Cavins 
(Cavin 1-4) are associated with caveolins to regulate the formation of caveolae. These 
proteins also regulate the signal transduction and govern the fate of caveolae (Parton 
and del Pozo, 2013). The endocytosed cargo is localized into neutral pH vesicles 
called caveosomes (Figure 1-7). Due to the physiological pH inside caveosomes, their 
content is not degraded hydrolytic enzyme of lysosomes. Caveosomes may later 
deliver their cargo to the Golgi apparatus and endoplasmic reticulum. Negative 
surface charged particles have been found to be endocytosed predominantly via 
caveolae (Sahay, Alakhova and Kabanov, 2010). 
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Figure 1-7 Pathways of entry of NPs into the cells. 
Phagocytosis engulfs large particles using surface receptors and plasma membrane. 
Macropinocytosis mainly involves internalization of extracellular fluids. Clathrin-
dependent endocytosis involves the organization of clathrin and adaptor proteins on the 
plasma membrane to form a nascent vesicle for internalization. Caveolin-dependent 
endocytosis involves the assembly of caveolin coated and forms vesicle for 
internalization. Clathrin-independent endocytosis does not require coat proteins for 
vesicle formation and internalization but actin and associated proteins help to form the 
membrane into a vesicle. Except for caveolin-dependent endocytosis, all other 
endocytosis eventually leads to fusion with a lysosome. Internalized cargo may escape 
from early endosome and reside in other subcellular compartment like Golgi, 
mitochondria, endoplasmic reticulum (ER) and nucleus.  Image is taken from  (Yameen 
et al., 2014) 
1.7 Intracellular distribution 
The therapeutic potential of the nano drug is highly dependent upon the endocytosis 
process and subsequent intracellular distribution, thus it is important to understand the 
physicochemical properties of NPs so that necessary modulation can be carried out to 
lessen the effect of any digestive process after cellular uptake and determine their 
intracellular fate.  
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In general, the intracellular localisation and distribution of the NPs are strongly 
guided by the route of entry. Clathrin-mediated endocytosis pathway occurs upon 
specific interaction of ligand and receptor on the extracellular surface. Particles are 
internalized and are generally delivered to endosomes. These endosomes later fuse with 
acidic lysosomes containing lysosomal enzymes resulting in degradation of the 
bioactive molecules carried by the NPs (Watson, Jones and Stephens, 2005). Thus, it is 
warranted to programme the NPs to be internalised through an alternative route like 
caveolae. This pathway is non-specific and is devoid of both acidic and digestive 
degradation. Caveolae leads to the formation of a large endocytic compartment formed 
from the plasma membrane and do not fuse with lysosome thus avoiding lysosomal 
degradation of the nano-conjugates (Parton and del Pozo, 2013). This results in not only 
prevention of degradation but also provides an opportunity to distribute to other cellular 
organelles. The endocytosed NPs can be delivered to the Golgi complex, endoplasmic 
reticulum or even exocytosed. In this way, drugs targeting ER and Golgi complex can 
be programmed to be delivered via caveolae-mediated endocytosis and 
macropinocytosis mediated uptake (Sneh-Edri, Likhtenshtein and Stepensky, 2011). 
Very recently, such strategy has been employed to avoid lysosomal degradation by 
surface modification. PEG-modified zirconium terephthalate porous metal-organic 
frameworks (UiO-66) has been tuned to escape lysosomal degradation by enhancing 
caveolae-mediated uptake (Abanades Lazaro et al., 2017). Furthermore, surface 
modification of nanoparticles diverts or enhances quick escape from nanoparticles from 
lysosomal fusion and allows reaching target organelles. Such modification has been 
very successful in the delivery of doxorubicin to nucleus and mitochondria (Li et al., 
2017b; Zeng, Morgenstern and Nystrom, 2014; Qu, Ma and Zhao, 2015). Fusion with 
lysosome is sometimes favourable when NPs are designed for efficient drug release in 
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tumour cells where decreased pH is commonly observed in solid tumours. Fusion with 
lysosomes and release of the drug has three stages; minimum leakage of the drug in the 
blood circulation en route to the target site, a burst release at low pH generally at 
lysosomal fusion inside tumour cells and a slow and steady release of the drug. In order 
to achieve lysosomal fusion and drug release, NPs are modified to take the receptor-
mediated endocytosis route, which results in delivery to the endosome and later fusion 
with lysosomes. Functionalized carbon nanohorns were formulated with pH-sensitive 
phospholipids and polyethylene glycol and loaded with paclitaxel. Paclitaxel was 
released steadily over 30 days with a cumulative release of 90% of the loaded drug in 
breast cancer cells (Huang et al., 2013). Similarly, Poly (ethylene glycol)-poly(aspartic 
acid) [PEG-p(Asp)] micelles conjugated with doxorubicin (DOX) via a pH-sensitive 
hydrazine bond, were tuned to release the drug in the acidic (pH- 4-6) environment of 
endosomes and lysosomes controlling the systemic, local and cellular distribution of the 
drug (Ponta and Bae, 2010).  
1.8 Cytokine, chemokine, inflammation and immune response 
NPs have been shown to interact with serum plasma, complement system, and 
antibodies. Further understanding the profile of released cytokines and chemokines by 
immune cells can unveil the nature of nanoparticle interactions with the immune 
system. In fact, cytokine profiles can be used as a biomarker of immunostimulation by 
nanomaterials. High levels of pro-inflammatory cytokines such as TNF- and IL-1  
are usually associated with toxicity, low therapeutic outcome and adverse reactions. 
Hence, analysing and studying these signalling proteins would help to predict the 
immunotoxicity possessed by NPs. 
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Due to their fibrous morphology and high aspect ratio (length many times than 
diameter), CNTs are similar to asbestos; a mineral fibre have shown to cause pleural 
mesothelioma (Jaurand, Renier and Daubriac, 2009).  Recent studies have shown that 
carbon-based NPs are pro-inflammatory (Tan et al., 2014; van Berlo et al., 2014). The 
interaction between MWNTs and murine macrophages leads to secretion of 
macrophage-induced protein (MIP)-1α and MIP-2 that recruits naïve macrophages, and 
produces angiogenesis factors, Matrix metalloproteinase (MMP)-9 and vascular 
endothelial growth factor (VEGF)  (Meng et al., 2015). The size of the CNTs plays a 
vital role in the nature of inflammatory response: long MWNTs induce significant 
release of IL-1β, TNF-α, IL-6 and IL-8 in breast cancer cell line (MCF-7) (Murphy et 
al., 2012) and murine macrophage cell line (RAW) (Liu et al., 2012). A recent study 
has demonstrated that carboxylic MWNTs on their own act as chemoattractant and 
activate the PLC/IP3 (Phospholipid C/ Inositol 1,4,5-triphosphate) signalling pathway 
and stimulate the migration of RAW264.7 macrophages (Li et al., 2017a). A list of 
secreted small soluble proteins in response to CNTs and IONP administration studied in 
this thesis are presented in Table 1-3, Table 1-4 and Table 1-5. 
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Table 1-3 List of cytokine released by macrophages in response to various CNTs and IONP 
Types Main source Target cells Major functions References 
IL-1β 
IL-1α 
Macrophages, B 
cells, DCs 
B cells, NK cells, 
T-cells 
Pyrogenic, pro-inflammatory, BM cell 
proliferation 
(Dinarello, 1985) 
TNF- α Macrophages Macrophages Pro-inflammatory, phagocyte cell activation, 
endotoxin shock 
 
(Pfeffer, 2003) 
TNF-β Monocytes, T-
cells 
Tumour cells, 
phagocytes 
Oncostatic, cachexia, pro-inflammatory, tumour 
cytotoxicity 
(Sugarman et al., 1985) 
(Pfeffer, 2003) 
IL-6 Th cells, 
macrophages 
Activated B-cells Production and release of acute phase proteins (Tanaka, Narazaki and 
Kishimoto, 2014) 
IL-9 T cells, 
macrophages 
T cells Growth and proliferation (Schmitt and Bopp, 2012) 
IL-10 T cells, 
macrophages 
B cells, 
macrophages 
Anti-inflammatory (Iyer and Cheng, 2012) 
IL-12 (p70) 
IL-12 (p40) 
T cells and 
macrophages 
NK cells Activates NK cells by stimulating interferon γ. (Iyer and Cheng, 2012; Ma 
et al., 2015) 
IL-13 Th cells, 
macrophages, 
basophils 
Basophils Anti-parasitic agent, stimulate an isotype switch to 
IgE 
(Hershey, 2003) 
IL-15 Macrophage NK cells and Tc 
cells 
Stimulation of NK and Tc cells (William E. Carson et al., 
1994) 
IL-17A Th cells,  Neutrophils Pro-inflammatory signalling (Gaffen, 2008) 
IFN- α 
 
Leukocytes, T 
cells 
Various Anti-viral (Kamijo et al., 1994; 
Samuel, 2001) 
IFN- γ Th1 and NK 
cells 
Macrophage Macrophage activation, increase MHC expression (Kamijo et al., 1994) 
Chapter I 
 46 
Table 1-4: List of chemokines released by macrophages in response to various CNTs and IONP 
Types Main source Target cells Major functions References 
MCP-1 
Endothelial, 
monocytes, 
fibroblast,  
Monocytes, NK cells, T 
lymphocytes 
Regulate migration and infiltration of 
monocytes 
(Deshmane et al., 2009) 
MCP-3 
Macrophages, 
tumour cells 
Macrophage, neutrophils 
Chemo attracts monocytes and neutrophils 
and regulates macrophage function 
(Dahinden et al., 1994; 
Xu et al., 1995) 
MDC Macrophage 
DC, NK cells and T cell 
subsets 
Polarizes Th2 and Tc2 cells. (Godiska et al., 1997) 
Eotaxin 
Eosinophil, 
macrophages, T 
cells 
Basophils, 
Induce histamine-release from basophils, 
respiratory burst and leukotriene-release 
 
(Matthews et al., 1998) 
Fractalkine 
Microglial, 
endothelial cells 
T cells and monocytes 
Chemo attractants to T cells and monocytes. 
Promotes adhesion of leukocytes to 
endothelial cells 
(Owlasiuk et al., 2009) 
GRO 
Macrophages, 
Neutrophils  
Epithelial cell 
Neutrophil Angiogenesis, inflammation, wound healing 
(Ahuja and Murphy, 
1996) 
IL-8 Macrophages Neutrophils Chemo taxis (Bickel, 1993) 
IP-10 
Monocytes, 
fibroblast, 
endothelial cells 
T cells, NK cells, DCs 
Anti-cancer activity, attract T cells NK cells 
and dendritic cells 
(Dufour et al., 2002) 
MIP-1α 
 
 
Macrophages, 
DC, lymphocytes 
Granulocyte, Endothelial 
cells 
Inhibit proliferation of hematopoietic stem 
cells, activate granulocytes. 
(Dorner et al., 2002) 
MIP-1β 
Macrophages, 
DC, lymphocytes 
NK cells, monocytes Chemo attractant for NK cells, monocytes. (Dorner et al., 2002) 
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Table 1-5 List of growth factors, ligand and receptors released by macrophages in response to CNTs and IONP 
Types Main source Target cells Major functions References 
EGF 
Macrophages, fibroblast and 
other  
M + Cellular proliferation, differentiation and survival 
(Todderud and 
Carpenter, 1989) 
G-CSF 
Macrophages, endothelial 
cells, fibroblast 
Stem cells Granulocyte production 
(Bendall and 
Bradstock, 2014) 
GM-
CSF 
Macrophages, endothelial 
cells, T cells 
Stem cells 
Differentiation and growth of stem cells and monocytes 
progenitors. Development of osteoclasts.  
(Shi et al., 2006) 
VEGF 
Macrophages, endothelial 
cells, fibroblast 
Stem cells, 
endothelial cells 
Stimulation of endothelial cells. Angiogenesis 
(Ferrara et al., 
1992) 
FGF-2 Fibroblast, macrophages Fibroblast Angiogenesis wound healing, embryonic development. (Yun et al., 2010) 
IL-2 T cells 
Activated T and B 
cells 
Proliferation and activation, Development of T 
regulatory cells 
(Malek, 2003) 
IL-3 T cells, NK cells Stem cells Hematopoietic precursor proliferation and differentiation 
(Lindemann and 
Mertelsmann, 
1993) 
IL-4 Th cells 
B cells, T cells, 
Macrophages 
The proliferation of B and Tc cells, IgG and IgE 
production 
(Brown and Hural, 
1997) 
IL-5 Th cells B cells, Eosinophil IgA and IgM production, maturation and proliferation 
(Greenfeder et al., 
2001) 
IL-7 BM stromal cells Stem cells, T cells B and T cells growth factor 
(ElKassar and 
Gress, 2010) 
TGF- α 
Macrophages, keratinocytes, 
astrocytes 
Various Wound healing, cellular proliferation 
(Snedeker, Brown 
and DiAugustine, 
1991) 
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FLT-3L Lymphocytes, macrophages Lymphocytes Activate hematopoietic progenitors 
(Harada et al., 
2007) 
IL-1RA 
Macrophages, epithelial cells, 
adipocytes 
Various 
Inhibitor of the pro-inflammatory effect of IL-1β and IL-
1α 
(Arend and Gabay, 
2000) 
sCD40L 
Macrophages, endothelial 
cells, muscle cells 
Platelet 
Platelet activation, the release of inflammatory 
mediators, increase the activity of MMP and coagulation 
cascade. 
(Aoui et al., 2014; 
Bou Khzam et al., 
2013) 
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1.8.1 Minimizing the pro-inflammatory nature of NPs 
Strategies to lower the inflammatory properties of CNTs have been implemented by 
using biocompatible polymers. Use of medical grade polycarbonate urethane in the 
functionalization of MWNTs has been shown to significantly reduce TNF-α and IL-
1β production by mouse macrophages. Furthermore, the release of nitric oxide was 
also decreased in mouse macrophages (Khang, 2015). Similarly, Pondman et al have 
shown the reduction in expression of pro-inflammatory cytokines and increased 
expression of anti-inflammatory cytokines (IL-10 and TGF-β) in monocytes and 
macrophages upon exposure to complement deposited CNTs (Pondman et al., 2014; 
Pondman et al., 2016). This suggests that under physiological conditions, the threat 
posed by complement-activating NPs like CNTs and SPION could be lower than as 
observed in vitro and complement deposition might signal the cells to remove the 
NPs swiftly. Though complement deposited CNTs lower pro-inflammatory cytokine 
release but there are no marked decrease in chemokine secretion (Pondman et al., 
2016) Members of IL-1 and TNF receptor families and TLR receptors are thought to 
be involved in inflammation signalling (Dinarello, 2009; Aggarwal et al., 2002; 
Drexler and Foxwell, 2010). Signal transduction to nuclear factor-kappa B (NF-kB), 
a regulator of expression of pro-inflammatory genes, through these receptors leads to 
transcription of pro-inflammatory cytokines (Ghosh and Karin, 2002). Some NPs 
induce nod-like receptor protein 3 (NLRP3) inflammasome resulting in secretion of 
pro-inflammatory cytokines, IL-1β. DWNTs enhanced the secretion of IL-1β from 
monocytes via NLRP3 activation pathway (Meunier et al., 2012). Interestingly, 
complement-activating NPs could induce the release of various cytokines via 
complement component receptors, C3aR and C5aR (Wolf-Grosse et al., 2017). 
Anaphylatoxins (C5a and C3a) generated during complement activation of IONP 
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trigger C5aR and C3aR to release IL-1β, TNF- α, IL-8, MCP-1 and MIP-1β. 
Blockage of these receptors resulted in a reduction of cytokine release suggesting a 
complement-dependent manner of cytokine secretion (Wolf-Grosse et al., 2017). 
Intravenously administered NPs have the ability to polarize the balance of Th1 and 
Th2 cytokines. Metallofullerenes have been reported to show specific 
immunomodulatory effects on T cells and macrophages and polarized the cytokine 
balance toward Th1 cytokines (IL-2, IFN-γ, TNF- α) by decreasing the production of 
Th2 cytokines (IL-4, IL-5 and IL-6) (Liu et al., 2009)in a mice serum by 
differentiating T cell into Th1 cells in contrast to SWNTs and MWNTs (Wang et al., 
2013).   
1.9 Lung innate immunity and pulmonary surfactant proteins 
The lung innate immune system comprises soluble proteins, leukocytes and the large 
epithelial lining the alveolar surface. Inhaled foreign agents are trapped by the 
mucociliary surface in the airways passage and propelled upward by the force of the 
mucociliary system. Some particles may find them on the alveolar surface where 
they interact with soluble components in alveolar fluids that opsonize the particle and 
alveolar macrophages clear them. Lung innate immune defence is governed by these 
soluble components such as IgG, complement, surfactant and surfactant-associated 
hydrophilic proteins (SP-B and SP-C). 
Pulmonary surfactant is a multi-layered lipoprotein constituted of up to 10% 
proteins and 90% lipid (Goerke, 1998).  These lipoproteins line the alveolar 
epithelial surface and perform two important functions in the lung; defence against 
microbial infection and reduction of alveolar surface tension. Four surfactant 
proteins (SPs); SP-A (5.3%), SP-B (0.7%), SP-C (0.4%) and SP-D (0.6%) are found 
associated with surfactant lipids (90%) (Kishore et al., 2002; Weaver and Whitsett, 
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1991).  SP-B and SP-C are small hydrophobic proteins having the main role in 
reducing surface tension, phospholipid packaging and adsorption and organization of 
air-liquid interface (Ding et al., 2001; Tchoreloff et al., 1991).  SP-A and SP-D are 
large collagenous and hydrophilic proteins. They have an important role in surfactant 
homeostasis, a defence mechanism against pathogens and allergens (Kishore et al., 
2002; Kishore et al., 2006). SP-A and SP-D have a multimeric structure similar to 
C1q and MBL and belong to a family of mammalian C-type lectins, called collectins. 
The primary structural organization consists of a cysteine-containing N-terminal 
region, a triple-helical collagen region composed of repeating Gly-X-Y triplets, an α-
helical coiled-coil neck region, and a globular structure at the C-terminal comprising 
a C-type lectin or CRD (carbohydrate recognition domain) (Figure 1-8) (Kishore et 
al., 2006; Crouch et al., 1994). CRD region binds to invading pathogens, 
carbohydrate, phospholipid, etc. in a Ca
2+
dependent manner. SP-A has a hexameric 
structure consisting of 6 structural subunits of 105 kDa each to form a molecule of 
630 kDa (King, Simon and Horowitz, 1989). Each polypeptide is held together by 
disulphide bonds located in the N-terminal halves of the chains forming a similar 
structure to C1q (Figure 1-8).  SP-D is composed of oligomers of 130 kDa each 
subunit comprising of three identical polypeptide chains of 43 kDa, assembled into a 
520-kDa tetrameric structure. Presence of trimeric, dimeric and monomeric SP-D is 
also reported. SP-D might undergo further oligomerization to form multimeric SP-D 
of up to 96 CRDs (Crouch et al., 1994). 
1.9.1 Functions of SP-A and SP-D 
SP-A and SP-D bind to carbohydrate moiety present on various self and non-self 
ligands via CRD region in a calcium-dependent manner (Ogasawara, Kuroki and 
Akino, 1992; Ogasawara et al., 1994). Gardai et al have shown that both SP-A and 
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SP-D binds to LPS and apoptotic cells via CRD regions and interacts with 
macrophages via collagen region thereby inducing phagocytosis, pro-inflammatory 
cytokine production and enhancement of adaptive immune response (Gardai et al., 
2003). Both SP-A and SP-D are very versatile proteins and play an important role in 
dampening inflammation and allergic reactions, binding to various fungi and 
opportunistic fungal pathogens and enhancing phagocytosis. SP-A and SP-D are also 
found in the non-pulmonary region such as in gastric tract, urinary tract, and female 
reproductive tract and in amniotic fluid and highly expressed during labour. They 
play a role in non-antibody-mediated innate immune responses such as modulation 
of host defence and inflammation. Some of their functions are summarized in Table 
1-6.  
 
Figure 1-8: Multimeric structure of SP-A and SP-D. 
SP-A and SP-D are assembled from three-polypeptide subunit. Six and four 
structural unit assembles at cysteine-rich N-terminal to form SP-A and SP-D 
respectively.  SP-D and SP-A have N-terminal triple-helical collagen region, 
followed by a trimerizing alpha-helical coiled neck region and C-terminal 
homotrimeric carbohydrate recognition domain (CRD). (Image is taken from (Jakel 
et al., 2013) 
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Table 1-6: The diverse function of SP-D, SP-A, and a recombinant fragment of human SP-D (rfhSP-D)] 
 Functions SP Reference: 
L
u
n
g
 h
o
m
o
eo
st
a
si
s 
P
ro
p
er
ti
es
 Control the secretion and uptake of phosphatidylcholine to regulates its own 
secretion by type II cells 
SP-A 
 
(Dobbs et al., 1987; Rice et al., 
1987) 
Protect surface activity properties of surfactant 
from functional inhibitors such as fibrinogen and albumin. 
 
SP-A 
(Cockshutt, Weitz and Possmayer, 
1990) 
Inhibition of lung phospholipase A2 that promote inflammation during lung 
disease.  
SP-A 
SP-D 
(Fisher, Dodia and Chander, 
1994) 
Formation of tubular myelin such as tubular myelin  
SP-A 
(Suzuki, Fujita and Kogishi, 
1989) 
Lung remodelling in idiopathic pulmonary fibrosis by regulating 
macrophages, fibrocytes, cytokine expression 
 
SP-D 
(Aono et al., 2012) 
Regulates surfactant phospholipid homeostasis and maintain type II cells 
morphology. 
SP-D (Korfhagen et al., 1998; Botas et 
al., 1998) 
A
n
ti
-v
ir
a
l 
p
ro
p
er
ti
es
 
Influenza A virus inactivation by inhibiting hemagglutination and promote 
viral precipitation and aggregation  
SP-A 
SP-D 
(Hartshorn et al., 1997; Hartshorn 
et al., 2010) 
Defence against respiratory syncytial virus and adenovirus SP-A 
SP-D 
(Hartshorn et al., 2010) 
Enhancement of phagocytosis by macrophages and superoxidative burst by 
neutrophils 
SP-A 
SP-D 
(Hartshorn et al., 1994; Hartshorn 
et al., 1996) 
Binds to glycosylated HIV envelope protein, gp120 of HIV and inhibit its 
binding to CD4 T cells 
SP-A 
SP-D 
(Madsen et al., 2013; Gaiha et al., 
2008) 
A
n
ti
-
b
a
ct
er
ia
l 
p
ro
p
er
ti
es
 Antibody-independent pathogen recognition and clearance of H.pylori 
interacting with O-antigen causing immobilization and aggregation 
SP-D (Khamri et al., 2005) 
Agglutinates E.coli, Salmonella, Pseudomonas aeruginosa, Klebsiella 
pneumoniae 
by interacting with lipopolysaccharides and phospholipids. 
SP-D (Kuan, Rust and Crouch, 1992; 
Kishore et al., 1996) 
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Binding to Mycobacterium and increases fusion of phagosomes with 
lysosomes. 
SP-D 
SP-A 
(Ferguson et al., 2006; Fergusonet 
al., 1999; Lemos, McKinney and 
Rhee, 2011) 
Aggregate and opsonizes H. influenza type A SP-A (McNeely and Coonrod, 1994) 
Modulate reactive oxygen and nitrogen intermediates in the killing of 
Mycobacterium spp, Mycoplasma pulmonis 
 
SP-A 
SP-D 
(Weikert et al., 2000; Hickman-
Davis et al., 1999) 
Protection in ocular S. aureus infection SP-D (Zhang et al., 2015) 
Binds to flagella of Pseudomonas aeruginosa enhancing phagocytosis but 
induction of IL-1 through inflammasome pathway 
SP-A (Ketko et al., 2013) 
A
n
ti
-f
u
n
g
a
l 
p
ro
p
er
ti
es
 
Growth inhibition of Histoplasma capsulatum by increasing the permeability 
of the cell membrane 
SP-A 
SP-D 
(McCormack et al., 2003) 
Agglutination of C. neoformans and A. fumigatus SP-D 
SP-A 
(Schelenz et al., 1995)(Madan et 
al., 1997) 
Reduction in the growth of fungal hyphae of Aspergillus fumigatus in murine 
lungs. 
SP-D (Singh et al., 2009) 
Binds to glycoproteins secreted by Pneumocystis jirovecii and S. cerevisiae SP-D 
SP-A 
(Zimmerman et al., 1992; Allen, 
Voelker and Mason, 2001) 
Enhance the phagocytosis of C.neoformans by murine alveolar macrophages SP-D 
SP-A 
(Geunes-Boyer et al., 2009) 
Binds to -glucan on the surface of B. dermatitidis blocking the access to 
receptors on alveolar macrophages to stimulate TNF- production. 
SP-D (Lekkala et al., 2006) 
A
ll
er
g
en
s 
a
n
d
 
H
y
p
er
se
n
si
ti
v
it
y
 
Reduces allergic responses in mice sensitized to house dust mite allergens. rfhSP-D (Strong et al., 2003) 
Suppresses basophil activation and Th2 cytokine production and IgE 
synthesis in response to grass pollen. 
rfhSP-D (Qaseem et al., 2017) 
Binds to pollen grains, Aspergillus fumigatus allergen, Afu and inhibit 
specific IgE bindings to allergens 
SP-A 
SP-D 
(Madan et al., 1997b; Malhotra et 
al., 1993; Kishore et al., 2002) 
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Inhibition of the differentiation of Th2 cells in the nasal mucosa, reduced the 
level of Th2 cytokines, inhibition of increase of specific IgE production in 
Allergic rhinitis 
SP-A (Ren et al., 2013) 
Increase in selective induction of phagocytosis of allergic eosinophil in 
inflammation 
rfhSP-D (Mahajan et al., 2008) 
Enhance binding, aggregation and phagocytosis of starch granules containing 
grass pollen allergens via alveolar macrophages. 
Dodecame
ric SP-D 
(Erpenbeck et al., 2005) 
M
o
d
u
la
ti
o
n
 o
f 
a
p
o
p
to
si
s 
a
n
d
 
n
ec
ro
ti
c 
ce
ll
s Binds genomic DNA, apoptotic cells and enhance their clearance SP-D 
SP-A 
(Palaniyar et al., 2003; Vandivier 
et al., 2002) 
Attenuates sepsis-induced acute pancreatic injury through modulating 
apoptosis and NF-kB mediated inflammation 
SP-D (Liu et al., 2015) 
Induction of apoptosis in pancreatic cancer cell lines via Fas-mediated 
pathway 
rfhSP-D (Kaur et al., 2018)Frontiers in 
immunology, in press 
P
u
lm
o
n
a
ry
 
in
fl
a
m
m
a
ti
o
n
 a
n
d
 
si
g
n
a
ll
in
g
 
Downregulation of IL-13 and IL-5 responsible for eosinophilia and lung 
tissue damage. 
SP-A (Erpenbeck et al., 2006) 
Binds to calreticulin/CD91 receptor complex and initiates a pro-
inflammatory response through NF-kB activation 
S.nitrosyla
ted SP-D 
(Guo et al., 2008) 
Chemotaxis: CRD region of SP-D and collagen region of SP-A being 
chemotactic 
 
SP-D 
SP-A 
(Madan et al., 1997a) 
Enhancement of TNF-α, IL-1α, IL-1β, IL-6 and IFN-γ production by human 
PBMCs 
SP-D 
SP-A 
(Wright, 2005) 
N
o
n
-
p
u
lm
o
n
a
ry
 
fu
n
ct
io
n
 
in
 t
h
e 
F
em
a
le
 
re
p
ro
d
u
ct
iv
e 
tr
a
ct
, 
p
re
g
n
a
n
cy
, 
U
ri
n
a
ry
 
tr
a
ct
, 
g
a
st
ro
in
te
st
in
a
l 
tr
a
ct
 
a
n
d
 
ti
ss
u
e 
re
m
o
d
el
li
n
g
 
Innate immune protection against sexually transmitted infection caused by 
Chlamydia 
SP-A 
SP-D 
(Oberley et al., 2004) 
Protects amnion and amniotic cav ty from inflammation during pregnancy 
and preventing preterm birth 
SP-A (Lee et al., 2010) 
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Regulation of onset of labour by inhibiting TNF- production in response to 
prostaglandin F2α released by intrauterine tissue macrophages 
SP-D 
SP-A 
(Alcorn and Wright, 2004; 
Norwitz, Lopez Bernal and 
Starkey, 1992) 
Suppress preterm delivery and inflammation via TLR2 signalling SP-A (Agrawal et al., 2013) 
 
Role in intrauterine tissue remodelling during parturition and controls 
inflammation during pregnancy 
SP-D (Nadesalingam et al., 2003; 
Groeneveld et al., 2005) 
Reduces bacterial (E.coli) adherence to the human bladder and inhibit the 
growth 
SP-A 
SP-D 
(Hu et al., 2016) 
Control inflammatory bowel disease, Crohn‟s disease and necrotising 
enterocolitis 
SP-A 
SP-D 
(Saka et al., 2016; Quintanilla et 
al., 2015) 
Upregulation during inflammation of salivary gland and periodontal diseases SP-A 
SP-D 
(Schicht et al., 2015) 
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1.9.2 Ligands and receptors for SP-A and SP-D 
The wide range of functions of SP-A and SP-D is due to their ability to bind and 
interact with various molecules and receptors expressed on micro-organisms, viruses, 
pathogens, self and non-self agents, apoptotic and necrotic cells via their collagens or 
CRD region. They recognize bacteria, fungi and viruses by binding to surface 
carbohydrates such as mannose, fucose, glucose, galactose, N-acetylglucosamine 
residues mainly through the CRDs region in a calcium-dependent manner (Persson, 
Chang and Crouch, 1990; Childs et al., 1992). However, LPS and phospholipids 
require alpha-helical neck region of SP-D to facilitate CRD region to bind them. SP-
A binds to lipid derivatives such as dipalmitoylphosphatidylcholine (DPPC) (Kuroki 
and Akino, 1991) glycolipids (Kuroki et al., 1992) phosphatidylserine (Jakel, Reid 
and Clark, 2010) via CRD region in sugar moiety independent manner. Furthermore, 
both, SP-D and SP-A have been shown to bind nucleic acid (DNA and RNA), 
predominately by SP-D, for the clearance of apoptotic and necrotic cells via their 
CRDs as well as collagen-like regions (Palaniyar et al., 2003; Palaniyar et al., 2004). 
SP-D and SP-A interact with cell-surface receptors such as SPR-210, CD14, 
calreticulin-CD91 complex, SIRP, TLR4, MD-2 and CR3, and binds to soluble 
molecules (ligands) (Gp 340, MPO, C1q, Ig, defensins, decorin) acting as receptors. 
The mechanism of bindings and their functions are summarized in Table 1-7 
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Table 1-7:Ligands and receptors of SP-A and SP-D 
 Protein Cells expressing Protein and 
domain 
Mechanism/ 
functions 
Reference 
L
ig
a
n
d
s 
Glycoprotein 
(Gp) 340 
Soluble proteins/opsonin SP-A / SP-D 
CRD region 
Ca
2+
 dependent protein-protein interaction  (Holmskov et al., 1997) 
Myeloperoxidase 
(MPO) 
Neutrophils SP-A / SP-D 
CRD region 
Ca
2+ 
independent binding to late apoptotic 
neutrophils expressing MPO 
(Jakel et al., 2010) 
C1q Soluble proteins SP-A / SP-D 
CRD region 
Ca
2+
 dependent (Watford et al., 2002; Oosting 
and Wright, 1994) 
Igs (IgG, IgM, IgE, 
secretory IgA) 
Soluble opsonins SP-A 
rfhSP-D, CRD 
region 
Ca
2+ 
dependent binding to Fab and Fc 
domain of Ig. 
(Oosting and Wright, 1994; 
Qaseem et al., 2017; Lin and 
Wright, 2006) 
Defensins Neutrophils SP-D/Neck and or 
CRD region 
Ca
2+ 
dependent binding to Neck /CRD 
region of SP-D 
(Hartshorn et al., 2006) 
Decorin Endothelial cells, tumour cells SP-D 
CRD region 
Ca
2+ 
dependent binding to a sulfated moiety 
of decorin  
(Nadesalingam et al., 2003) 
R
ec
ep
to
r
 
SPR-210/ 
mysosin 18A 
Bone marrow-derived macrophages, 
Alveolar macrophages type II cells 
SP-A 
Collagen region 
Phagocytosis, inhibition of T-cell 
proliferation,  
(Chroneos et al., 1996; Yang 
et al., 2005) 
CD14 Alveolar macrophages SP-A(Neck 
region) 
SP-D(CRD) 
Modulation of CD14-LPs interaction and 
release of pro-inflammatory cytokines 
(Sano et al., 2000; Sano et al., 
1999) 
Calreticulin-CD91 
complex 
Ubiquitous SP-A/SP-
D(Collagen 
region) 
Phagocytosisandproduction of pro-
inflammatory cytokines 
(Vandivier et al., 2002) 
Signal-inhibitory 
regulatory protein 
α(SIRP α) 
Myeloid cells, neurons, B-cells, APCs, 
Endothelial cells 
SP-A / SP-
D(Collagenous 
region) 
Inhibition of pro-inflammatory cytokine 
production 
(Gardai et al., 2003) 
TLR2, TLR4 MD-2 Macrophages, B-cells, T-cells, Endothelial 
cells 
SP-A, SP-D(CRD) Modulation of cellular response through 
TLRs 
(Nie et al., 2008; Yamada et 
al., 2006) 
CR3(CD11b, CD18) Alveolar macrophage,macrophage, NK and 
T cells 
SP-A(CRD) Enhance CR3 mediated phagocytosis (Gil, McCormack and Levine, 
2009) 
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1.9.3 Pulmonary toxicity and immune reactivity due to NPs 
Animal models demonstrated that SP-D expression is upregulated in thelung in 
response to carbon nanotubes exposure (Clement et al., 2008; Kang et al., 2010). 
Inhaled or instilled, the NPs are expected to come in contact with innate immune 
molecules in the lungs such as SP-A and SP-D. In this study, we have examined the 
interaction between SP-D and CNTs and possible downstream effects on the immune 
response via macrophages response (Chapter 4).  
Due to the potential use in the area of electronics, automobiles, constructions, 
aerospace, and medicine, occupational exposure to carbon NPs is considerably higher. 
Inhaled NPs deposit in the lung and interact with lung surfactant components before 
cellular interactions (Lundqvist et al., 2008). Extracellular molecules such as 
fibrinogen, fluid can modulate NPs properties, reduce surface charge as measured by 
zeta potential and promote particle agglomeration (Kendall, Ding and Kendall, 2011). 
Once inside the airways, NPs adsorb onto the mucosal surface and pulmonary surfactant 
lining of the lower airways. Similar to the formation of plasma corona in blood, 
pulmonary biological molecules form a corona, which influences the clearance, 
bioavailability and toxicity of the NPs (Kendall and Holgate, 2012). Human exposure to 
MWNTs at manufacturing sites and its consequences on human health was first 
examined by Lee et al (Lee et al., 2015) and shown to have higher levels of oxidative 
stress markers such as malondialdehyde (MDA), 4-hydroxy-(2E)-hexanal (4-HHE) and 
n-hexanal.  Fibrogenic and tumorigenic potential of CNTs have also been reported 
(Voronkova et al., 2017; Luanpitpong et al., 2014b). However, the extent of damage to 
the lung is partly determined by physical properties like diameter and length and partly 
by fibrous or straight nature of CNTs (Luanpitpong et al., 2014b).  Mercer et al showed 
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the progressive presence of collagen deposition in the mouse lung over a period of 11 
months post-exposure to long MWNTs (Mercer et al., 2011)  
Granuloma formation and fibrosis after intratracheal instillation of SWNTs in 
mice have also been reported (Lam et al., 2004; Ryman-Rasmussen et al., 2009).  Lung 
exposure to MWNTs has been shown to stimulate inflammatory cytokine and 
chemokine secretion, production of fibrogenic growth factors such as TGF-β and PDGF 
that can promote the transformation of lung fibroblasts into myofibroblasts; a potential 
mechanism in human lung fibrosis (He et al., 2011). Similarly, an increased cellular 
influx in BALF (Bronchoalveolar lavage fluid), altered expression of genes involved in 
cell cycle and microtubule assembly and interstitial pneumonia were observed after 
exposure to small (0.8 ± 0.1μm in length) and long CNTs (4 ± 0.4 μm in length). Only 
long CNTs caused early inflammation by infiltration of neutrophils, eosinophils and 
macrophages, DNA strand break and induction of hepatic fibrosis as indicated by 
expression of fibrosis-associated genes such as matrix metallopeptidases (MMP) 12, 
Mmp12 in mouse lungs (Poulsen et al., 2015). Recently, Kinaret et al have 
demonstrated that inhalation and low-dose aspiration of long rod-like CNTs (~13μm in 
length) enhanced accumulation of neutrophils in the airways and giant cell formation in 
a mouse model (Kinaret et al., 2017). Such size dependent variability in the in vivo 
results can be attributed to the variations in CNT types; multiwalled, double walled, 
single-walled; shape and size, metal contamination, aggregation, route of administration 
and surface coating (Madani, Mandel and Seifalian, 2013). A link between inhalation of 
IONP and COPD (chronic obstructive pulmonary disease) and atherosclerosis has been 
suggested due to increase in iron oxide-mediated oxidation of α1-antitrypsin and low-
density lipoprotein in an alveolar-capillary co-culture model (Sun et al., 2016). Rats 
exposed to magnetite dust particles showed increased neutrophils in BALF and 
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eosinophilic globules in lower and upper respiratory tract, concomitant with 
translocation of particles into local lymph nodes (Pauluhn, 2012).  
1.10 Genomic toxicity associated with NPs 
SWNTs have been shown to cause alveolus haemorrhage, infiltration of alveolar 
macrophages and neutrophils in a mouse model after intra tracheal instillation, without 
leading to tumour formation (Naya et al., 2012). However, chronic exposure of the non-
tumorigenic human lung epithelial cell to SWNTs induced the appearance of cancer 
stem cell (CSC)-like properties as evident by over expression of stem cell markers such 
as SOS2, SOX17 and repression of E-cadherin (Luanpitpong et al., 2014a). 
Furthermore, tumour formation has been observed when these CSC-like cells were 
implanted subcutaneously into mice (Luanpitpong et al., 2014a). It has also been shown 
that induction of tumours in mice was due to overexpression of tumour promoter 
caveolin-1 (Cav-1) and p53 dysregulation in lung stem-cell-like cells (Luanpitpong et 
al., 2014c). Similar effects of SWNTs, lesser than MWNTs and carboxy functionalized 
MWNTs, were observed in primary human lung fibroblasts upon exposure to SWNTs 
which induced appearance of cancer-associated fibroblast (CAF) cells as indicated by 
overexpression of -smooth muscle actin (-SMA), podoplanin  and increased 
secretion of TGF- (Luanpitpong et al., 2016). Like CSC-like cells, CAF cells also 
induced lung carcinoma in mice subcutaneously injected with CAF cells. Furthermore, 
long-term exposure of mice (1yr post-exposure) to SWNTs (40 g/mouse) and carbon 
nanofibres (40 g/mouse), regardless of the mode of administration (pharyngeal 
aspiration or inhalation), induced oncogenic K-ras mutation in the lung (Shvedova et 
al., 2014). This potentially suggests the tumourigenic activity of CNTs. Exposure to 
MWNTs has been shown to induce genetic aberration and can induce tumours if 
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humans are co-exposed to mutagens like cigarette smoke and particles present in diesel 
fumes such as radon (radioactive noble gas), naphthalene (polycyclic aromatic 
hydrocarbon) and anthracene (polycyclic aromatic hydrocarbon) acting as initiators of 
tumour formation (Sargent et al., 2014). The presence of iron contamination in CNTs 
has been related to ROS generation, which could account for the observed 
genotoxicities. CNTs have been shown to physically interact with DNA in G-C rich 
regions (Kato et al., 2013; van Berlo et al., 2012). Furthermore, CNTs, irrespective of 
their physical properties, induce DNA strand breaks, the formation of gammaH2Ax foci 
(a marker of double DNA strand breakage) and activation of poly(ADP-
ribose)polymerase (PARP) enzyme for DNA repair in lung epithelial cells (van Berlo et 
al., 2012). CNTs have also been linked to interfering with cell division by inducing 
aneuploidy, formation of three spindle poles, centrosome and microtubules 
fragmentation and cell division arresting in G1/S and G2/M phase in human small 
airway epithelial cells (SAEC) (Siegrist et al., 2014). Further to their toxicities to 
humans and other animals, CNTs have been shown to physically interact with aquatic 
microalgae causing oxidative stress, agglomeration, and inhibition of photosynthesis 
(reviewed in (Jafar, Alshatti and Ahmad, 2016). 
 IONPs, on the other hand, are generally considered safe due to their 
biocompatibility and have shown no severe side effects and toxicity in vivo, therefore, a 
few SPIONs are already FDA approved for use in the clinical settings as MRI contrast 
agents and also as iron supplement, others are still undergoing clinical trials (Jin et al., 
2014). Despite the FDA approval and their usefulness, there are continuous 
controversies on their toxicity. Oxidative stress caused by ROS generation by metallic 
NPs are well documented in various studies (Abdal Dayem et al., 2017; Fu et al., 2014; 
Qiu et al., 2016). Buzea et al have demonstrated that ROS generation and oxidative 
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stress development would lead to an inflammatory response (Buzea, Pacheco and 
Robbie, 2007).  One of the proposed mechanisms of inflammatory signalling and 
response is via modulating intracellular calcium concentration (Moller et al., 2010). 
Dextrose functionalized SPION are found to cause DNA strand break as evident by 
comet assay in a dose-dependent manner. Furthermore, genotoxicity in human 
hepatoma (HepG2) cells line was also evaluated by observing micronucleus formation, 
which was due to reactive oxygen species (ROS) generation (Seo et al., 2017).  High 
ROS levels have been linked to lipid peroxidation, protein oxidation, DNA aberration 
and mitochondrial damage. These disruptions can lead to up-regulation of calcium-
dependent signalling mechanisms resulting in an imbalance of homeostasis and 
ultimately in cell apoptosis and death (Stroh et al., 2004). ROS production as a key 
mediator of cytotoxicity has been further proven by depletion of glutathione and 
inactivation of several antioxidant enzymes as shown in Chinese hamster lung cells 
upon exposure to IONPs (Zhang et al., 2012).  IONPs, upon endocytosis and 
metabolization, release free iron and thus modulate the intracellular iron concentration. 
Iron, due to its ability to switch between ferrous (Fe
2+
) and ferric (Fe
3+
), is essential for 
life. This redox reaction is critical to DNA synthesis, oxygen transport, cytochrome 
P450 function and oxidative phosphorylation (Shander, Cappellini and Goodnough, 
2009). Imbalances in intracellular iron concentration, which is tightly regulated, would 
be extremely toxic. Increases in intracellular iron concentration alter the expression of 
transferrin receptor and cellular proliferation. Furthermore, vital organs with highly 
active mitochondria are likely to be susceptible to toxicity from a high iron 
concentration environment (Huang et al., 2009).  
 There are conflicting and inconsistent results regarding genotoxicity of IONPs 
in various cells regardless of IONP dose and functionality. Micronucleus (MN) tests 
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and comet assays show genotoxicity in MCL5 lymphoblastoid cells (Singh et al., 2012), 
A549 alveolar adenocarcinoma cells (Konczol et al., 2011), murine fibroblast cells (L-
929)  (Hong et al., 2011) and human lung fibroblasts (IMR-90). Similarly, DNA adduct 
formation was observed in human BEAS-2B bronchial epithelial cells but no DNA 
breakage (Bhattacharya et al., 2009). Contradictory to these reports, Karlsson et al 
found no DNA damage in A549 cells upon exposure to IONPs (Fe2O3), although Fe3O4 
produces considerably higher oxidative DNA damage (Karlsson et al., 2009). Similarly, 
no increase in micronucleus formation and DNA damage as revealed by comet assay in 
human lymphoblast cells (Singh et al., 2012) and Syrian hamster embryo cells 
(Guichard et al., 2012) treated with magnetite NPs regardless of functionalization. 
Mutagenic potentials of IONP have also been investigated which turned out to be 
negative in different strains of S. Typhimurium treated with AMI-25 ION and 
ferumoxtran-10, an FDA approved contrast agent (Weissleder et al., 1989; Bourrinet et 
al., 2006). In vivo genotoxicity of IONPs has been studied in mice exposed to Fe3O4, 
which developed DNA-protein crosslinks and oxidative DNA damage in hepatic and 
renal tissues (Ma et al., 2012). In contrast, orally administration of Fe2O3 to wistar rats 
indicated that IONPs were accumulating in the liver, kidney, spleen and bone barrow 
upon crossing intestinal barrier but not inducing genotoxicity as evaluated by the comet 
assay in leucocytes and bone marrow cells (Singh et al., 2013). Intraperitoneal exposure 
to IONPs increased MN frequency in bone marrow cells of mice (Freitas et al., 2002), 
in contrast to reports from Estevanato et al (Estevanato et al., 2011) and Bourinet et al 
(Bourrinet et al., 2006). 
 These studies show that IONPs induce ROS and have the potential to induce 
DNA breaks due to oxidative damage to DNA. However, the ability to cause these 
complications is hugely based on shape, size and functionality of NPs used. 
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Nevertheless, a large percentage of studies are also inconclusive due to inconsistency. 
More studies are needed to pinpoint the underlying DNA damage induced by these NPs. 
1.11 Thesis scope 
The successful translation of nanomedicine from concept through pre-clinical testing to 
therapeutic use in the clinical setting is very challenging.  Despite the tremendous 
medical need for anti-cancer therapeutic and numerous NPs that have been developed to 
meet the requirement, only a few have been approved for use.  The interactions between 
NPs and the immune system is one of the key players in creating such challenges which 
is evident by the withdrawal of approved MRI contrast agents, Feridex, Sinerem, 
Combidex from clinical use on the ground of complement-related side effects and 
hypersensitivity in patients (Banda et al., 2014). In recent years, our understanding of 
the interaction of NPs with the immune system has significantly improved, but several 
questions still remain unanswered. 
Before the biological effects of radiation were known to the scientist, many 
physicians and corporations had marketed radioactive substances like radium as 
patented medicine, Radithor or Radium water and advertised as „cure for the living 
dead‟. However, later on, risk and safety of these radioactive substances were fully 
characterized and they were banned from use as tonic water. Likewise, we do not want 
the history to repeat itself due to the poor characterization of NPs and their use in 
biomedicine. So, a detailed understanding of risks and safety of nanoparticles is needed. 
This thesis combines the development of new NPs with the careful 
characterization of the response of the immune system towards CNTs and IONPs or 
magnetite NPs. In the study of the immune system, the focus lays on the innate immune 
system and the way the response of the complement system influences further immune 
response. 
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The thesis includes 6 chapters. 
Chapter 2: It includes all the methods and methodologies. 
Chapter 3: It includes an in-depth study of a complement protein, properdin and its 
recombinant small fragment, TSR4+5. Properdin, a C3 convertase stabilizer in 
alternative pathway also acts as PRR and bound properdin on CNTs modulates the 
immune response. TSR4+5 on the other hand also adsorb onto NPs and do not allow 
complement pathway activation, unlike properdin and uncoated NPs. TSR4+5: CNT is 
able to inhibit the alternative pathway, which may have potential implications on 
therapeutic drug delivery. On the other hand, we have demonstrated that adsorbed 
properdin on CNTs still retains its bioactivity and can stabilize C3 and C5 components.  
Chapter 4: It includes pulmonary lung surfactant protein D (SP-D) and its bindings to 
NPs and immune modulation.  We found that CNTs coated with a recombinant 
fragment of SP-D (rhSP-D) were cleared by macrophages very rapidly and enhanced 
the production of pro-inflammatory cytokines. However, adding complement 
components on SP-D coated CNTs reduced both phagocytosis and enhanced anti-
inflammatory cytokines release. We have demonstrated that complement deposition can 
be vital in designing NPs that reduce immune modulation.  
Chapter 5: Here, IONPs immune response has been studied particularly; activation of 
the complement system as part of the innate immune response. Analysis of cytokine 
released by macrophages after complement activation and phagocytosis will be 
included. In brief, intracellular localization of IONPs will be discussed. Activation of 
the complement system is generally considered to have an adverse effect. However, we 
show that complement activation by both NPs could have a positive effect on their 
uptake by phagocytes and subsequent immune response by these cells. 
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Chapter 6: It provides the general conclusion and perspectives of the results presented 
in this thesis. 
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2.1 Preparation of NPs (CNTs and IONPs) 
Purified catalytic vapour deposition DWNTs were provided courtesy of Dr E. Flahaut 
(CIRIMAT, Toulouse University, France). Preparation and purification of these CNTs 
were described earlier (Bortolamiol et al., 2014; Flahaut et al., 2003). Dispersion of 
these pristine DWNTs was done using carboxymethyl Cellulose (CMC) (Sigma; CN: 
2101). 1mg of CNTs was added to 2% w/v CMC solution prepared in PBS. The 
solution was ultrasonicated for 2 min. After sonication, the samples were centrifuged at 
8000g for 5 min to remove aggregates. The supernatants were washed by vacuum 
filtering using a 0.2 µm polycarbonate filter (Whatman) with PBS. Functionalized 
CNTs were re-suspended in PBS-EDTA. Magnetic IONP (nano-screenMAG/R) were 
purchased from Chemicell. These particles consist of a magnetite core first covered by a 
lipophilic fluorescence dye and second a layer enveloped with a hydrophilic 
polysaccharide (starch). 
2.2 Transmission electron microscopy contrast staining 
Uranyl acetate and lead citrate stain were prepared to enhance the contrast of organic 
material within the TEM. 
2.2.1 Preparation of uranyl acetate and lead citrate 
Uranyl acetate was dissolved in distilled water until the solution is saturated. Saturated 
solution was filtered through a 0.45m filter and stored in an opaque sealed container 
for up to 1 week. Distilled water was boiled to get rid of dissolved carbon dioxide and 
allowed to cool. 33.1g of lead nitrate, 37.7g of tri-sodium and 4g of sodium hydroxide 
was dissolved in 100ml of cool boiled water and labelled as solution A, solution B and 
solution C.  3ml of solution A and 2ml of solution B was mixed and 16ml of boiled 
distilled water was added. The mixture was stirred and left for 30min. 4ml of solution C 
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was added to the mixture of solution A and solution B to dissolve the precipitate. Thus, 
prepared lead citrate was filtered through a 0.45um filter and stored up to 1 week. 
2.2.2 Staining for TEM 
2 μg of well-dispersed CNTs and protein-coated CNTs were adsorbed onto carbon-
coated grids. The grid was placed on to parafilm and placed on Petri dishes with 
potassium hydroxide on it. 20μl of uranyl acetate was placed onto the grid and 
incubated for 60 min. After incubation, grids were rinsed in distilled water. 20l of lead 
citrate was added to the grid in close proximity to the potassium hydroxide pellets to 
absorb any carbon dioxide. Grids were incubated for 5 min, rinsed in distilled water and 
allowed to dry. Dried grids are ready for TEM inspection. Micrographs were recorded 
using a JEOL 2100 FEG-TEM operating at 80Kv, and the images were processed using 
Gatan microscopy suite software (Gatan, Inc). Surface visualization of CNTs was 
performed using a Zeiss Supra 35vP scanning electron microscope operating at 5 keV. 
2.3 Biotinylation of CNTs 
CNTs were biotinylated as follows:  1 mg of CNTs was suspended in 1 mL 0.1 M MES 
buffer (2-(N-morpholino) ethanesulfonic acid, pH 5.0) (Sigma; CN:1.06126). 1 mg of 
pentylamine biotin (Thermo Fisher Scientific; CN:21345) and 4 µg EDC [1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide] (Sigma) were added in the suspension and mixed 
for 2 h at room temperature and the reaction was stopped by addition of 0.1 M 
ethanolamine (Sigma; CN:E9508). The resulting biotin-CNTs were centrifuged at 
10,000 g for 10 min in order to remove remaining reactants and MES. Finally, labelled 
CNTs were resuspended by sonication using water bath sonicator  (Transsonic t460 
water bath sonicator, 85 Watt, 35 kHz), for 5-10 min. The efficiency of biotinylation 
was determined by incubating 10 µg of biotinylated CNTs with Alexa Fluor 488-
 Chapter II 
 
 72 
conjugated streptavidin(1:1000) (Thermofisher Scientific; CN:S11223) for 1 h and then 
washed extensively via centrifugation at 17,000 g for 10 min three times and re-
dispersed. Dispersed biotinylated CNTs were observed under a Leica microscope and 
images were taken using manufacturer supplied software, Leica application software. 
2.4 Coating of CNTs with Proteins. 
Recombinant full-length human properdin was expressed in human embryonic kidney 
(HEK) cells. Purification of properdin was carried out as explained in Kouser et al. 
(Kouser et al., 2018). MBP fused TSR4+5 and MBP was expressed on E.coli BL21 as 
explained in Kouser et al.(Kouser et al., 2016). Purified properdin and LPS free TSR 
4+5 and MBP was kindly provided by Dr Lubna Kouser (Brunel University) to conduct 
this study. rfhSP-D was expressed in E.coli (λDE3) pLysS and purified as described in 
Pondman et al.(Pondman et al., 2017). Purified LPS free rfhSP-D was kindly provided 
by Dr Anuvinder Kaur (Brunel University) for the study. Purified properdin, TSR4+5, 
MBP or BSA  and rhfSP-D were incubated in a w/w ratio of 2:1 with 100µg of CNTs in 
the affinity buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 5mM CaCl2), overnight at 
4°C. Excess protein was removed by repeated centrifugation and washing at 17000 g for 
10 min to wash away any unbound proteins trapped within the CNTs. CNTs were re-
dispersed in affinity buffer between centrifugations.  
2.5 Complement activation and consumption assay 
2.5.1 Classical pathway 
To examine complement consumption in human serum, CNTs and various protein 
coated 10 µg CNTs, 10 µg of IONP and 10 µg of zymosan (Sigma; CN:Z4250)  as 
positive control were incubated in a ratio 1:1 diluted normal human serum in Dextrose 
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veronal buffer with Mg
2+
 and Ca
2+
 (DGVB 
++
) [2.5 mM sodium barbital (Sigma; 
CN:B0500), 71 mM NaCl, 0.15 mM CaCl2, 0.5 mM MgCl2, 2.5% w/v glucose, 0.1% 
w/v gelatin (Sigma; CN:, pH 7.4) for 1 hr at 37
0
C following the standard protocol for 
complement consumption assay(Whaley and North, 1997). After incubation, NPs were 
centrifuged at maximum speed in a microcentrifuge for 10 min and the supernatant was 
collected. The capacity to lyse antibody-sensitized sheep erythrocytes (EA) (TCS, 
Buckingham) was tested. Sheep erythrocytes were washed twice for 10 min with PBS-
EDTA until the supernatant was cleared and resuspended in DGVB
++
 buffer. Cells were 
adjusted to 10
9
/ml by measuring the absorbance at 540 nm. Absorbance 0.7 at 541nm 
will give approximately 10
9/ml cells. 10μl of haemolysin (Sigma; CN:S1389) was 
added to 1ml of cells and incubated for 15 min at 37
0
C followed by 15 min on ice. Cells 
were washed with PBS and suspended in DGVB
++
 to 10
8
 cells/ml. The serum was 
serially diluted 2-fold (1/10-1/5120) in DGVB
++) in 96 well plate. Then, 100 μl of EA 
cells at 10
8
cells/ml were added to each dilution and incubated for 1 hr at 37
0
C. Total 
haemolysis (100%) was measured by lysing EA with undiluted normal human serum.  
2.5.2 Alternative pathway 
For alternative pathway, CNTs and various protein coated 10 µg CNTs, 10 µg of IONP 
and 10 µg of zymosan (Sigma; CN:Z4250)  as positive control were incubated in a ratio 
1:1 diluted normal human serum in DGVB-MG-EGTA buffer ((2.5 mM sodium 
barbital, 71 mM NaCl, 7 mM MgCl2, 10 mM EGTA, 2.5% w/v glucose, 0.1% gelatin, 
pH 7.4) for 1h at 37
0
C following the standard protocol (Whaley and North, 1997). This 
buffer prevents the activation of classical and lectin pathway because of lack of Ca
2+ 
in 
the buffer. After incubation, NPs were centrifuged at maximum speed in a micro 
centrifuge for 10 min and the supernatant was collected. The capacity to lyse rabbit 
erythrocytes (TCS, Buckingham) was tested. Rabbit erythrocytes were washed by 
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repeated centrifugation for 10min, 700g in PBS + 5mM EDTA, pH 7.4 until the 
supernatant was clear. The cells concentration was adjusted to 1X10
9
/ml in DGVB-MG-
EGTA. The serum samples were serially diluted 2-fold (1/5-1/320) in DGVB-MG-
EGTA and 100μl of rabbit erythrocytes at 109cells/ml concentration was added to each 
dilution and incubated for 1 hr at 37
0
C. After incubation, cells were pelleted by spinning 
(700g, 10min) and released haemoglobin was measured at 541nm in the supernatant.  
2.5.3 Activity of bound properdin in complement consumption 
To check whether the CNTs with bound properdin retained capacity to activate the 
complement alternative pathway, we used properdin deficient serum obtained from the 
properdin gene-deficient mice kindly gifted by Dr Stover, Leicester University. 
Properdin-coated CNTs (properdin-CNT), TSR-coated CNTs (TSR4+5-CNT) and CNT 
alone were incubated with properdin deficient serum (1/2 dilution) in DGVB-Mg-
EGTA buffer and incubated for 1 h at 37
o
C. After incubation, CNTs were removed by 
centrifugation at 17000 g for 10 min, and serum was collected. To each of the collected 
sera, purified properdin (1 g/ml) was added and the reconstituted sera were tested for 
the lysis of rabbit erythrocytes. Rabbit erythrocytes were prepared as described above. 
After incubation, cells were pelleted by spinning (700g, 10min) and released 
haemoglobin was measured at 541 nm in the supernatant.  
2.6 SDS (Sodium dodecyl sulphate) and sample preparation 
SDS-PAGE has carried out bye the method of Laemmli (Laemmli, 1970) to detect 
purified proteins, rhSP-D, TSR4&5 and properdin or adsorbed protein in CNTs. Sample 
was denatured in 2 X treatment buffer (50 mM Tris pH 6.8, 2% β-mercaptoethanol, 2% 
SDS, 0.1% bromophenol blue, and 10% glycerol) and heated at 100
0
C for 7 min prior to 
running on a 12% SDS-PAGE. SDS gel was prepared using the ingredient as shown in 
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Table 3.1. 20ul of the sample was loaded on the gel and ran for 90 min at 120V for 
analysis of the expressed protein in the samples. After the completion of SDS-PAGE, 
the gel was either transferred to nitrocellulose membrane (Thermofisher, CN:LC2006) 
using western blot method or stained using staining solution ((1 g of brilliant blue, 50% 
v/v Methanol, 10% v/v acetic acid, 40 ml d.H2O), and left overnight on a rotary shaker. 
The gel was then de-stained using a de-staining solution (40% v/v methanol, 10% v/v 
acetic acid) for 1 h on a rotary shaker or until the protein bands were visible. 
Table 2-1:  Components and volume for preparing 12% and 15% SDS-PAGE 
Resolving gel 12% 15% Stacking gel  
Components Volume (ml) Components Volume (ml) 
dH2O 3.3 2.3 dH2O 3.4 
30% Bis-Acrylamide  4 5 30% Bis Acrylamide  0.83 
1.5M Tris-HCl, pH8.8 2.5 2.5 1.0M Tris-HCl, pH6.8 0.63 
10% SDS  0.1 0.1 10% SDS 0.05 
10% APS (Ammonium 
Persulfate) 
0.1 0.1 10% APS 0.05 
TEMED 
(Tetramethylethylenedia
mine) 
0.015 0.015 TEMED 0.014 
2.7 Western blot 
Initially, an SDS-PAGE is prepared to separate protein based on their molecular weight 
as mentioned above. The protein bands were transferred on to a nitrocellulose 
membrane in transfer buffer (25 mM Tris, 192 mM Glycine, 20% v/v methanol, pH 8.3) 
at 320 mA for 2 h. The membrane was then blocked with 5% semi-skimmed milk 
powder (Tesco, UK) in PBS, pH 7.4 overnight at 4°C and washed with 20ml 1X PBS.  
Rabbit anti-human properdin (0.92 mg IgG/ml) polyclonal antibodies (donated by Prof. 
R.B Sim, Oxford University) were diluted 1:500 in PBS and incubated with the 
membrane for 2 h at room temperature. The membrane was washed three times, 10 min 
each, with PBS + 0.05% Tween 20 (PBST). Protein A-Horseradish peroxidase (PA-
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HRP; 1:1000) (Thermo Scientific, CN:21041) in PBS was added and left at room 
temperature for 1 h. The blot was washed again with PBST three times and the colour 
was developed using 3,3‟-diaminobenzidine (DAB) (Sigma-Aldrich, CN:8001)). 
2.8 Fluorescence Microscopy 
2.8.1 Cell culture and differentiation of monocytes 
THP-1 cells(ATCC TIB-202), Human embryonic kidney (ATCC 87258) and U937 
(ATCC CRL-1593.2) were maintained in complete RPMI 1640 (Sigma, CN: R6504) 
containing 10% v/v Fetal Bovine Serum (FBS) (Thermofisher, CN:11573397), 2 mM 
L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (Thermofisher, 
CN:15140122) and 1 mM sodium pyruvate (Thermofisher, CN:11360039). 
Differentiation of monocytes, THP-1 and U937, into macrophages was carried out with 
100 nM Phorbol myristate acetate (PMA) (Sigma, CN:P8139) for 24 h. Differentiated 
cells were washed three times with PBS to remove excess PMA and then rested for 
another 24 h in complete RPMI media prior to the experiment. 
2.8.2 Microscopy of uptake of CNTs 
Uptake of biotinylated CNTs, coated with various proteins or uncoated was examined 
using differentiated THP-1 macrophages. For fluorescence microscopy, 1 x 10
5 
THP-1 
cells were plated and differentiated with PMA on 13 mm coverslips in complete RPMI 
1640 medium. Differentiated cells were exposed to 4 μg/ml biotinylated CNT, proteins 
coated or uncoated in 500 µl of serum-free RPMI medium for 2 h. After washing the 
cells with PBS, cells were fixed with 4% paraformaldehyde (PFA) (Sigma, CN:158127) 
for 10 min. Coverslips were washed, mounted on mounting slide and processed for 
fluorescence microscopy. The cells on coverslips were permeabilized using a 
permeabilizing buffer (20 mM HEPES pH 7.4, 300 mM sucrose, 50 mM sodium 
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chloride, 3 mM MgCl2, 0.5% Triton X-100) for 5 min on ice and then stained for 30 
min with Hoechst 33342 (1:10,000) (Thermofisher, H3570 ), Alexa-Fluor546-
conjugated wheat germ agglutinin (1:250) (ThermoFisher, W11261) and Alexa fluor 
488-conjugated streptavidin (1:500) (Thermo Scientific, CN:S11223)  to reveal 
biotinylated CNTs. Cells were washed, mounted on the glass mounting slide using 
Citifluor anti-fade (Citifluor, UK), and viewed under a Nikon Eclipse TE2000-S 
confocal microscope with 62 X oil lens.  
2.8.3 Co-localization of IONPs with dextran (a marker for fluid phase 
endocytosis). 
5x10
4
THP-1 cells were seeded in 24 well plates with 13mm coverslips. Cells were 
differentiated with 100 nM of PMA for 24 h and left to rest for another 24 h. Cells were 
treated with 10ug/ml of complement deposited and undeposited IONPs together with 
100ug/ml of FITC labelled dextran particles (M. wt: 21,200) (Sigma, CN:FD20) for 2 h 
and a further 18h after washing (pulse chase).  After incubation, cells were washed with 
PBS three times and fixed with 4% PFA, mounted and observed under a Leica 
fluorescent microscope using LAS software. 
2.8.4 Co-localization of IONPs with lysotracker 
THP-1 cells were differentiated and maintained on coverslips as described above. After 
incubation and resting for 24h, cells were treated with 10ug/ml of serum coated and 
uncoated IONPs for 2h, 4h, 6h and 24 h continuous exposure as well as for 2h with 
subsequent 18h chase. 15 min prior to the observation, 100 nM of lysotracker green 
(Cell Signalling, CN:8783S) was added to the cells and incubated. Cells were washed 
three times with warm PBS, mounted using imaging medium (140mM NaCl, 2.5 mM 
KCl, 1.8 mM CaCl2, 1.0mM MgCl2, 20mM HEPES, pH=7.4 )on mounting slides and 
observed under a microscope.  
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2.8.5 NF-kB nuclear translocation 
To observe nuclear translocation of NF-κB, 1x105THP-1 cells were differentiated with 
100 nM PMA, as described above, in 13mm of glass coverslip in 24 well plate and 
incubated with 4 μg/ml of rfhSP-D bound CNTs (rhSP-D + CNT), rfhSP-D bound and 
complement deposited CNTs (rfhSP-D + serum + CNT), complement deposited CNTs 
(serum + CNTs), properdin-CNTs, TSR4+5-CNTs or CNTs alone in 500 μl of serum-
free medium for 2 h. Cells were fixed and permeabilized using permeabilization buffer 
for 5 min on ice. The cells were probed with rabbit anti-NF-κB p65 polyclonal 
antibodies (1:250) (Santa Cruz Biotech, CN:sc8008), followed by Alexa Fluor 488-goat 
anti-rabbit antibody (1:500) (Abcam, CN:ab150077), and viewed under a leica 
fluorescent microscope. Images were processed using LAS software. 
2.9 Determination of cytotoxicity of NPs 
Cytotoxicity assay was performed to determine the cytotoxicity of NPs. 1x10
4
of THP-1 
cells per well were differentiated in 96-well cell culture plate and left overnight with 
PMA. Cells were washed and fresh RPMI medium was added and cells were rested for 
another 24h. 10 μg/ml of IONPs and 5 μg/ml of CNTs and their respective complement 
deposited version were added to each well in serum free medium and incubated for 24h. 
0.05% saponin (Sigma, CN:47036) was used as positive control and cell only well was 
used as negative control. After incubation, medium was aspirated and replaced with 100 
μl of fresh culture medium. 12 mM of MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma, CN:M5655) was prepared in sterile PBS. 10 μl of 
12 mM freshly made MTT solution was added to each well and incubated at 37
0
C for 
4h. After incubation, the media was discarded gently and 50ul of DMSO (Dimethly 
sulfoxide) (Sigma. CN: W387520) was added to each well to solubilize the formazan 
crystals and mixed thoroughly shaking on a shaker for 10min. The absorbance of 
 Chapter II 
 
 79 
formazan was read at 540 nm using a BioRad plate reader. Number of viable cells were 
expressed in percentage with respect to negative control (cells only) using the following 
formula:% of viable cells =(Mean absorbance of sample/Mean absorbance of negative 
control)x100%. 
2.10 Quantification of uptake of CNTs 
For quantification, 5 x 10
5
 THP-1 cells were plated in 12 well plates and differentiated 
with PMA for 24h and rested for 24 in complete RPMI media. Cells were washed with 
PBS and challenged with 4 μg/ml biotinylated CNTs coated with properdin (properdin-
CNTs), MBP-TSR4+5 (TSR4+5-CNT), or biotin-CNTs, SP-D or serum deposited SP-D 
in 500 µl of serum-free RPMI medium for 2 h. Cells were washed three times with PBS 
and lysed with lysis buffer (10 mM HEPES, 20 mM NaCl, 0.5 mM EDTA, 1% v/v 
Triton X 100). An ELISA type assay was employed to quantify the number of CNTs 
taken up by THP-1 cells (Pondman et al., 2016). Microtitre wells (NUNC, polysorbate) 
were coated with 100 μl Avidin (Sigma, CN:9275, ) at 50 μg/ml in 0.1 M carbonate-
bicarbonate buffer, pH 9 (Sigma, CN: 08058) for 1 h at RT, followed by blocking with 
0.05% of Bovine serum albumin (BSA) for 1 h at RT. 50 μl of a solution or cell lysate 
containing biotin- CNTs and 50 μl of 0.05% BSA were added in each well and 
incubated for 1 h at RT. The plate was washed with PBS to remove unbound CNTs and 
then incubated with 1:2000 dilution of Streptavidin-HRP (Invitrogen, CN:434323) for 1 
h at RT. Following washing again, O-Phenylenediamine dihydrochloride (OPD) 
(Sigma, CN:P9187) was used as a substrate for the HRP and the yellow 2, 3-
Diaminophenazine product was read at 450 nm using a BioRad plate reader. 
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2.11 Measurement of THP-1 cell cytokine and transcription factor mRNA 
expression using quantitative RT-PCR 
In a 12 well cell culture plate (Nunc), THP-1 cells (1 x 10
6
/well) were differentiated 
with 100 nM PMA in RPMI 1640 complete medium for 24 h and then rested (without 
PMA) for 24 h. Cells were incubated with 5 µg/ml of various protein coated or  CNT 
alone and 10 µg/ml of IONP and various protein coated IONP to wells in serum-free 
RPMI 1640 medium and incubated for 30, 60, 120 or 360 min. Cells at each time point 
were washed with PBS and lysed within the wells using lysis buffer from GenElute 
Mammalian Total RNA Purification Kit (Sigma, CN:RTN350). Total RNA was 
extracted from the lysate using the GenElute Mammalian Total RNA Purification Kit 
(Sigma). To inactivate both DNase I and RNase, samples were heated at 70°C for 10 
min and cooled on ice. The concentration and purity of extracted RNA were determined 
using a NanoDrop 2000/2000c spectrophotometer (Thermo-Fisher Scientific). The 
cDNA was synthesized using High Capacity RNA to cDNA Kit (Applied Biosystems, 
CN:4387406) following manufacturer protocol using 2 g of RNA. Primers (Table 2-2) 
were used and designed using Primer-BLAST(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
The qPCR reaction mixture was prepared following manufacturer protocol 
containing 5μl Power SYBR Green MasterMix (Applied Biosystems, CN:4367659) 
which contains SYBR green dye, DNA polymerase, dNTPs, passive reference and 
optimized buffer components, 75 nM of forward primer, 75 nM of reverse primers and 
500 ng template cDNA.. PCR was carried out in a Step One Plus Real-Time PCR 
System (Applied Biosystems). The initial steps involved 2 min at 50
0
 C and 10 min at 
95
0
 C. The template was amplified for 40 cycles, each cycle consists of 15 s at 95
0
C and 
1 min at 60
0
C.Human 18S rRNA target was used as an endogenous control and data 
were analysed using manufacturer software, the Step One software v2.3. Ct (cycle 
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threshold) values for each cytokine target gene were extracted and relative expression of 
each target gene was calculated using the equation: RQ = 2
-ΔΔCt
 for each cytokine target 
gene and log10 of relative expression (RQ) was plotted, and comparing relative 
expression with that of the 18S rRNA constitutive gene product. 
Table 2-2: Terminal primers used for qPCR analysis 
Targets Forward primer Reverse primer 
18S ATGGCCGTTCTTAGTTGGTG CGCTGAGCCAGTCAGTGTAG 
IL-1β GGACAAGCTGAGGAAGATGC TCGTTATCCCATGTGTCGAA 
IL-6 GAAAGCAGCAAAGAGGCACT TTTCACCAGGCAAGTCTCCT 
IL-10 TTACCTGGAGGAGGTGATGC GGCCTTGCTCTTGTTTTCAC 
IL-12 AACTTGCAGCTGAAGCCATT GACCTGAACGCAGAATGTCA 
TGF-β GTACCTGAACCCGTGTTGCT GTATCGCCAGGAATTGTTGC 
TNF-α AGCCCATGTTGTAGCAAACC TGAGGTACAGGCCCTCTGAT 
NF-κB GTATTTCAACCACAGATGGCACT AACCTTTGCTGGTCCCACAT 
2.12 Multiplex cytokine array analysis 
Supernatant from THP-1 cells, incubated with various protein coated or uncoated CNTs 
for 24 h and 48 h, were collected to measure Secreted cytokines [interleukin (IL)-6, IL-
10, IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, IL-15, IL-17A, IL-9, TNF-β, IFN-α2], 
chemokines [monocyte chemo attractant protein (MCP)-3, interferon gamma-induced 
protein (IP)-10, eotaxin, growth regulated oncogene (GRO), IL-8, MCP-1, macrophage-
derived chemokine (MDC), fractalkine, macrophage inflammatory protein (MIP)-1α, 
MIP-1β, growth factors [vascular endothelial growth factor (VEGF), IL-9, fibroblast 
growth factor (FGF)-2, IL-2, epidermal growth factor (EGF), granulocyte macrophage 
(GM)-CSF, IL-3, granulocyte colony stimulating factor (G-CSF), IL-7], and ligand and 
receptors [FMA like tyrosine kinase 3 ligand (FLT-3L), sCD40L, interleukin 1 receptor 
antagonist (IL-1RA)].  
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The analytes were measured using MagPix Milliplex kit (EMD Millipore) following 
the manufacturer‟s protocol. MagPix Milliplex kit consists of quality controls (QCs) for 
quality assay performance, standard (calibrator) to a reference lot to ensure lot-to-lot 
consistency, optimized assay buffer to mimic native analyte environment, and a cocktail 
of detection antibody for each analyte bound on magnetic beads. MILLIPLEX map is 
based on the Luminex xMAP technology capable of performing a variety of 
immunoassays on the surface of fluorescent-coded magnetic beads known as MagPlex-
C microspheres. Magnetic beads are 6.45m in size and each is coated with antibodies 
against analytes. These antibodies bind to analytes like TNF-, IL-1 etc. Detection 
antibody conjugated with biotin binds to these captured analytes and was detected using 
streptavidin conjugated with phycoerythrin (PE) (Figure 2-1).  
;
 
Figure 2-1: The schematic representation of the principle of the Milliplex assay. 
Fluorescent beads coupled with capture antibody are used to capture analyte target. The 
analyteis detected using biotinylated detection antibody. Detection antibodies are 
detected using streptavidin conjugated with phycoerythrin. The assay is carried out in 
96-assay well plate and read using Luminex Magpix instrument and data is analysed 
using Milliplex analyst software. 
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2.12.1 Preparation of reagents and sample for immunoassay 
Each individual vial of beads was sonicated for 30 seconds and vortexed for 1 minute. 
70 l of each bead were mixed with bead diluent and made the final volume up to 
3.5ml. Diluted beads were mixed welled and stored at 2-8
0
C for up to a month. 
Manufacture provided 10X wash buffer was diluted to a 1X working buffer in deionized 
water. THP-1 supernatant of various time points (24h and 48h) from each experiment 
were stored at -80
0
C. The supernatantwas thawed and centrifuged to remove debris. 
Prior to the use of the assay, all reagents were warm to room temperature. 
2.12.2 Multiplex procedures 
The assay plate was washed with 200 l of wash buffer by shaking for 10 min. Wash 
buffer was discarded from all wells by inverting the plate and tapping it onto absorbent 
several times. 25 l of standard, or control or test supernatant was added.  25 l of assay 
buffer provided by the manufacturer was added to each sample well. 25 l of matrix 
solution was added to the background, standard and control well. Culture medium 
(RPMI 1640) was used as matrix solution. 25 l of a diluted mixed cocktail of magnetic 
beads were added to each well. The plate was sealed with a plate sealer and incubated 
for overnight at 4
0
C. The plate was washed 2 times with 200 l of wash buffer using 
handheld magnet plate washer. 25 l of detection antibodies were added to each well, 
sealed and incubated with agitation on a plate shaker for 1h at room temperature. 25 l 
of streptavidin-PE was added to each well-containing detection antibodies. The plate 
was sealed and incubated again with agitation on a plate shaker for 30 min at room 
temperature. Contents on the plate were washed 2 times with 200 l of wash buffer 
using handheld magnetic plate washer. 150 l of sheath fluid (manufacturer provided) 
was added to each well to serve as the delivery medium to transport the sample to the 
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instrument‟s optics. The beads were resuspended by shaking on the plate shaker. The 
plate was read using Luminex Magpix instrument and results were obtained using 
Milliplex analyst software. Medium fluorescent intensity (MFI) data was exported and 
presented using GraphPad Prism 7.0 software.  
 
2.13 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism version 7.0 (GraphPad 
software). An unpaired to two-sidedt-test and 2 –way ANOVA test was used on the data 
for analysing any significant difference between test samples. P values were computed 
and graphs were compiled and analysed using GraphPad Prism version 7.0. 
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Interaction between human properdin and carbon 
nanotubes 
 
 Chapter III 
 
 86 
3.1 Abstract 
Development of NPs as tissue-specific drug delivery platform can be significantly 
influenced by complement components due to their inherent pro-inflammatory and 
tumorigenic consequences. Activation of complement pathways and interactions with 
recognition subcomponents can modulate the clearance of the NPs and subsequent 
inflammatory response. Such modulation could affect the intended translational 
applications. Here, we report, that human properdin, an up-regulator of the complement 
alternative pathway and stabilizer of C3 convertase, can opsonize CNTs via its 
thrombospondin type I repeat (TSR) 4 and 5. Binding of properdin and TSR4+5 is 
likely via charge pattern/polarity recognition on the surface of NPs. Uptake of properdin 
bound CNTs was enhanced by a macrophage cell line, THP-1, surging a robust pro-
inflammatory immune response, as evident by qRT-PCR, multiplex cytokine array, and 
NF-κB nuclear translocation tests. Thus, properdin interaction with NPs is of 
considerable importance as immune cells can locally synthesize properdin in an 
inflammatory microenvironment. In addition, recombinant TSR4+5 on CNTs, inhibited 
complement consumption, suggesting that TSR4+5, can be potentially used as a 
complement inhibitor in a number of pathological circumstances arising due to 
unintentional complement activation. Furthermore, properdin coated NPs are still 
functionally active and can regulate alternative pathway activation. Properdin-CNTs can 
be used as a platform for drug delivery where properdin deficiency causes susceptibility 
to a range of infections in the condition like a rare X-linked properdin deficiency 
disease in human.  
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3.2 Introduction 
Properdin, a highly positively charged molecule at neutral pH (Smith et al., 1984). The 
human properdin monomer has seven TSRs denoted as TSR0-TSR6. Properdin consists 
of identical monomers of 53 kDa joined with each other in a head-to-tail manner (Nolan 
et al., 1992; Discipio, 1982) to form cyclic polymers (dimers, trimers, and tetramers) in 
a ratio of 26:54:20 (Smith et al., 1984) (Figure 3-1). A recent electronic microscopic 
study has shown that vertexes of oligomeric properdin are formed by four TSR from 
two neighbouring monomers (Alcorlo et al., 2013). Each TSR is 60 amino acids long 
and has sequence similarities with circumsporozoite protein of malaria parasite 
thrombospondin (adhesive glycoprotein) (Dame et al., 1984,Lawler and Hynes, 1986) 
and a membrane-attack component of component C9 (DiScipio et al., 1988). TSR4 and 
TSR5 module in properdin helps in the stabilization of C3 convertase by binding to C3b 
(Higgins et al., 1995; Perdikoulis, Kishore and Reid, 2001; Kouser et al., 2016).  
The concentration of properdin is 25 μg/ml in plasma (Pillemer et al., 1954). 
However, in some condition such as anti-neutrophil cytoplasmic antibody-associated 
vasculitis (AAV), properdin level is lowered (Gou et al., 2013). It can be locally 
secreted by variety of stimulated cells, such as endothelial cells (Bongrazio, Pries and 
Zakrzewicz, 2003), neutrophils (Wirthmueller et al., 1997), dendritic cells (Dixon et al., 
2017), peripheral blood monocytes (Schwaeble et al., 1994), and both CD4
+
 and CD8
+
 
T cells (Schwaeble et al., 1993). Local production of properdin is crucial for immune 
cells such as DCs, macrophages and T cell response. DCs treated with properdin-siRNA 
shown a reduction in proliferation of allogenic T cells and the effect were more 
prominent in combined with IFN- stimulation (Dixon et al., 2017). Furthermore, 
macrophages in properdin-deficient mice have associated with the tumour-promoting 
activity by increasing production in the M2 phenotype (arginase-1, MCP-1 and IL-10) 
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and reducing M1 phenotype (IL-1) thereby, enhancing tumour environment(Al-
Rayahi, Browning and Stover, 2017).  
The structural organization of properdin (multi-subunit, multiple potential 
binding domains, potential multivalency) appears to suggest a possible role as a soluble 
PRR as evident by various published reports. It has been reported to bind to several self 
and non-self-target ligands such as zymosan (Harboe et al., 2012) inducing-antibody-
independent complement activation (Spitzer et al., 2007), rabbit erythrocytes, Neisseria 
gonorrhoeae (Spitzer et al., 2007), apoptotic CD4
+
 T cells facilitated by the 
glycosaminoglycan chains of surface proteoglycans (Kemper et al., 2008), human 
proximal tubular epithelial cells (Gaarkeuken et al., 2008), and cartilage oligomeric 
matrix protein (Happonen et al., 2010). Properdin directly interacts with target ligands 
such as heparin (Yu et al., 2005), heparan sulphate (Zaferani et al., 2012; Kemper et al., 
2008), dextran sulfate, fucoidan (Holt, Pangburn and Ginsburg, 1990), and chondroitin 
sulfate (Kemper et al., 2008). Properdin also binds to activated platelets via surface 
GAGs (Saggu et al., 2013). Properdin, secreted by DCs and tolerogenic DCs can bind 
DNA on late apoptotic and necrotic cells (Ferreira, Cortes and Pangburn, 2010) in a 
C3b-independent manner (Xu et al., 2008) and also bacterial LPS of E. coli (Kimura et 
al., 2008). Furthermore, properdin can also bind to natural cell activating receptor 
(NKp46) on NK cells and innate lymphoid cell (ILC) 1 and ILC3, natural cell activating 
receptor required for the fight against Neisseria meningitidis infections. Properdin‟s 
direct interaction with such large number of cell surface molecules may indicate its 
selective pattern recognition properties and thus, can be hypothesized that it can also 
bind to a wide range of nanotherapeutics. 
Here, we showed that properdin binds to CNTs as a pattern recognition receptor 
via at least TSR4+5 domains, and enhances their uptake by macrophages. Properdin 
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bound CNTs promoted a robust pro-inflammatory immune response. TSR4+5, when 
coated on CNTs, inhibited complement alternative pathway activation, reduced 
macrophage sequestration but induced a robust pro-inflammatory immune response. 
 
 
 
Figure 3-1: Sketch of trimeric properdin (Left) and its TSR modules (Right). 
 
Schematic representation of the modular organization of human properdin including 
thrombospondin type 1 repeats (TSRs) domain. In serum, properdin is found in 
monomers, dimers or cyclic trimer or tetramers joined together with head to the tail 
orientation of monomers made up of seven TSRs domain. N-terminal, TSR0 is 
connected with C-terminal TSR6 thus forming a cyclic structure. TSR4 and TSR5 
domain, main C3b binding domain, are expressed in E.coli. 
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3.3 Results 
3.3.1 Properdin and TSR4+5 bind CNTs. 
Well-dispersed CNTs were incubated overnight with purified recombinant full-length 
properdin as well as TSR4+5 modules. After incubation, CNTs were washed with PBS 
extensively via centrifugation. Western blot analysis showed that properdin and MBP-
TSR4+5 bound CNTs, in their denatured formed, and appeared in the 12% SDS-PAGE 
at their expected molecular weight at ~ 55kDa. However, CNTs remained in the loading 
wells (Figure 3-2). This suggested that properdin and TSR4+5 can bind to CNTs and 
binding to CNTs surface is likely to be through charge pattern/polarity recognition on 
the surface. 
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Figure 3-2: Binding of recombinant full-length properdin and MBP-TSR4+5 to 
CNTs 
(A) SDS-PAGE: CNTs were incubated with recombinant human properdin, or MBP-
TSR4+5 (kindly provided by Dr Lubna Kouser) and BSA overnight in the affinity 
buffer. CNTs were washed extensively via centrifugation and ran on an SDS-PAGE 
(12%) under reducing conditions. Properdin and MBP-TSR4+5 migrated as a single 
band at ~55 kDa and ~53 kDa respectively. (B) Western blot of properdin and 
TSR4+5 binding to CNTS. Separated proteins were blotted onto nitrocellulose 
membrane for 2 h at 320 mA. The blot was blocked with semi skimmed milk and 
probed with anti-human properdin (polyclonal) antibodies, followed by Protein A-HRP 
conjugate and developed using DAB. 
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3.3.2 MBP-TSR4+5 coated on CNTs inhibited complement consumption via the 
alternative pathway 
Properdin-coated and MBP-TSR4+5 coated CNTs were examined for their ability to 
activate the complement alternative pathway compared with uncoated CNTs, zymosan 
(positive control) and serum (negative control). Properdin coated CNTs did not interfere 
with alternative pathway activation; showing the same extent of complement activation 
as CNTs alone and MBP-CNTs. However, TSR4+5-bound CNTs showed ~60% less 
complement consumption. This suggests that the CNT-surface bound TSR4+5 acted as 
an inhibitor of the complement alternative pathway. TSR4+5 have previously been 
shown inhibit complement alternative pathway in solution (Kouser et al., 2016). These 
results suggest that binding of properdin to CNTs is via TSR4+5 domain and that pre-
coated TSR4+5 inhibited the binding of serum properdin, and thereby weakening the 
alternative pathway activation. Properdin-coated CNTs also consumed (activated) the 
alternative pathway (Figure 3-3A), in properdin-deficient serum. Complement 
consumption was upregulated by ~60% compared to uncoated CNTs (Figure 3-3B). 
Complement activation by TSR4+5-coated CNTs was not significant compared to 
uncoated CNTs. This suggested that the properdin activity was not inhibited upon 
binding to CNTs.  
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A) 
 
B) 
 
Figure 3-3: Complement alternative pathway activation by properdin and TSR 
4+5 coated CNTs. 
A) Properdin, TSR4+5, or MBP coated CNTs were incubated with human serum in 1:5 dilution 
with alternative pathway buffer (DGVB-Mg-EGTA buffer) for 1 h shaking at 37°C. CNTs were 
spun down and serum was collected for complement consumption assay. Zymosan and serum 
only were used as positive and negative control respectively. (B) Protein-coated CNTs were 
incubated with mouse properdin deficient serum diluted in 1:2 with DGVB
 -
Mg-EGTA buffer 
for 1h at 37°C. The samples were centrifuged and properdin deficient serum supernatant was 
collected. Collected serum was reconstituted by adding purified recombinant properdin to give a 
final concentration of 1µg/ml. Serum was then assayed for complement consumption. Percentage 
complement consumption was calculated using (C − Ci)/C × 100%, where C represents the % hemolysis 
of the negative control, and Ci is the % hemolysis with the test samples; properdin or TSR4&5 coated 
CNTs or uncoated CNTs or zymosan-treated sampleThe experiments were repeated 3 times; error 
bars represent ± standard deviation. Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and 
***p < 0.001) (a 2-tailed, unpaired t-test between complement consumption of properdin coated 
CNTs and TSR4+5 coated CNTs with CNTs only) 
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3.3.3 Properdin, but not TSR4+5, enhanced CNT uptake by THP-1 cells 
PMA differentiated THP-1 macrophages were challenged with properdin and TSR4+5 
bound CNTs for analysis of their uptake. ELISA results showed that full-length 
recombinant properdin enhanced the uptake of CNTs more than TSR4+5 bound CNTs 
compared to uncoated at 2 h in a complement-independent manner (Figure 3-4B). 
Previous studies reported that pre-coating with C1q enhanced phagocytosis of CNTs by 
U937 monocytes and human monocytes, whereas, factor H, a negative regulator of the 
complement system, inhibited the uptake of CNTs and CNTs were observed adhered on 
the surface of the plasma membrane (Pondman et al., 2015). Here, confocal 
microscopic images showed that properdin-CNTs were significantly taken up more by 
THP-1 cells, as compared to CNT alone and TSR4+5-CNT (Figure 3-4). CNTs (green) 
were observed within the cell membrane boundary as revealed by staining with Alexa 
Fluor 546 conjugated wheat germ agglutinin (red) for plasma membrane and the 
nucleus (Hoechst, blue) (Figure 3-4). The orthogonal confocal sections (right panel) 
revealed Properdin-CNT within the cell; however, very few CNTs could be seen 
intracellular in the case of TSR4+5-CNT (Figure 3-4A). This suggests that full-length 
properdin molecule is required for this function as „opsonin‟. This also indicates that 
macrophage may interact with other TSRs domains, not limited to TSR4+5 only. 
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Figure 3-4: Uptake of biotin-CNTs coated with properdin and TSR 4+5 by 
differentiated THP-1 
A) To observe internalization of CNTs, PMA-differentiated THP-1 cells were treated 
with properdin or MBP-TSR4+5 coated biotinylated CNTs and uncoated biotinylated 
CNTs for 2 h. Cells were washed, fixed, permeabilised and stained with Alexafluor-488 
labelled Streptavidin (green) to reveal internalized biotin-CNTs. Orthogonal views of 
the confocal images demonstrate internal localisation of CNTs (green), plasma 
membrane in red, scale bar 20μm, arrow heads point to the CNTs adhering to the 
plasma membraneB) To quantify the amount of uptake of protein-coated or uncoated 
CNTs, THP-1 cells were incubated with 4μg/ml of protein-coated biotin CNTs or 
uncoated CNTs for 2 h. The cells were lysed and the amount of CNTs was quantified by 
an ELISA type assay. All experiments were done in triplicate; error bars represent 
mean± SDNs: not significant (p>0.05)*p < 0.05, *p < 0.01, and ***p < 0.001)(An 
unpaired t-test, 2-tailed between the uptake of properdin coated CNTs and TSR4+5 
coated CNTs with CNTs only) 
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3.3.4 Pro-inflammatory cytokines are upregulated by both properdin and 
TSR4+5 CNTs 
Properdin-CNT and TSR4+5:CNTs significantly upregulated transcriptional expression 
of TNF-α, IL-1β, IL-6 and IL-12 in THP-1 cells (Figure 3-5). In contrast, IL-10 and 
TGF-β were initially up-regulated at 30 min, but decreased by 6 h, suggesting that the 
anti-inflammatory response was very transient and dampened later. Consistent with the 
up-regulation of TNF-α, properdin and TSR4+5 coated CNTs upregulated the 
expression of NF-κB at 6h incubation. However, the NLRP3 expression was not 
significant in all cases, suggesting that none of the CNTs activated NLRP3 
inflammasome formation.  
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Figure 3-5: Cytokine gene expression profile of THP-1 cells treated with properdin 
or TSR 4+5 coated or uncoated CNTs. 
mRNA expression of pro- and anti-inflammatory target genes were measured. THP-1 
cells were incubated with coated and uncoated CNTs for 30 min, 1h, 2h and 6h (X-
axis). The data were normalized using 18S rRNA gene expression as an endogenous 
control. Error bars represent ± S.D. Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, 
and ***p < 0.001)(A 2-way ANOVA test between properdin or TSR4+5 coated CNTs 
with uncoated CNTs. 
 
 Chapter III 
 
 99 
3.3.5 Properdin or TSR4+5 CNTs up-regulate pro-inflammatory 
cytokines/chemokines and other soluble factors in THP-1 cells 
Multiplex array analysis on supernatants collected at 24 h and 48 h time points from the 
phagocytosis assay showed a dramatic increase in the secretion of pro-inflammatory 
cytokines (IL-1α, IL-1β, TNF-α, IL-6, IL12p40, IL12p70, IL-13, IL-15, IL-9) (Figure 
3-6) for both properdin-CNTs and TSR4+5-CNTs. There was an enhancement in 
chemokinereleases, such as MCP-3, MDC, Eotaxin, Fractalkine, GRO, IL-8, IP-10, 
MCP-1, MIP-1α (Figure 3-7) by properdin and TSR 4+5-CNTs. A number of anti-
inflammatory cytokines, chemokines, growth factors and immune ligands were also 
differentially regulated by exposure to protein-coated CNTs.  This suggests that 
properdin and its small fragment, TSR4+5 are very pro-inflammatory in nature when 
bound to NPs. Furthermore, properdin and TSR 4+5 have been shown to both enhance 
the chemoattractant function of CNTs.  Moreover, CNTs themselves act as a 
chemoattractants and stimulate macrophages migration by activating the 
PLC/IP3/CRAC channel signalling pathway (Li et al., 2017a).  
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Figure 3-6: Multiplex array analysis of supernatants of THP-1 cells following 
treatment with properdin and TSR 4+5 or uncoated CNTs. 
Protein-coated CNTs (properdin and TSR4+5) were incubated with THP-1 cells for 30 
min, 1h, 2h, 6h, 12h, 24h and 48h. Supernatant from 24h and 48h time points (X-axis) 
were used for the measurement of the levels of secreted cytokines (IL-1α, IL-1β, TNF-
α, IL-6, IL-10, IL12p40, IL12p70, TNF-β, IL-15, IL-17A, IL-9, IL-13) ) by using a 
MagPix Milliplex kit. Error bars represent ± standard deviation Ns: not significant 
(p>0.05)*p < 0.05, *p < 0.01, and ***p < 0.001 (2-way ANOVA test between 
properdin or TSR4+5 coated CNTs with uncoated CNTs). 
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Figure 3-7: Multiplex array analysis of supernatants of THP-1 cells following 
treatment with properdin and TSR 4+5 or uncoated CNTs. 
Protein-coated CNTs (properdin and TSR4+5) were incubated with THP-1 cells for 30 
min, 1h, 2h, 6h, 12h, 24h and 48h. Supernatant from 24h and 48h time points (X-axis) 
were used for the measurement of the levels of secreted chemokines (MCP-3, MDC, 
Eotaxin, MIP-1α, MIP-1β, Fractalkine, GRO, IL-8, IP-10, MCP-1)  by using a MagPix 
Milliplex kit. Error bars represent ± standard deviation Ns: not significant (p>0.05)*p < 
0.05, *p < 0.01, and ***p < 0.001 (2-way ANOVA test between properdin or TSR4+5 
coated CNTs with uncoatedCNTs). 
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Figure 3-8: Multiplex array analysis of supernatants of THP-1 cells following 
treatment with properdin and TSR 4+5 or uncoated CNTs. 
Protein-coated CNTs (properdin and TSR4+5) were incubated with THP-1 cells for 30 
min, 1h, 2h, 6h, 12h, 24h and 48h. Supernatant from 24h and 48h time points (X-axis) 
were used for the measurement of the levels of secreted growth factors (IL-2, FGF-2, 
G-CSF, GM-CSF, IL-3, VEGF) by using a MagPix Milliplex kit. Error bars represent ± 
standard deviation Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and ***p < 
0.001(2-way ANOVA test with column mean effect was used in between properdin or 
TSR4+5 coated CNTs with uncoated CNTs). 
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Figure 3-9: Multiplex array analysis of supernatants of THP-1 cells following 
treatment with properdin and TSR 4+5 or uncoated CNTs. 
Protein-coated CNTs (properdin and TSR4+5) were incubated with THP-1 cells for 30 
min, 1h, 2h, 6h, 12h, 24h and 48h. Supernatant from 24h and 48h time points (X-axis) 
were used for the measurement of the levels of related ligands and receptors (IFN-γ, 
FLT-3L, IL-1RA, sCD40L) by using a MagPix Milliplex kit. Error bars represent ± 
standard deviation Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and ***p < 
0.001(2-way ANOVA test between properdin or TSR4+5 coated CNTsand uncoated 
CNTs.) 
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3.3.6 Properdin or TSR4+5 -CNTs induced nuclear translocation of NF-κB 
Fluorescence microscopy images revealed the translocation of NF-κB into the nucleus 
following challenge with properdin-CNTs or TSR4+5-CNTs. The transcription factor, 
NF-κB, has a main role in the downstream signalling pathway of many pro-
inflammatory cytokines that are activated when cells are exposed to external stimuli. 
THP-1 cells were incubated with properdin-CNTs or TSR4+5-CNTs for 2 h and 
subsequently stained with an antibody against the p65 subunit of NF-κB (green) (Figure 
3-10). The merged image shows induction of translocation of NF-κB to the nucleus 
(blue), which is significantly enhanced by properdin-CNTs and TSR4+5-CNTs, 
compared to CNTs alone. Properdin & TSR4+5 coated CNTs also induced an up-
regulation of NF-κB mRNA levels at 6 h by THP-1 cells (Figure 3-5). This is consistent 
with the nuclear localization of NF-κB (Figure 3-10). This reflects on the up-regulation 
of the pro-inflammatory response by TNF-α, IL-1β, IL-2 and IL-6 (Figure 3-5). 
Upregulation of pro-inflammatory cytokines (TNF-, IL-1) and nuclear translocation 
of NF-B suggests that properdin-CNTs and TSR4+5-CNTs might have triggered 
TLRs, especially TLR4 via the MyD88-dependent pathway, on the macrophages to 
initiate transcription of pro-inflammatory cytokines (Yamamoto et al., 2004). 
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Figure 3-10: Properdin-CNTs and TSR4+5-CNTs induce nuclear translocation of 
NF-B in THP-1 cells. 
Differentiated THP-1 cells were incubated with properdin-coated or TSR4+5-coated 
CNTs for 2 h. Cells were washed and fixed using 4% PFA, permeabilized, blocked with 
5% FBS and incubated with rabbit anti-NF-κB p65 antibodies, followed by secondary 
Alexa Fluor 488-goat anti-rabbit antibody (Green). The nucleus was stained with 
Hoechst 33342 (Blue). Arrowhead in merged images shows the translocation of NF-B 
from the cytoplasm to nucleus. Scale bar 20 μm.  
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3.4 Discussion 
Previously, we have shown that complement components like C1q and Factor-H (F-H) 
can absorb on CNTs and modulate the uptake of opsonized CNTs in which C1q 
enhanced the uptake of CNTs in PBMCs in contrast to F-H (Pondman et al., 2015; 
Pondman et al., 2014). Various CNTs, pristine, Ox-CNTs, CMC-CNTs, appeared to 
provide molecular charge pattern recognition for C1q to bind and initiate classical 
pathway activation. C1q appeared to bind CNTs via its globular head (gC1q), as 
revealed by binding using individual globular head domains, enhanced uptake of CNTs 
by human monocytic cell lines (U937) and up-regulated the pro-inflammatory immune 
response (Pondman et al., 2015). Although complement factor H, a negative regulator 
of the alternative pathway, also bound to CNT derivatives, it did not enhance uptake but 
exerted an anti-inflammatory response. Bound recombinant forms of globular head 
modules of C1q (ghA, ghB and ghC) on CNTs inhibited classical pathway activation 
but augmented the uptake of CNTs leading to a significant dampening of pro-
inflammatory response (Pondman et al., 2014). Thus, pre-coated NPs with recombinant 
globular heads domain have been proposed to be a good strategy to avoid complement 
activation and the subsequent release of anaphylatoxins (C3a, C5a, C2b) there by 
suppressing pro-inflammatory cytokine/chemokine responses (Pondman et al., 2015). 
Here, we have examined whether properdin can interact with NPs, thus potentially 
acting as a pattern recognition innate immune molecule, similar to C1q, globular heads 
modules and factor H, and modulate CNT handling by macrophages. 
CNTs are hydrophobic in nature but are made biocompatible by coating with polymers 
such as Carboxymethyl cellulose (CMC), which gives negative polarity in solution, 
making the particles water soluble, less -toxic, and more biodegradable and bio-
 Chapter III 
 
 107 
tolerable (Bourdiol et al., 2013). Properdin is a highly positive charged molecule at 
neutral pH (Smith et al., 1984). Many cell surface molecules identified so far that 
interact directly with properdin are negatively charged. Thus, the direct and stable 
binding of properdin and TSR 4+5 proved to be a charge/polarity interaction in the way 
to retain its biological activity as evidenced by activation of complement alternative 
pathway (Figure 3-3). Contrasting to properdin binding and retaining its biological 
activity when bound to CNTs, C1q has been shown to adsorb on CNTs upon binding, to 
crystallize and lose its biological activity (Ling et al., 2011). This report is in contrast to 
recent findings from Pondman et al where they have shown that adsorbed C1q does 
activate complement classical pathway and enhance the uptake of CNTs and modulate 
the immune response. Another complement component, factor-H.can also binds to 
CNTs (Pondman et al., 2015).graphene oxide and reduced graphene which protects the 
NPs against complement activation (a “stealth effect”) (Belling et al., 2016). Here, we 
have shown that one of the key players in the alternative pathway, properdin does act as 
soluble pattern recognition receptor and bind to CNTs. Several studies have 
demonstrated the role of properdin as a PRR. A recent study by Dixon et al., 2017 has 
shown that properdin produced by DCs and tolerogenic DCs binds to necrotic cells. 
This finding is consistent with previous observations that properdin interacts with 
apoptotic and necrotic cells (Kemper et al., 2008; Xu et al., 2008) in a complement-
independent manner due to its local synthesis. Furthermore, properdin is also involved 
in the interaction of DC and T cells (Dixon et al., 2017). Properdin also binds to several 
pathogen surfaces such as Neisseria gonorrhoeae, Salmonella typhimurium 
lipopolysaccharide (LPS), Neisseria meningitidis lipooligosaccharide (LOS), and 
Chlamydia pneumonia, Zymosan, E-coli strains, live human leukemia T cell lines, as 
well as rabbit erythrocytes as mentioned by several studies described in the introduction 
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section. Properdin‟s direct interaction with cell surface moieties may further confirms 
itas an independent recognition molecule. Such locally released properdin has a 
potential to bind to therapeutic nano drugs and can influence their pharmacokinetics and 
biodistribution.  
In contrast to properdin, TSR4+5 bound CNTs dampened alternative pathway 
activation in vitro similar to the globular heads modules of C1q (Pondman et al., 2014). 
The recombinant TSR4+5 has recently been shown to compete with properdin binding 
to C3b (and other ligands), and to inhibit the alternative pathway in solution (Kouser et 
al., 2016). Here, TSR4+5 bound CNTs inhibited alternative pathway activation on the 
surface of the bound NPs. Coating complement inhibitors onto therapeutic NPs like 
CNTs, IONPs, gold NPs, offers a simple approach to regulate immune response 
triggered by different NPs and improve their presence and persistence in the blood. 
Inhibition of complement alternative pathway has been previously reported to be 
advantageous in pathological conditions using antibody against other regulatory 
complement components such as mAb 1379, (anti-factor B antibody) against anti-
phospholipid antibody-induced complement activation (Thurman et al., 2005), 
eculizumab (Anti-complement C5 antibody) against paroxysmal nocturnal 
hemoglobinuria (Wong and Kavanagh, 2015).  
We next assessed the uptake of properdin-CNT and TSR4+5-CNT by THP-1 
macrophages (Figure 3-4). Properdin was able to enhance the phagocytosis of CNTs 
considerably more than TSR4+5. Low uptake of TSR4+5-CNTs indicates the 
requirement of additional TSR modules or multimers of properdin to engage with 
receptors on the cell surface. Properdin proved to act as an opsonin for CNTs without 
involving complement recruitment and activation, and enhance their uptake and 
clearance by a macrophage cell line. However, it is possible that THP-1 cells could 
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synthesise a sufficient quantity of complement proteins (eg C3) to contribute to this 
apparent opsonisation as THP-1 harbour properdin RNA and traces of C3 RNA as 
reported by The World Protein Atlas (http://www.proteinatlas.org). However, Takizawa 
et al (1996) argued that addition of serum as a complement source was required to 
observe phagocytosis of apoptotic cells by activated THP-1 cells (Takizawa, Tsuji and 
Nagasawa, 1996).  
Although uptake of CNTs was exclusive to properdin, TSR4+5 and properdin 
were able to trigger the pro-inflammatory cytokine response. This suggests that though 
additional receptors were needed for phagocytic uptake, cell stimulation and 
cytokine/chemokine release did not require more modules. CNTs on their own were not 
able to produce a significant signal for tested cytokines compared to protein coated. 
However, expression of IL-10 was up-regulated at an early time point (30min) 
dampening the activation of macrophages which may explain the lower uptake of 
uncoated CNTs. Expression of pro-inflammatory cytokines, TNF-α, IL-1β, and IL-6, 
was dramatically up-regulated at 6 h, suggesting that both properdin and TSR4+5 
coated CNTs can alter the immune response. Further analysis was carried out to 
measure the secreted cytokine levels at late time points (24 h and 48 h) following THP-
1-CNT interaction, using multiplex array analysis (Figure 3-9). A dramatic up-
regulation of pro-inflammatory cytokine response was observed consistent with the 
early mRNA response for TNF-α, IL-1β, and IL-6. These cytokines are potent inducers 
of GM-CSF (Chung, Kim and Ma, 2006) as a result GM-CSF was dramatically up-
regulated by both protein coated CNTs. Upregulation of IL-1α and IL-1β (Figure 3-9) 
indicates the activation of TLR-Myd88 mediated pro-inflammatory pathway resulting 
NF-κB nuclear translocation (Figure 3-10). Additionally, IL-8, a chemoattractant for 
neutrophils was also upregulated, which in vivo may induce local production of 
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properdin by neutrophils and enhance activation of the alternative pathway 
(Wirthmueller et al., 1997). Complement proteins have a significant contribution to the 
tumour microenvironment and have become a focus of intense research. An 
immunosuppressed microenvironment facilitates tumour cells growth. To this effect, 
conditioned medium from melanoma B16F10 tumour cells has been shown to prime M1 
macrophages, characterised by upregulation of iNOS, IL-1β, TNF-α, IL-12, IL-23, 
CXCL-9 and CXCL-10 (Al-Rayahi, Browning and Stover, 2017). Thus, locally 
synthesized properdin could potentially modulate the tumour microenvironment by 
binding to CNTs if these were used for drug delivery. 
From a therapeutic point of view, properdin-CNTs not only allowed alternative pathway 
activation but also retained its biological activity and ability to activate the alternative 
pathway in properdin deficient conditions. These results pave the way for its 
development as a prophylactic and therapeutic agent for treatment in the rare condition 
of X-linked properdin deficiency. Properdin-CNTs used as a platform for drug delivery 
may mediate a protective role in this disease. These results are of pathophysiological 
significance since properdin deficiency has been linked with a range of bacterial 
infections especially Neisseria (Soderstrom et al., 1991). The properdin gene-deficient 
mice are susceptible to a number of bacterial infections (Stover et al., 2008). 
Furthermore, an inhibitor of the alternative pathway, TSR4+5 delayed endocytosis, 
which has potential implications for therapeutic drug delivery in alternative pathway 
related diseases.  Though we observed a significant upregulation of pro-inflammatory 
cytokines and chemokine release upon exposure to properdin and TSR4+5 coated 
CNTs, this can be successfully reduced by C3b deposition on the CNTs as reported by 
Pondman et al. where they downregulated pro-inflammatory nature of SP-D coated 
CNTs by complement deposition (Pondman et al., 2017a). 
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Interaction between Surfactant Protein D and carbon 
nanotubes 
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4.1 Abstract 
Carbon nanotubes (CNTs) are progressively being investigated for use in biomedical 
applications, including biological agents delivery like gene delivery, drug and protein 
delivery. One of the most promising applications under assessment is in treating 
pulmonary diseases such as tuberculosis and lung cancer. Besides therapeutic NPs, 
exposure to airborne NPs is not a new phenomenon. Once inhaled either intentional or 
accidental, the NPs are likely to be recognized by innate immune molecules in the lungs 
such as hydrophilic pulmonary surfactant proteins with the ability to bind or opsonise 
foreign particles. Here, we set out to study the interaction between surfactant protein D 
(SP-D), a key lung pattern recognition molecule and NPs, CNTs, and potential 
downstream effects on the immune response via macrophages. We observed that a 
recombinant form of human SP-D (rfhSP-D) bound to carboxymethyl cellulose (CMC) 
coated CNTs via its C-type lectin domain and augmented phagocytosis by THP-1 
macrophages/monocytic cell lines, together with an increased pro-inflammatory 
response. This suggests that immobilization of SP-D by CNTs in the lungs can initiate 
an unfavourable immune response. Furthermore, rfhSP-D opsozined CNTs continued to 
activate complement pathway via the classical pathway, suggesting that SP-D and C1q, 
an initiator of classical pathway do not interfere in the complement activation and SP-D 
and C1q have distinct pattern recognition sites on the CNTs. Complement deposition on 
the rfhSP-D opsonised CNTs led to dampening of the pro-inflammatory immune 
response by THP-1 macrophages, as evident from qPCR, cytokine array and NF-κB 
nuclear translocation examination. This study emphasises the significance of 
understanding the interaction between innate immune humoral factors including 
complement in developing nanoparticle-based drug delivery strategies.  
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4.2 Introduction 
The assessments of how the innate immune system is able to recognize and process these 
NPs, with the goal of extrapolating this knowledge for the development of a new generation 
of nanotherapeutics has already been carried out in previous chapters. One of the most 
promising applications under assessment is in treating pulmonary diseases such as 
tuberculosis and lung cancer. Drug delivery to the lung through aerosol inhalation is widely 
used for the treatment of several diseases such as cystic fibrosis, asthma, COPD and more 
recently for the treatment of lung cancer (Hershey et al., 1999).  But still, the nano-based 
drug delivery has not reached to the acceptable stage and studies have been regularly 
conducted to examine the challenges in delivering for the treatment of pulmonary diseases 
like tuberculosis (Bonner, 2011; Choudhary and Kusum Devi, 2015). Therefore, it is vital 
to understand the way therapeutic NPs interacts with the pulmonary innate immune system 
and their mechanism and consequences. 
Recent studies in animal model demonstrated that SP-D expression is 
upregulated in the lung in response to ambient particulate matter from air pollution 
(Clement et al., 2008; Kang et al., 2010). Accidentally inhaled or therapeutically 
administered NPs both would be recognized and processed by innate immune molecules 
in the lungs such as pulmonary surfactant proteins. Pulmonary surfactant is a multi-
layered lipoprotein constituted up to 10% proteins and 90% lipid. (Goerke, 1998).  
These lipoproteins line the alveolar epithelial surface and provide two important 
functions to the lung; defence to the microbial infection and reducing alveolar surface 
tension. Both SP-A and SP-D opsonise pathogens and foreign particles and interact with the 
alveolar macrophages via putative receptors. Opsonisation assists in their uptake and 
downstream immune response (Kishore et al., 2006), suggesting that they can have a 
critical role in the processing of inhaled NPs. 
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Homotrimeric C-type lectin domain or carbohydrate recognition domain (CRD) 
facilitates the binding of SP-D and SP-A with Oxidized (Ox) double-walled CNTs 
(DWNTs), as shown by transmission electron microscopy (Rybak-Smith et al., 2011; 
Salvador-Morales et al., 2007).  Bound SP-A on CNTs enhanced their uptake by 
alveolar macrophages, without any significant inflammatory response evident by no 
marked rise of nitric oxide levels (Salvador-Morales et al., 2013). Similarly, the 
formation of lung surfactant protein corona on NPs consisting of SP-A and SP-D 
enhances the uptake of SWNTs by RAW murine macrophages (Kapralov et al., 2012). 
Furthermore, pulmonary surfactant proteins have shown to stabilize the suspensions of 
CNTs, however, cluster of CNTs was observed in monocytes derived-macrophages 
(Gasser et al., 2012). This could be due to enhanced uptake of CNTs, accumulation and 
prolonged holding of CNTs inside the macrophages. Enhanced uptake of CNTs has also 
been reported upon coating with SP-A as well as phosphatidylserine (Konduru et al., 
2009; Stringer and Kobzik, 1996). As surfactants proteins are available in very low 
amount, immobilization of these proteins on NPs can potentially cause significant 
depletion of proteins, which can have a detrimental effect on the lung innate immune 
defence (Salvador-Morales et al., 2007). In contrast, bound SP-A or SP-D on 
unmodified polystyrene (U-PS) and amino-modified polystyrene (A-PS) NPs were 
found to neutralise influenza A viral cellular infection in vitro (McKenzie et al., 2015a). 
Recently, Kendall et al group found that SP-D adsorbs on the various NPs (polystyrene, 
carbon black and silica NPs) and enhance their uptake by alveolar macrophages and 
mouse dendritic cells (Kendall et al., 2013). In a mouse model, alveolar macrophages, 
SP-A was found to inhibit agglomeration and uptake of A-PS, whilst it promoted uptake 
of U-PS (McKenzie et al., 2015b).  
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The mechanistic pulmonary toxicity of NPs still remains unexplained but 
surface area, insolubility of NPs, particle sizes are significant factors (Kendall, Brown 
and Trought, 2004). Inhaled NPs deposits in the lungs and interacts with lung surfactant 
components before involving cellular interactions (Lundqvist et al., 2008). Extracellular 
molecules modulate the NPs properties, reduce surface charge as measured by zeta 
potential and promote particle agglomeration (Kendall, Ding and Kendall, 2011). Once 
inside the airways, NPs adsorb onto the mucosal surface and pulmonary surfactant 
lining of the lower airways. Similar to the formation of plasma corona in blood, 
pulmonary biological molecules form a corona, which influences the clearance, 
bioavailability and toxicity of the NPs (Kendall and Holgate, 2012).  
Here, we have set out to investigate the interaction of SP-D with CNT and their 
subsequent effect on complement activation, phagocytosis and immune response by 
macrophage cell lines. 
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4.3 Results 
4.3.1 SDS PAGE and TEM analysis showing rfhSP-D bound to CNTs 
CNTs were incubated with rfhSP-D for overnight at 4
0
C shaking. CNTs were washed 
extensively and redispersed to wash away any trapped protein. Uniformly suspended CNTs 
ran in 12% SDS-PAGE to analyse the binding of rfhSP-D on CNTs. TEM micrograph 
further also revealed that rfhSP-D was bounded on to the CNTs. Figure 4-1 shows the 
rfhSP-D were bound to CNTs NPs stably. 
 
 
 
Figure 4-1: Binding of rfhSP-D to CNTs. 
A) rfhSP-D bound to CNTs. CNTs were incubated with rfhSP-D in 1 : 2 weight ratio for 
overnight and repeatedly shaking. CNTs were washed extensively via centrifugation to 
remove unbound or trapped SP-D. Lane 1: molecular weight marker; lane 2: CNTs only, 
lane 3: rfhSP-D coated CNTs. CNTs incubated with rfhSP-D was adsorbed on carbon 
grid and counterstained with uranyl acetate and lead citrate and micrographs were 
recorded using a JEOL 2100 FEG-TEM operating at 80Kv, and the images were 
processed using gatan microscopy suite software (Gatan, Inc). B) CNTS only C) CNTs 
coated with rfhSP-D as shown by the arrow.  
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4.3.2 Coating of CNTs with rfhSP-D enhances complement consumption 
It has been established that CNTs can activate complement classical pathway. Here, we 
set out to investigate whether CNT coated with rfhSP-D can activate complement 
pathway and what extent it does. rfhSP-D coated CNTs showed a very significant 
enhancement (≈2 fold) in complement consumption compared to uncoated CNTs 
(Figure 4-2). Complement activation, therefore, appears to be facilitated by rfhSP-D 
coating on CNTs, suggesting that rfhSP-D and C1q do not compete for binding to the 
same sites on the CNTs, i.e. rfhSP-D does not inhibit C1q binding, an initiator of the 
classical pathway. Bound rfhSP-D could provide more site for the covalent binding of 
C3b or C4b, thus enhancing formation of the convertase enzymes, C3bBb or C4b2a., 
which would increase consumption (activation) of complement as evident by earlier 
report stating that coating of DWNT with other protein, e.g. BSA and fibrinogen, can 
also enhance complement consumption (Pondman et al., 2014). 
 
Figure 4-2: Complement consumption by rfhSP-D coated CNTs. 
rfhSP-D coated CNTs and CNTs alone were incubated with human serum (1/10 diluted 
in DGVB for a classical pathway for 1h at 37
0
C. Samples were spun down and serum 
was collected for complement inhibition assay. Zymosan was used as positive control 
and serum only was used as negative control. Percentage complement consumption was 
calculated using (C − Ci)/C × 100%, where C represents the % hemolysis of the negative 
control, and Ci is the % hemolysis with the rhSP-D coated or uncoated CNTs or zymosan-
treated sample. Experiments were conducted in triplicate. Multiple T-test was performed 
to determine significant differences between each uncoated and coated CNTs. All error 
bars represent ± standard error of the mean, Ns: not significant (p>0.05)*p < 0.05, *p < 
0.01, and ***p < 0.001) 
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4.3.3 rfhSP-D enhances uptake of CNTs  by THP-1 macrophage cell lines 
Like serum treated CNTs (serum+CNTs), rfhSP-D enhanced the uptake of CNTs by 
differentiated THP-1 cells as revealed by confocal microscopy (Figure 4-3). Orthogonal 
section of the THP-1 cells shows the endocytosed CNTs inside the cells within plasma 
membrane boundary (Figure 4-4A). Interestingly, at both, early (2 hours) and late (4 
hours) time points complement deposition on rfhSP-D coated CNTs (SP-D+serum-
CNTs) reduced uptake compared to rfhSP-D coating alone or serum treatment alone. 
Quantitative analysis of uptake of CNTs shows that binding of rfhSP-D increased 
cellular uptake by about 40% (Figure 4-4B), similar to previously shown increase in 
uptake of CNTs coated with serum and C1q  (Pondman et al., 2015; Pondman et al., 
2016). In contrast, uptake of rfhSP-D coated and complement deposited CNTs were 
inhibited by three-time compared to rfhSP-D coated CNTs The reduction in uptake of 
rfhSP-D deposited CNTs with additional complement deposition could be due to steric 
hindrance or competition for a receptor.  
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Figure 4-3: Differential uptake of CNTs by macrophage (THP-1) after coating 
with rfhSP-D, and with or without serum treatment (i.e. complement deposition). 
THP-1 cells on a 13mm glass coverslip were exposed to rfhSP-D bound biotinylated 
CNTs (rfhSP-D+CNT), rfhSP-D deposited biotinylated CNT with complement 
deposition (rfhSP-D+serum+CNT), complement deposited biotinylated CNTs 
(serum+CNTs), or biotinylated CNTs alone for 2 h and 4 h. After incubation, cells were 
washed, fixed, permeabilised. Alexafluor-488 labelled streptavidin and alexafluor 546-
conjugated wheat germ agglutinin were to stain internalized biotinylated CNTs and 
plasma membrane (red) respectively. The nucleus was stained with Hoechst 33342 
(Blue). Prepared slides were viewed under Nikon confocal microscope; scale bar 20μm. 
Arrows highlight internalised CNTs. (A) Confocal microscopy images showing uptake 
of coated or uncoated CNTs 
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A)
 
 
B) 
 
Figure 4-4: Differential uptake of CNTs by macrophage (THP-1) after coating 
with rfhSP-D, and with or without serum treatment (i.e. complement deposition). 
THP-1 cells on 13mm glass coverslip were exposed to rfhSP-D bound biotinylated 
CNTs (rfhSP-D+CNT), rfhSP-D deposited biotinylated CNT with complement 
deposition (rfhSP-D+serum+CNT), complement deposited biotinylated CNTs 
(serum+CNTs), or biotinylated CNTs alone for 2 h and 4 h. After incubation, cells were 
washed, fixed, permeabilised. Alexafluor-488 labelledStreptavidin and alexafluor 546-
conjugated wheat germ agglutinin was to stain internalized biotinylated CNTs and 
plasma membrane (red) respectively. The nucleus was stained with Hoechst 33342 
(Blue). Prepared slides were viewed under Nikon confocal microscope; scale bar 20μm. 
Arrows highlight internalised CNTs.(A) Orthogonal views of the confocal images 
demonstrate internal localisation of CNTs (green), plasma membrane in red, scale bar 
20μm. (B) For quantification of internalized CNTs, differentiated THP-1 cells were 
incubated with 20µg of various versions of CNTs for 2h. Following extensive washing 
in PBS, the cells were lysed after extensive washing and the amount of internalised 
CNTs was quantified by an ELISA assay. All experiments were carried out in triplicate; 
error bars represent ± SEM, Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and 
***p < 0.001) (A 2-tailed, unpaired t-test between uptake of CNTs between rfhSP-D 
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coated CNTs and complement deposited rfhSP-D coated CNTs (rfhSP-D+serum CNT) 
with CNTs only) 
 
4.3.4 Cytokine and transcription factor mRNA expression THP-1 treated with 
rfhSP-D and complement bound CNTs 
 
Cytokine and transcription factor gene expression profiles of THP-1 cells were 
measured at six time-points up to 6 h, following treatment with various CNTs, with and 
without rfhSP-D and serum coatings. In THP-1 cells, mRNA levels for the pro-
inflammatory cytokines (IL-1β, TNF-α) were up-regulated by rfhSP-D CNTs, when 
compared to CNTs (Figure 4-5) but significantly downregulated by complement 
deposited rfhSP-D coated CNTs. However, IL-12 mRNA level showed an opposite 
trend. For anti-inflammatory cytokines, unlike IL-10, complement-deposited and rfhSP-
D coated CNTs slightly upregulated the expression of TGF-β. NLRP3 was upregulated 
however, NF-κB mRNA level was downregulated by complement deposition on the 
rfhSP-D coated CNTs. Thus, rfhSP-D coated CNTs are pro-inflammatory but the pro-
inflammatory effect was dampened by complement deposition on CNTs. 
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Figure 4-5: Cytokine gene expression of differentiated THP-1 cells challenged with 
rfhSP-D coated CNT with or without serum deposition. 
For the measurement of mRNA expression of pro- and anti-inflammatory target genes, 
PMA differentiated THP-1 cells were exposed with each CNTs 30 min, 1h, 2h and 6h 
(X-axis). Error bars represent ±standard deviation. Ns: not significant (p>0.05)*p < 
0.05, *p < 0.01, and ***p < 0.001) (A 2-way ANOVA test to determine significant 
differences in expression among various version of CNTs; uncoated (CNT only), serum-
rfhSP-D coated (rfhSP-D +serum CNT) and rfhSP-D coated CNTs (rfhSP-D+CNT). 
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4.3.5 Multiplex array analysis revealed dramatic down-regulation of pro-
inflammatory cytokines/chemokines by THP-1 cells when challenged with 
complement deposited rfhSP-D coated CNTs. 
mRNA expression suggests the pro-inflammatory nature of rfhSP-D bound on CNTs. 
However, mRNA expression at early time points does not always give all the clues 
about immune response over an extended period, cytokine array analysis was performed 
on the supernatants obtained at 24h and 48 h after treatment of THP-1 and with CNTs. 
Significant secretion amount of IL-1α, IL-1β, TNF-α, IL-12p40 and IL-12p70, indicates 
the pro-inflammatory properties of rfhSP-D bound CNTs (Figure 4-6). A similar profile 
of chemoattractant was seen in IL-8, MDC, IP10, MCP-3, MCP-1,MIP-1α and MIP-1β 
indicating inflammatory potential of rfhSP-D(Figure 4-8). There was also an increase in 
G-CSF levels (Figure 4-7), in CNTs coated with rfhSP-D, suggesting a dampening of 
fibrotic responses consistent with an increase in the inflammatory response (Romero et 
al., 2015). rfhSP-D coated CNTs downregulated the level of IL-10 levels. 
Though, rfhSP-D-coated CNTs produced an increased pro-inflammatory 
response in THP-1 cells upon challenged, this effect was prominently reduced by 
complement deposition. We, observed a dramatic downregulation of IL-1β, TNF-α, IL-
1α, IL-6, IL-8, MCP-1, MCP-3, MDC, GRO, IP-10, MIP-1β, C-CSF, GM-CSF and 
VEGF when challenged with complement deposition on rfhSP-D coated CNTs (Figure 
4-6,Figure 4-7,Figure 4-8). The levels of TNF-β, IL-17A, IL-12, IL-9 and IL-15 were 
also significantly downregulated (Figure 4-6). Targets like IL-10, IL-12p40, eotaxin, 
IFN-α2, MIP-1α, fractalkine, EGF, FGF-2, IL-3, IL-7, FLT3L and soluble CD40L were 
not significantly altered. qPCR analysis and multiplex analysis, both demonstrate that 
complement deposition on rfhSP-D coated CNTs, modulates the immune response and 
polarize to anti-inflammation. 
 Chapter IV 
 
 124 
 
Figure 4-6: Cytokines analysis of supernatants of THP-1 cells treated with rfhSP-D 
bound CNT with or without serum. 
rfhSP-D bound CNTs (rfhSP-D+CNT), rfhSP-D and complement deposited CNTs (rfhSP-D +serum 
CNT) and CNT only were incubated with differentiated THP-1 cells for various time points (30 min, 
1 h, 2 h, 6 h, 12 h, 24 h and 48 h). Supernatants from time points; 24 h and 48 h (X-axis) were taken 
for measurement of different cytokines (IL-6, IL-10, IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, IL-
13, IL-15, IL-17A, IL-9, TNF-β, IFN-α2, IFN-γ),by using a MagPix Milliplex kit (EMD Millipore). 
Error bars represent ±standard deviation. Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and 
***p < 0.001) (A 2-way ANOVA test to determine significant differences in expression among 
various version of CNTs. 
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Figure 4-7: Growth factors, ligand and receptor analysis of supernatants of THP-1 
cells treated with rfhSP-D bound CNT with or without serum. 
rfhSP-D bound CNTs (rfhSP-D+CNT), rfhSP-D and complement deposited CNTs (rfhSP-D 
+serum CNT) and CNT only were incubated with differentiated THP-1 cells for various 
time points (30 min, 1 h, 2 h, 6 h, 12 h, 24 h and 48 h). Supernatants from time points; 24 h 
and 48 h (X-axis) were taken for measurement of growth factors, ligands and receptors 
(IL-2, EGF, FGF-2, G-CSF, GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-7 VEGF, (FLT-3L, IL-
1RA and sCD40L),by using a MagPix Milliplex kit (EMD Millipore). Error bars represent 
±standard deviation. Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and ***p < 
0.001) (A 2-way ANOVA test to determine significant differences in expression between 
various version of CNTs) 
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Figure 4-8: Chemokine analysis of supernatants of THP-1 cells treated with rfhSP-
D bound CNT with or without serum. 
rfhSP-D bound CNTs (rfhSP-D+CNT), rfhSP-D and complement deposited CNTs (rfhSP-D 
+serum CNT) and CNT only were incubated with differentiated THP-1 cells for various 
time points (30 min, 1 h, 2 h, 6 h, 12 h, 24 h and 48 h). Supernatants from time points; 24 h 
and 48 h (X-axis) were taken for measurement of chemokines (MCP-3, fractalkine, MDC, 
IL-8, IP-10, eotaxin, GRO, MCP-1, MIP-1α and MIP-1β),by using a MagPix Milliplex kit 
(EMD Millipore). Error bars represent ±standard deviation. Ns: not significant 
(p>0.05)*p < 0.05, *p < 0.01, and ***p < 0.001) (A 2-way ANOVA test to determine 
significant differences in expression between various version of CNT. 
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4.3.6 NF-κB nuclear translocation in response to rfhSP-D coated CNTs can be 
halted by complement deposition 
 
A transcription factor, NF-κB, is a central regulator of transcription expression of various 
pro-inflammatory cytokines induced in response to external stimuli. THP-1 cells were used 
to observe nuclear translocation of NF-κB after CNT treatment was observed in THP-1 cells 
using fluorescent staining techniques. Figure 4-9 shows fluorescence in cells exposed to 
CNTs for 2 h. As shown in the figure, CNT exposure stimulated NF-κB nuclear 
translocation compared to the control (cells only). rfhSP-D coated CNTs induced prominent 
nuclear translocation unlike complement deposited, rfhSP-D-coated CMC-CNTs. This 
suggests that serum deposition on rfhSP-D decreases or negates the pro-inflammatory 
potential of rfhSP-D coated CNTs. This effect is further marked by the downregulation of 
TNF-α and IL-1β mRNA levels (Figure 4-5) and the secretion of pro-inflammatory 
cytokines (TNF-α, IL-1β, IL-2 and IL-6), and chemokines (IL-8, MCP-1, IP-10) (Figure 
4-6, Figure 4-8) 
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Figure 4-9: Effect of rfhSP-D and /or complement deposition on CNT on nuclear 
translocation of NF-B. 
Differentiated THP-1 cells on 13mm glass coverslips were treated with rfhSP-D bound 
CNTs (rfhSP-D + CNT), rfhSP-D bound CNT with serum deposition (rfhSP-D + serum + 
CNT), complement deposited CNTs (serum + CNTs), or CNT only for 2 h. After 
incubation, cells were washed, fixed and permeabilised, probed with rabbit anti-NF-κB 
p65 antibodies and revealed using alexa Fluor 488-goat anti-rabbit antibody (green). To 
reveal nucleus, Hoechst 33342 (blue) were used. Scale bar 20 μm. Arrows highlight nuclear 
NF-κB in the merged images. 
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4.4 Discussion 
Carbon nanotubes (CNTs) have exceptional physical properties that make them 
attractive and amenable for their exciting use as drug delivery in the lungs  (Li et al., 
2007; Bianco, Kostarelos and Prato, 2005; Bonner, 2011; Choudhary and Kusum Devi, 
2015) Thus, it is of great importance to understand the biological interactions these 
CNTs govern in the lungs, especially with innate immune components, which are likely 
to be the first host defence system to recognize and process these NPs (Pondman et al., 
2015; Pondman, Sim and Kishore, 2015). Inevitably, use of CNTs into the lungs for a 
therapeutic purpose or even accidental exposure of various other nanomaterials will 
bring them into contact with pulmonary surfactant, including hydrophilic surfactant 
proteins, SP-A and SP-D, which are Ca
2+
-dependent pattern recognition innate immune 
molecules (Kishore et al., 2006). 
Of the two hydrophilic surfactant proteins, SP-D has been shown to mount a 
strong pro-inflammatory response when engaging with a diverse of pathogens (Kishore 
et al., 2005; Nayak et al., 2012). The primary structural organization consist of a 
cysteine-containing N-terminal, a triple-helical collagen region composed of repeating 
Gly-X-Y triplets, an α-helicalcoiled- neck region and a globular structure at the C-
terminal comprising a C-type lectin or CRD (carbohydrate recognition domain). The C-
terminal homotrimeric CRD region being the principal recognition and ligand-binding 
domain of SP-D that binds carbohydrate and/or charge patterns on foreign moieties like 
carbohydrate on pathogens, allergens, receptors/binding proteins, and apoptotic cells 
(Silveyra and Floros, 2012). A modified SP-D, with three CRDs, a neck and eight Gly-
Xaa-Yaa collagen region repeats was used in this study. Xaa and Yaa could be any 
amino acid in the collagen region. CRD region acts as a pattern recognizing receptor 
and binds the ligands causing opsonic effects, enhanced phagocytosis and clearance 
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mechanisms via superoxidative burst and mostly pro-inflammatory immune response by 
phagocytic cells (Kishore et al., 2002). SP-D knock-out studies have revealed that SP-D 
can modulate adaptive immune responses further downstream from its effector 
functions that can include helper T cell polarisation (Madan et al., 2001)as 
demonstrated in in vivo models of infection and allergy (Madan et al., 2001; Madan et 
al., 2005; Qaseem et al., 2013) It also caused apoptosis induction in immune-activated 
cells (Pandit et al., 2016; Mahajan et al., 2013). This shows that there is some sort of 
interaction between SP-D and NPs and such interaction can have a profound and wide-
ranging impact on the lung immune, innate and adaptive, mechanisms.  
Both SP-A and SP-D can be adsorbed and immobilize with NPs and modulate 
their phagocytosis. Schulze et al have shown that metallic oxide NPs like IONP, gold 
nanoparticle is able to sequester SP-A purified from bronchoalveolar lavage (Schulze et 
al., 2011). SP-A prefers hydrophobic coating whilst SP-D prefers hydrophilic coating 
on NPs and binding of these proteins on NPs enhance the uptake of NPs by alveolar 
macrophages (Ruge et al., 2012; Ruge et al., 2011). Enhanced uptake of NPs upon 
coating of these surfactant proteins has further proved by demonstrating the decreased 
uptake of NPs in alveolar macrophages and lung dendritic cells isolated from SP-D 
knockout mice when compared to wild-type mice (Kendall et al., 2013).  
In this study, we set out to examine the effect of rfhSP-D binding to the surface 
of CNTs on their uptake by macrophage cell lines. Haniu et al. observed that SP-A 
coated particles are endocytosed via receptor-mediated and reported that CR3 
recognizes, binds and internalise (Haniu et al., 2013). Likewise, here, internalisation of 
rfhSP-D coated CNTs could also be via CR3 mediated. Moreover, THP-1 cells 
constitutively express complement receptor 3 (CR3) and their surface expression is 
further upregulated by PMA treatment (Plescia and Altieri, 1996). The hemolytic assay 
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was conducted to test whether rfhSP-D coated CNTs continue to activate the 
complement classical pathway like CNTs alone, exploring the possibility of 
independent and multiple interactions of key innate immune molecules with CNTs. It 
has been already established that serum treatment (i.e. complement deposition) on 
CNTs enhances their uptake by macrophages and B cells (Pondman et al., 2016) and 
human bronchial epithelial cells (Haniu et al., 2013).  
Components deposition on CNTs enhances their uptake by complement 
receptors on macrophages, whilst down-regulating the pro-inflammatory cytokine 
response as evident by the up-regulation of potent anti-inflammatory cytokine, IL-10. 
Pondman et al have previously reported that C1q binds to CNTs via its ligand 
recognizing globular (gC1q) domain, as evident by the use of recombinant globular 
head modules (ghA, ghB and ghC)  (Pondman et al., 2015; Pondman et al., 2016) and 
binding of C1q and globular head domain to CNTs is likely though recognition of 
charge patterns or polarisation (Pondman et al., 2015; Kishore and Reid, 2000; 
Pondman et al., 2016; Ghai et al., 2007). Being a similar structure to C1q, SP-D is 
mainly a carbohydrate or a charge pattern recognition molecule, which perhaps 
recognize vicinal diol groups as does its homologue Mannose-Binding Lectin 
(Salvador-Morales et al., 2007). Thus, in addition to observation of rfhSP-D binding to 
CNTs, we also investigated the effect of rfhSP-D bound CNTs in the modulation of 
complement activation. Intriguingly, we observed the 2-fold enhancement in 
complement activation by rfhSP-D CMC-CNTs. These observations advocate the 
presence of differential recognition sites on CNTs by SP-D and C1q and thus do not 
inhibit binding of C1q to CNTs.  Enhanced complement activation by rfhSP-D bound 
CNTs is most likely caused by the formation of additional binding sites for C4b and 
C3b and facilitating their binding by rfhSP-D. In contrast to the effect of rfhSP-D on 
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CNTs, the recombinant globular head of C1q (ghA, ghB and ghC), bound to CNTs, 
have been shown to diminish classical pathway activation (Pondman et al., 2015; 
Pondman et al., 2016) as they compete with native C1q for binding to the CNTs and 
activation of complement pathway.  
Downstream cytokine response from macrophage cell lines treated with CNTs 
with and without rfhSP-D coating showed modulation of cytokines release. rfhSP-D 
bound CNTs up-regulated the pro-inflammatory response in differentiated THP-1 
macrophages.  Upregulation is more likely through the interaction of rfhSP-D bound 
CNTs with Toll-like receptor 4 (TLR4), and resulting in initiation of the IL-1β pathway 
and NLRP3 inflammasome activation (Meunier et al., 2012). The up-regulation of IL-
12 may indicate the polarisation of Th1 cell (Athie-Morales et al., 2004), signifying the 
switches from Th2 to a th1 response during interaction with CNTs. These findings are 
consistent with previously reported by Pondman et al (Pondman et al., 2016). The 
rfhSP-D coating on both types of CNTs was also found to up-regulate G-CSF and IL-8, 
which are important for the mobilisation of neutrophils and T cells, respectively. IL-8, 
as a crucial neutrophil chemoattractant, has been shown to be involved in acute lung 
injury (Allen and Kurdowska, 2014), which has been reduced in secretion by 
complement deposition. Nuclear translocation of NF-κB by NPs has been previously 
demonstrated in human kidney cells (Pujalte et al., 2011).  Activation of NF-B and 
subsequent release of pro-inflammatory signalling molecules such as TNF-α, IL-1β, IL-
8 and IL-6 by metallic NPs (Monteiller et al., 2007) and single-walled CNTs (Pacurari 
et al., 2008) has been previously observed in in vitro and in in vivo. This further 
indicates the potential of rfhSP-D to produce an inflammatory response in combination 
with CNTs. 
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IL-1α and IL-1β are potent inflammatory cytokines, which can additionally 
induce endothelial cells to produce infiltration-causing MCP-1 release (Sica et al., 
1990). Furthermore, IL-1 also induces IFN- γ production by Th1 and NK cells via IL-12 
secretion by antigen presenting cells (Billiau, 1996). In addition, IL-1 induces 
metallomatrix proteins (MMP) production by lung fibroblasts resulting extracellular 
matrix degradation. Thus, suppression of these cytokines, whose generation involves 
lung fibrosis, inflammasome and TLR4, is favourable to maintain pulmonary 
homeostasis. IL-1 also upregulates the pyrogenic and acute phase protein TNF-α and 
TLR4 mediated interaction involving SP-D and CNT (Yamazoe et al., 2008). 
Upregulation of IL-13 and eotaxin by rfhSP-D bound CNTs strongly suggests the 
likeliness of idiopathic lung fibrosis, pulmonary inflammation and asthma (Passalacqua 
et al., 2017). One crucial up-regulation that we observed in response to CNTs is VEGF. 
VEGF is known to increase oedema (vascular permeability) involving Th2 dependent 
sensitisation and pulmonary inflammation and asthma (Lee et al., 2004). It has been 
established that CNT-bound rfhSP-D differs with the soluble rfhSP-D in murine models 
(Madan et al., 2001); however, this effect can be overcome by complement deposition 
on them.  
Here we observed that functionalized CNTs act as a charge pattern recognition 
target, for SP-D and C1q simultaneously but the binding sites are not overlapping. 
Binding of several other proteins and subsequent modulation of complement activation 
has been previously reported. This includes efficient binding of human serum albumin 
(HSA), fibrinogen (Salvador-Morales, Green and Sim, 2007), human C1q, bovine 
serum albumin (BSA) and recombinant fragments of C1q (Pondman et al., 2014; 
Pondman et al., 2015) and SP-A (Salvador-Morales et al., 2008; Salvador-Morales et 
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al., 2013). Furthermore, a coating of CNTs with other proteins like BSA and fibrinogen 
enhance complement activation (Pondman et al., 2014).  
SP-D opsonisation leads to enhanced uptake of CNTs by macrophages, similar to 
complement deposition. However, we observed a restriction of entry of the CNTs, when 
both opsonins (SP-D and complement) were bound together and also suppressed pro-
inflammatory response by rfhSP-D bound CNTs. These findings make a good argument 
for coating of CNTs with complement components for therapeutic applications.  
As some of the properties of CNTs resembles with asbestos, for the use of 
therapeutic, a careful consideration is a warrant due to their interaction with SP-D and 
subsequent potential harmful inflammation (Cassel et al., 2008; Dostert et al., 
2008). Furthermore, it has been demonstrated that SP-D gets completely sequestered 
from suspension by binding to carbon black particles (Kendall, Brown and Trought, 
2004). Such sequestration of SP-D intensified Streptococcus pneumonia infection in 
rats exposed to airborne particles (Zelikoff et al., 2003) It has also been reported that 
immobilization of SP-D and SP-A by NPs was shown to modulate the function of these 
proteins to combat and neutralize influenza A infection in vitro (McKenzie et al., 
2015a). Sequestration of these immune molecules by NPs make host prone to viral and 
bacterial infection. The SP-D bindings should thus be considered separately for every 
modification (also for therapeutics bound onto the surface coating).  
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5 Chapter V 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immune Interaction with Iron Oxide Nanoparticles 
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5.1 Abstract 
NPs have promised a range of diagnostic and therapeutic applications in biomedicine. 
They are attractive drug delivery vehicles for targeted organs or tissues. However, their 
interaction with the immune system is very intriguing and poses challenges to develop 
themfor in vivo applications. Here, we report that iron oxide particles (IONP) are 
recognized by complement pathway, mainly by alternative complement pathway. 
Complement deposition enhanced their uptake by activated THP-1 macrophages. 
Furthermore, secreted cytokines, chemokines and growth factors analyses showed 
complement-dependent downregulation of pro-inflammatory cytokines, TNF-α, IL-1, 
IL-6, IL-12, although the intracellular fate of IONP is independent of complement 
deposition. We propose that complement activation by the iron particles may cause 
immune cells activation and infiltration due to the release of cytokines and chemokines 
and growth factors. 
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5.2 Introduction 
IONPs have been widely used as contrast agents for magnetic resonance imaging 
(Daldrup-Link et al., 2011). They have also been used as intravenous iron preparations, 
iron dextran, iron sucrose, iron gluconate, ferric carboxymaltose, iron isomaltoside 
1000, and ferumoxytol, to treat iron deficiency and as an iron replacement (Singh et al., 
2008; Auerbach and Ballard, 2010). Recently, ferumoxytol, one of the Food and Drug 
Administration (FDA)-approved iron supplements, has shown an intrinsic therapeutic 
effect on early breast cancer and metastatic lung cancer by increasing caspase-3 activity 
in macrophages. Furthermore, in vivo, it significantly inhibited proliferation of 
subcutaneous adenocarcinoma in mice and prevented the development of liver 
metastasis accompanied by the pro-inflammatory immune response with M1 
macrophage polarization in the tumour microenvironment (Zanganeh et al., 2016).  
It is inevitable that intravenously delivered NPs will have direct access to blood 
and hence the immune system. NPs injected into the bloodstream encounter the immune 
system and can cause an inflammatory response. The immune system attempts to clear 
them, as they are foreign materials. Therefore, the immune response to NPs must be 
considered prior to the development of in vivo applications. NPs in the blood may 
undergo immune-mediated clearance via phagocytosis or damage the immune system 
via immunotoxicity or there could be no interference with immune responses due to 
immunocompatibility (Boraschi, Costantino and Italiani, 2012). Immune components, 
especially macrophages and complement proteins, actively participate in clearance of 
foreign particles. Macrophages and dendritic cells express receptors like Toll-like 
receptors (TLRs), scavenger receptors, complement receptors, integrins, lectin-like 
receptors and Fc receptors.  These receptors recognize and bind foreign particles and 
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help in phagocytic clearance, ultimately influencing the fate of NPs (Silva et al., 2016; 
Yameen et al., 2014).  
Surface coatings of NPs interact with biological systems first and provide a 
physical barrier between the NP core and the immune system. It has been shown that 
surface properties of NPs like the presence of the functional group, the net charge of 
surfactants and overall size are critical for their cellular uptake (Mahmoudi et al., 2011), 
bio-distribution and toxicity (Albanese, Tang and Chan, 2012; Salatin, Maleki Dizaj and 
Yari Khosroushahi, 2015). Besides NP surfaces, size and charges, non/specific 
absorption of serum proteins also critically affect NP–immune cell interactions. Contact 
of NPs with a biological system like blood, cells and tissues, forms a thin layer of 
soluble proteins called „protein corona‟ (Pelaz et al., 2015; Vroman, 1962). The 
formation of protein corona reconfigures the native structure of NPs and, subsequently, 
affects their internalization (Pondman et al., 2014) and has an impact on cell response 
eg. Cytotoxicity, immunotoxicity (Monopoli et al., 2011) and intracellular localization 
(Lesniak et al., 2012). On the other hand, there is a continuous and rapid turnover of 
adsorbed proteins based on their binding affinity. Adsorbed proteins could alter their 
conformation, leading to activation of particular cell signalling pathways (Deng et al., 
2011) or facilitate the absorption of another protein forming protein-protein interactions 
(Vroman, 1962). Such protein-NP interaction can be predominately seen in one of the 
components of the innate immune system, specifically the complement pathway, which 
is initiated by the binding of the antibody complex by C1q (classical pathway) or C3b 
deposition (alternative pathway) on NPs or recognition by pattern recognition molecules 
such as MBL (Lectin pathway) (Merle et al., 2015). Initial binding leads to sequential 
adsorption of other small complement proteins eventually forming membrane attack 
complex (MAC) (Serna et al., 2016). Thus, activation of the complement system can 
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influence therapeutic activity and effectiveness of NPs, as it can, in principle, cause NPs 
to adhere to immune cells (Dobrovolskaia et al., 2008). Further understanding of the 
interactions between NPs and human monocyte cell lines will be beneficial for 
predicting NP-induced inflammatory responses and provide valuable information for 
NP design to alleviate inflammation in biological systems facilitating strategic and 
specific in vivo delivery. 
Previously, we have reported that pristine CNTs, CMC-functionalized CNTs, 
Oxidized CNTs activate the complement pathway prerdominantly via classical pathway 
(Pondman et al., 2014). Complement deposited CNTs modulated the immune response 
by downregulating pro-inflammatory cytokines and upregulating anti-inflammatory 
cytokines in human monocytic cells (U937), B cells (Raji) and T (Jurkat) cells 
(Pondman et al., 2016). Furthermore, complement deposition on CNTs enhanced their 
uptake by U937 (Pondman et al., 2016; Pondman et al., 2014; Pondman et al., 2015). 
Here, we have aimed to analyse whether complement deposition, modulation of 
immune response and recognition by the immune cell is consistently observed with 
other differently functionalized NPs. We have also aimed to analyse the effect of 
complement deposition on nanoparticles‟ intracellular fate. Here, the surface effects of 
IONPs on cellular uptake and their ability to induce immune responses were studied in 
human monocyte cell line, THP-1. We found that starch coated IONPs activate the 
complement system predominantly via alternative pathway unlike carboxymethyl 
cellulose coated carbon nanotubes (CMC-CNTs) (Pondman et al., 2014). Complement 
opsonisation enhanced the uptake of IONPs by THP-1 cells, leading to modulation of 
pro-inflammatory and anti-inflammatory cytokine expression as evident by qPCR and 
multiplex assays. Intracellular localization of serum coated (complement deposited) and 
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uncoated IONPs showed no distinct differences. Both, complement deposited and 
uncoated were shown residing in lysosomes.    
5.3 Results 
5.3.1 CNTs and Iron oxides NPs activates the complement pathway 
Both functionalized and pristine IONPs were assessed for their ability to activate the 
complement pathway. Functionalized IONPs predominantly activated alternative 
pathway (Figure 5-1). The activation was 5 times more than that of the classical 
pathway. Pristine IONPs activated both complement pathways equally but for the 
alternative pathway to a lesser extent than functionalized IONPs. This showed that 
starch functionalized IONPs activate the alternative pathway more readily.  
 
Figure 5-1 Complement activation via a classical and alternative pathway. 
Starch functionalized IONPs and IONPs were incubated with human serum (1/10 diluted in 
DGVB for classical pathway and 1/5 diluted in DGVB-Mg-EGTA buffer) for 1h at 37
0
C. 
Samples were spun down and serum was collected for complement inhibition assay. Zymosan 
was used as positive control and serum only was used as negative control. Percentage 
complement consumption was calculated separately for each pathway analysis and results were 
merged in one figure. Percentage complement consumption was calculated using 
(C − Ci)/C × 100%, where C represents the % hemolysis of the negative control, and Ci is the % 
hemolysis with the IONPs or zymosan-treated sample. Multiple T-test was performed to 
determine significant differences in complement activation between the two types of 
consumption pathway. All experiments were carried out in triplicate. All error bars represent ± 
standard deviation,; ns: not significant p>0.05, *p<0.05, **p<0.01, ***p<0.001. 
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5.3.2 Cytotoxicity of IONPs 
THP-1 cells were tested for potential cytotoxicity of IONPs before analysing for 
cytokine expression and various signalling molecule levels using multiplex. 10 g /ml 
of IONPs and equal concentrations of complement deposited IONPs (IONP+serum) 
were incubated with differentiated THP-1 for 24 h. None of the NPs at given 
concentration possessed any cytotoxic effect on THP-1 macrophages as shown in figure 
(Figure 5-2). Thus, based on the cytotoxic result, the concentration of 10ug/ml of 
IONPs was used for other analysis such as endocytosis assay, cytokine mRNA 
expression and multiplex cytokine/chemokine assays. 
 
 
Figure 5-2: MTT assay to determine cytotoxicity of different NPs. 
Differentiated THP-1 cells were incubated with 10ug/ml of serum treated or untreated 
IONPs for 24 h in serum-free medium. Percentage of viable cells was determined by 
MTT assay. 0.05% saponin was used as positive control. The experiment was carried 
out in triplicate. All error bars represent ± SD, Ns: not significant (p>0.05)*p < 0.05, 
*p < 0.01, and ***p < 0.001) (An unpaired t-test with Welch's correction was carried 
out to test the difference in cytotoxicity between the negative control and NPs) 
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5.3.3 Differential uptake of IONPs by THP-1 and U937. 
To determine the rate of NPs‟ internalization, serum treated and untreated IONPs were 
incubated with U937 and THP-1 cells lines for 15 min and 2 hrs (Figure 5-3). 
Internalization of serum treated IONPs were high in both U937 and THP-1 cell lines. 
Serum treatment enhances uptake of NPs but the amount of particle internalization is 
highly dependent upon cell type. Furthermore, at the earliest time point (15 min), 
internalization of particles was independent of serum treatment in U937. Internalization 
of serum treated particles was very prominent in THP-1 cells. At later time points (2 
hrs), IONPs accumulated in the perinuclear region. 
 
 
Figure 5-3: Differential uptake of IONPs by human monocytic cell lines THP-1 (A) 
and U937 (B) 
10 µg/ml of IONPs, serum treated or untreated (Red) was added to THP-1 (A) and 
U937 (B) cells and incubated for 15min and 2 hrs. Cells were washed, fixed and stained 
with AlexaFluor546-labeled WGA (Green) to reveal plasma membrane and Hoechst 
33342 to stain nucleus (Blue). Scale bars, 10μm. 
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5.3.4 Opsonisation enhanced IONPs’ endocytosis but does not modulate 
intracellular fate 
The efficiency of phagocytosis of IONPs by THP-1 cells is enhanced by the presence of 
serum proteins on their surface as shown in Figure 5-4 and Figure 5-5. Fluorescent 
microscopy shows that IONPs were readily endocytosed at 2h incubation when serum 
deposited but less so when left uncoated. After longer incubation times this difference 
was lost. This suggests that presence of serum protein on the surface makes the particles 
more visible to macrophages possibly mimicking opsonized bacteria or other pathogens. 
In contrast, uncoated iron particle devoid of complement fragments may take another 
route of uptake.  
Figure 5-4 shows that internalized IONPs co-localize with dextran particles that 
accumulate in cellular lysosomes. Co-localization is very prominent in serum deposited 
particles. However, after longer incubation, co-localization with dextran is observed 
independent of serum deposition. 
Similarly, serum treated IONPs colocalized with Lysotracker, which 
accumulates in the acidic environment of late endosomes and lysosomes, in early time 
points (6h) but upon longer incubation (18h and 24h continuous exposure), uncoated 
particles were also seen to co-localise with lysotracker.  
It shows that serum deposition is not modulating the intracellular fate of the particles 
but that it enhances uptake and may also contribute to the swift movement of IONPs 
within the different vesicles involved in the endocytic pathway.  
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Figure 5-4: Co-localization of IONPs with fluorescent dextran with MW20,000Da 
marker for fluid phase endocytosis) 
Serum coated and uncoated iron oxides particles (Red) and dextran (green) were co-
incubated with differentiated THP-1 cells for 2h (A) and 2h followed by18h of the 
chase in normal media (pulse-chase)(B). Cells were washed with PBS, fixed with 4% 
PFA, mounted and observed under a microscope. Green: dextran, Red: IONPs, Blue: 
Nucleus. Scale 20 µm. 
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Figure 5-5: Co-localization of IONPs with lysotracker 
Serum coated and uncoated iron oxides particles (Red) were incubated with 
differentiated THP-1 cells for 6h, 2h followed by18h of the chase in normal media 
(pulse-chase) and 24h continuous exposure. Prior to observation, lysotracker was added 
to the cells for 15 min, the cells were then washed and mounted on the slide. Green: 
lysotracker, Red: IONPs Scale 20µm 
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5.3.5 Complement deposition on IONPs modulates cytokine expression at 
transcriptional level. 
 
Though, both IONP activated the complement pathway, here, we used starched 
functionalized IONPs to study the immune response they modulate in macrophages. 
Cytokine profiles of THP-1 cells were measured at four time points up to 6h (30min, 
1h, 2h and 6h) via qPCR following treatment with iron oxides particles with and 
without serum deposition (Figure 5-6). mRNA levels of pro-inflammatory cytokine 
TNF-α were significantly downregulated by serum deposited IONPs compared to 
untreated IONPs in a time-dependent manner. No difference was seen in the case of IL-
1β at transcription level in THP-1 cells exposed to IONPs. However, IL-12 was 
downregulated by both serum treated and untreated IONPs. For anti-inflammatory 
cytokines, IL-10 was slightly downregulated by untreated IONPs. Similarly, TGF-β was 
downregulated by serum deposited IONPs. No significant changes were observed for 
NLRP3, suggesting that NLRP3 inflammasome activation was limited. Overall, serum 
deposited IONPs induce an anti-inflammatory response in THP-1 cells. 
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Figure 5-6: Cytokine gene expression profile of THP-1 cells in response to serum 
treated or untreated IONPs 
For the measurement of mRNA expression of pro- and anti-inflammatory target genes, 
PMA differentiated THP-1 cells were exposed to serum treated or untreated IONPs for 
30 min, 1h, 2h and 6h (X-axis). All error bars represent ± standard deviation, Ns: not 
significant (p>0.05)*p < 0.05, *p < 0.01, and ***p < 0.001) (2-way ANOVA test was 
performed between each uncoated and coated IONPs to determine the significance 
difference in the level of expression) 
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5.3.6 Serum deposition on IONPs modulates the expression of cytokines, 
chemokines and other soluble factors. 
 
Increased pro-inflammatory responses were observed in THP-1 cells when challenged 
with IONPs. Levels of chemokine secretion were also significantly high compared to 
cells only control (Figure 5-9). However, this effect was considerably downregulatedin 
samples treated with serum deposited IONPs, as indicated by IL-1β, IL-6, TNF-α, IL-12 
(p40). A similar trend was observed for the chemoattractant array in MCP-1, MDC, 
MCP-3, GRO, MIP-1α and IL-8 by serum deposited IONPs. However, MIP-1β and IP-
10 were significantly higher in the serum deposited IONP samples. IFNα2 and IFN-γ 
were upregulated by serum deposited IONPs as a result, Interferon gamma-induced 
protein 10 (IP-10) was significantly upregulated after 48h but not after 24 h. There was 
also significant downregulation of some growth factors; like GM-CSF, VEGF and TGF-
α. However, EGF and IL-2 showed significant upregulation. Other targets in the analyte 
arrays such as FGF-2, FLT-3L, IL-15, IL-12 (p70), IL-17A and were not altered upon 
IONPs exposure.  
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A) 
 
 
Figure 5-7: Cytokines analysis of supernatants of THP-1 cells following treatment 
with Iron oxides particles (with and without serum) 
THP-1 cells were incubated 30 min, 1h, 2h, 6h, 12h, 24h and 48h with serum treated 
and untreated IONPs. Supernatants from 24h and 48 h (X-axis) incubations were used 
for the measurement of the levels of cytokines released (IL-6, IL-10, IL12p40, 
IL12p70, IL-1β, TNF-α, IL-15, IL-17A, IL-9) by using a MagPix Milliplex kit (EMD 
Millipore). All error bars represent ± standard deviation, Ns: not significant 
(p>0.05)*p < 0.05, *p < 0.01, and ***p < 0.001) (2-way ANOVA test was performed 
between each uncoated and coated IONPs to determine the significance difference in 
the level of expression) 
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B) 
 
Figure 5-8: Multiplex cytokine array analysis of supernatants of THP-1 cells 
following treatment with Iron oxides particles (with and without serum) 
THP-1 cells were incubated 30 min, 1h, 2h, 6h, 12h, 24h and 48h with serum treated 
and untreated IONPs. Supernatants from 24h and 48 h (X-axis) incubations were used 
for the measurement of growth factors (IL-2, EGF, FGF-2, TGF- α, GM-CSF, IL-3, 
IL-4, VEGF) and related ligands and receptors (IFNα2, IFN-γ, IL-1RA), by using a 
MagPix Milliplex kit (EMD Millipore). All error bars represent ± standard deviation, 
Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and ***p < 0.001) (2-way ANOVA 
test was performed between each uncoated and coated IONPs to determine the 
significance difference in the level of expression) 
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C)
 
Figure 5-9: Multiplex cytokine array analysis of supernatants of THP-1 cells 
following treatment with Iron oxides particles (with and without serum) 
THP-1 cells were incubated 30 min, 1h, 2h, 6h, 12h, 24h and 48h with serum treated 
and untreated IONPs. Supernatants from 24h and 48 h (X-axis) incubations were used 
for the measurement of chemokines (MCP-3, MDC, GRO, IL-8, IP-10, MCP-1, MIP-
1α, MIP-1β), by using a MagPix Milliplex kit (EMD Millipore). All error bars represent 
± standard deviation, Ns: not significant (p>0.05)*p < 0.05, *p < 0.01, and ***p < 
0.001) (2-way ANOVA test was performed between each uncoated and coated IONPs 
to determine the significance difference in the level of expression) 
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5.4 Discussion 
Understanding of the interactions of nanomaterials with host immune system is 
instrumental to illustrate the biological and medical effects of these materials. Here, we 
have attempted to elucidate the activation of complement pathway, a crucial part of the 
innate immune system and subsequent immune modulation by complement activating 
NPs.  Previously, we have established that CNTs activate the complement pathway 
mainly via a classical pathway in human sera (Pondman et al., 2014). Here, we have 
reported that, unlike CNTs, starch-IONPs activate complement pathway predominantly 
via the alternative pathway. However, pristine IONPs showed no difference between 
classical and alternative pathway activation but still, considerable activation of classical 
pathway took place compared to starch-IONPs. This result highlights that starch 
functionalization can be a key activator of the alternative pathway. The starch surface is 
likely to induce the formation of fluid-phase AP convertase, C3 (H20) Bb, the initial 
deposition of C3b on the foreign surface (Bexborn et al., 2008). Deposition of C3b 
component induces the activation of alternative pathway cascade. It has also been 
reported that polymer like polystyrene can adsorbed C3 component to its surface 
causing conformational changes that turn C3 into a C3B-like component binding factor 
B forming a functional C3Bb convertase (Andersson et al., 2002; Nilsson et al., 1993). 
Alternative pathway activation has also been studied on other polymeric biomaterial 
surfaces like silicon and polypropylene (Gobel et al., 1987).  Furthermore, the hydroxyl 
group of starch ionizes in aqueous condition behaving as a nucleophilic group, which 
can not only bind to nascent C3b by attacking the thioester but also allows C3 to 
adsorbed through electrostatic or hydrophobic interactions (Andersson et al., 2002). 
Such duel effects might have contributed to the observed higher activation of alternative 
pathway than in case of non-functionalized IONPs. Besides, binding C3 and C3b 
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components on the surface, glucose and dextrose derived polysaccharides also bind to 
MBL (Mannose-binding lectins) and MBL –associated serine proteases like MASP-1 
and MASP-2 (Simberg et al., 2009) suggesting the activation of lectin pathway (Fujita, 
Matsushita and Endo, 2004), while negatively charge part of iron core binds to 
histidine-rich glycoprotein and kininogen (Simberg et al., 2009) thus playing a 
significant role in immunomodulation. As complement system is regarded as central in 
the sensing of foreign particles, their processing and elimination, activation of such 
cascade and the release of extremely potent anaphylatoxins like C3a and C5a may bring 
serious issues regarding IONPs‟ safety and efficacy (Peng et al., 2009). Liberated C5a 
recruits regulatory T cells, immunosuppressive monocytes into malignant tumours 
seriously affecting the prognosis of cancer (Markiewski et al., 2008; Moghimi and 
Farhangrazi, 2014). Complement activation, therefore, is of concern for the successful 
development of intravenous nano-based drug delivery. In order to dampen the inevitable 
complement activation, Moghimi and colleagues have modified sugar alcohols of 
surface polysaccharides in dextran with alkylating, acylating, or crosslinking agents but 
unfortunately did not overcome complement activation and C3 opsonization (Wang et 
al., 2016). Recently, our group has extensively investigated inhibition of complement 
activation using recombinant globular head modules of the human C1q molecule as well 
as factor H (Pondman et al., 2015). Surface adsorption of these soluble complement 
regulators offered a novel way of controlling complement pathway activation and also 
down-regulation of inflammation caused by NPs and design of immune-safe 
nanomedicine. 
Another part of the innate immune system, macrophages, was used to study the 
response to NPs. As we have already established that NPs do activate complement 
pathway and upon activation, NPsopsonize with C3b molecules and other plasma 
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proteins. Here we tested fixed concentration of IONPs (10ug/ml) for potential 
cytotoxicity. Based on MTT assay, none of the concentration was cytotoxic to the cells 
until 24h. These non-toxic concentrations of IONPs were used for all other assays. 
IONPs have been shown to have the cytotoxic potential to mammalian cells in higher 
concentration than 10g/ml and cytotoxicity has been shown to be mainly due to high 
ROS generation, oxidative stress and induction of apoptosis (Naqvi et al., 2010). 
Oxidative stress-mediated cytotoxicity has also been reported recently using in vivo test 
in Artemia salina cysts and three stages of larvae (Wang et al., 2017a). IONPs were 
highly pro-inflammatory as shown by qPCR and multiplex results. We have studied the 
cytokines, chemokines, growth factors and other ligand secretion by macrophage-like 
cell lines, in response to opsonized IONPs. We observed very early transcriptional up-
regulation of pro-inflammatory cytokines, TNF-α and IL-1β. Serum treated IONPs 
significantly downregulated the expression of TNF-α in contrast to results observed by 
Brown et al. (Brown et al., 2014) where they reported that IONPs incubated with 
culture media with serum enhanced cytokine response in mouse macrophage cell line 
(J774A.1). High levels of cytokine production in both healthy and patient‟s donor have 
been reported upon iron sucrose and iron dextrose administration (Pai et al., 2011; Fell 
et al., 2014). Both types of iron were pro-inflammatory and activated ROS generation. 
The release of reactive oxygen metabolites has previously been observed in starch 
coated IONPs via interaction of abundantly adsorbed immunoglobulin on IONPs with 
Fc receptors on macrophages (Artursson et al., 1987). We observed a dramatic 
dampening of pro-inflammatory cytokines, IL-1β, IL-6, TNF-α, IL-12 (p40), and IL-
12(P70), and chemokines MCP-1, MDC, MCP-3, GRO, MIP-1α by serum deposited 
IONPs. Dampening of pro-inflammatory cytokines and upregulation of anti-
inflammatory cytokines has previously been reported in human macrophages in 
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response to serum deposited CNTs (Pondman et al., 2014; Pondman et al., 2016). 
Though significant differences were not observed at the transcriptional level of these 
cytokines except for TNF-α, measurement of secreted cytokines and chemokines 
showed a shift of the pro-inflammatory response toward an anti-inflammatory 
environment by serum deposited IONPs. 
The production of IL-12 may indicate Th1 cell polarisation switching Th2 to 
Th1 response during interaction with IONPs. IL-1α and IL-1 β are prototypical 
inflammatory cytokines mostly induced by TLR signalling pathways (Chen, Kanehira 
and Taniguchi, 2013; Verhoef et al., 2017). Production of IL-1 induces Th1 type 
cytokine, IFN-γ (Cardozo et al., 2003) which in turn stimulates the production of IFN- γ 
induced protein 10 (IP 10).  Here, we also observed an increased level of IL-6 and TNF- 
α, though downregulated by serum deposited IONPs, which can otherwise activate 
inflammatory cells, induce vascular permeability causing swelling, redness and fever 
(Elsabahy and Wooley, 2013). Secretion of Th2-type cytokines like IL-4, IL-6 and IL-
10 indicate the activation of humoral immunity and IL-2, IFN- γ and TNF-β indicates 
the activation of cell-mediated immunity (Osugi et al., 1997; Rajananthanan et al., 
1999). IL-8, as a crucial chemoattractant can be associated with induction of chemotaxis 
in target cells, attracting neutrophils to the site of infection and promote angiogenesis 
(Baggiolini and Clark-Lewis, 1992).  
Another aspect of the innate immune system is a clearance of foreign particles 
via several endocytic pathways. Here, we studied how serum opsonized IONPs are 
cleared by macrophages and their intracellular fate after uptake. Complement deposition 
modulated the rate of uptake of IONPs by macrophages. Professional phagocytic cells 
deploy mostly receptor-mediated endocytosis like mannose receptor (MR), complement 
receptor (CR), Fcγ receptor (FcγR) and several scavenger receptors (SR). Mannose, 
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complement proteins and immunoglobulins are opsonins targeting the MR, CR and 
FcγR routes respectively (Aderem and Underhill, 1999). Internalization of starch-IONPs 
was enhanced by complement deposition. Serum treated NPs were not only 
endocytosed quickly and readily but also held for the considerably longer period than 
uncoated NPs (Pondman et al., 2014). The higher level of uptake of IONPs in the 
presence of serum suggests the involvement of complement receptor and receptor-
mediated internalization. Involvement of CR receptors in endocytosis of starch and 
mannan NPs has been reported earlier (Artursson, Johansson and Sjoholm, 1988). THP-
1 cells express high levels of CR3 on their surface. These receptors, alone or in 
combination, may be involved in their uptake. High levels of particle internalization by 
THP-1 could be due to extra complement receptor such as FCRI and FCRII receptors 
present on the surface of THP-1. These receptors are constitutively expressed three to 
four-fold more on THP-1 than U937 cells (Fleit and Kobasiuk, 1991). However, non-
opsonized IONPs could be taken up via a sugarr eceptor-mediated process involving 
MR (Artursson, Johansson and Sjoholm, 1988). It can now be suggested that 
complement receptor-mediated phagocytosis could override the sugar receptor-mediated 
(Mannon receptor) process in the case of phagocytosis of the particles that have a 
tendency to adsorbed significant amounts of serum protein. Involvement of SR-A 
mediated endocytosis has also been reported in macrophage uptake of non-opsonized 
superparamagnetic iron particles, ferumoxides and ferumoxtran-10, contrast agents 
(Raynal et al., 2004).  
Moreover, size of particles and surface coating highly influence their method of uptake. 
The known endocytic processes that cells employ are mainly phagocytosis, pinocytosis, 
Caveolae dependent or Clathrin-mediated endocytosis. These processes are energy 
dependent. Particles greater than 750nm are engulfed and transported into the cells via 
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phagosomes. Smaller particles of size around 100nm are mostly internalized by 
pinocytosis or macropinocytosis. Clathrin-mediated endocytosis or receptor-mediated 
endocytosis is probably the primary characterized mechanisms for NPs internalization 
in which particles are deposited in small endocytic vesicles which later fuse with early 
endosomes (Zhao et al., 2011). Organic molecules coated particles are endocytosed 
through different processes compared to their uncoated counterpart. Pristine gold NPs 
are endocytosed via macropinocytosis and clathrin-mediated endocytosis whereas PEG-
coated gold NPs mostly enter cells via clathrin-mediatedendocytosis, not by 
macropinocytosis (Brandenberger et al., 2010). Therefore, the mechanism of 
endocytosis of NPs cannot be generalized due to the fact that surface modification of 
particles, size of particles and cell type govern the uptake process. 
Though complement deposition and surface modification influenced the route of 
endocytosis it did not affect the intracellular localisation of IONPs, suggesting the fate 
of NPs is independent of opsonisation. Studies have shown conflicting results 
concerning localization of NPs. Here we found that non-opsonized IONPs of size 100 
nm were found within a lysosomal compartment at early time points (6h). However, at 
late time points (18h and 24h), both particles appeared to be localized within lysosomes. 
Some studies have shown that similar sized IONPs accumulated in endosomes by 24 h 
in human embryonic kidney cells (HEK) cells (Osman et al., 2012) and mouse 
macrophages (Raw 264.7) (Billotey et al., 2003). This suggests that different cell types 
employ their own preferred methods of endocytosis.  
This study has highlighted the ability of IONPs to bind complement proteins and 
to activate the complement pathway. The complement activation leads to altered uptake 
and cytokine expression by macrophages. Understanding of nanomaterials properties 
and their interaction with the immune system is a prerequisite for the design and 
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engineering of nanomedicine for safer use. Many pathogens have deployed innovative 
ways to mask themselves from immune recognition and clearance. Translation of such 
strategies could be pivotal in designing complement safe and phagocyte resistant drug 
carriers. Furthermore, complement activation is not always detrimental as evident by 
inhibition of pro-inflammatory cytokines and chemokines.  
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General Conclusion and Future Perspective 
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Results presented here demonstrate the immune response to nanoparticle exposure, in 
terms of complement activation, endocytosis and cytokine expression and secretion. 
Knowing the mechanism of immune response to any NPs designed for therapeutic use 
is vital to overcoming the barriers presented by the body‟s defence systems, which 
rapidly eliminate the particles from systemic circulation. Thus, one of many obstacles in 
nanomedicine is programming the nanoparticles to maximize the amount that reaches 
target the location thereby minimizing side effects. Undesired immune system 
activation can lead to fatal acute and chronic inflammatory reactions. Therefore, 
understanding the interaction between nanoparticles and the immune system is of 
outmost importance.  
Previously, analysis of nanoparticle uptake and immune response in presence 
and absence of complement have been investigated extensively in monocytes (U937), B 
cells (Raji cells) and T-cells (Jurkat cell) (Pondman et al., 2016; Pondman et al., 2014; 
Pondman et al., 2015). CNTs were shown to modulate expression and release of 
cytokines. Cytokine array studies in these cells lines have given a wide range of 
information on how individual cells respond to CNTs with or without complement 
deposition. We also investigated how classical complement components, C1q, 
individual globular head of C1q (ghA, ghB, ghC) and f-H, modulate immune responses 
upon depositing them on various CNTs. We demonstrated that f-H not only reduced 
complement pathway activation but also inhibited CNT uptake by macrophages 
(Pondman et al., 2015). Furthermore, C1q enhanced classical complement activation 
and also enhanced uptake of CNTs whereas recombinant globular heads inhibited 
classical complement activation but still enhanced the uptake of CNTs. This shows that 
each complement component recognizes different recognition pattern on CNTs and 
modulates immune response differently. In this thesis, we aimed to understand how 
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other soluble immune factors would modulate the immune response. With a view to 
understanding their immune modulatory effect, here, we have used recombinant full-
length properdin, the small fragment of properdin, recombinant TSR4+5 module, as 
well as a recombinant human fragment (rfhSP-D) and adsorbed them on CNTs. Their 
effect on complement activation, uptake by macrophages and inflammatory response in 
macrophages was then analysed.  
In Chapter 3, we reported that CNTs can bind to pulmonary surfactant protein 
SP-D and activate complement via the classical pathway. Complement deposition is 
more prominent in SP-D bound CNTs than CNTs alone. This shows that SP-D binds to 
CNTs in the orientation that activates the classical pathway.  In addition, we report that 
SP-D deposition enhances the uptake of CNTs by macrophages. Most surprisingly, we 
show that complement deposition on SP-D coated CNT surface reduces the uptake of 
CNTs. Furthermore, complement deposited SP-D coated CNTs dampen pro-
inflammatory cytokine production significantly compared to SP-D coated CNTs.  These 
findings give an insight into the ability of complement to suppress pro-inflammatory 
responses elicited by rfhSP-D bound CNTs, reducing their quick clearance by immune 
cells. This supports the hypothesis that coating of CNTs with small fragments of 
recombinant complement components provides a promising avenue for therapeutic 
applications. 
In chapter 4, we report for the first time, that properdin, a complement up-
regulator, which stabilizes alternative pathway C3-convertases, can bind on CNTs as a 
pattern recognition receptor and induce a massive pro-inflammatory response. 
Furthermore, biological activities of CNT bound properdin are not affected as evident 
by activation of the alternative pathway in properdin-deficient serum. These findings 
highlight the use of CNT bound properdin in properdin deficient disease like X-linked 
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properdin deficiency disease. We also report that a recombinant small fragment of 
human properdin, TSR4+5, when coated on CNTs, acts as a potent inhibitor of 
alternative pathway activation and interestingly, reduces endocytosis of TSR4+5 coated 
CNTs. These findings address two features needed for an ideal nanocarrier, low 
immunogenicity with stealth properties and slow elimination by the immune system.  
In chapter 5, we tested the interaction of IONPs with complement and their 
interaction with immune cells. It is evident from our study that all NPstested are viewed 
by complement recognition subcomponents as a non-self-pattern, which leads to 
theirsafesequestrationanda dampening of the pro-inflammatory cytokine, chemokines 
and growth factors release. Understanding how complement and immune cells engage 
with IONPs is likely to be crucial in the future design of nanotherapeutics.  
In this thesis, immune responses to NPs were studied in the macrophage-like cell line 
(THP-1), which has given an insight into how the immune system responds challenges 
with CNTs and IONPs at the single cell level. However, as the immune system is a 
complex network of various components and works in constant communication among 
these, studies in cell lines do not always reflect the actual polarization of the immune 
response. To overcome this drawback, an ex vivo model can be implemented to study 
NPsinteraction with the immune system. An ex vivo lepirudin-based human whole 
blood model, as first described by Mollnes et al, was adapted to assess the inflammatory 
effects of IONPs in a complex biological environment (Mollnes et al., 2002). The ex 
vivo whole blood model is presently one of the systems to closest mimic an in vivo 
situation. This model uses lepirudin as an anti-coagulant as it specifically inhibits 
thrombin without affecting the complement system, unlike heparin. The ex vivo human 
whole blood model would be a highly suitable model to study the interaction between 
NPs and the immune system. This system has advantages over the use of monoculture 
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model, although it lacks the complexity of a whole organism (Joris et al., 2013), 
importantly, it allows for intercellular communication and crosstalk with the protein 
cascades in the blood.  
Another important factor to be considering in nanomedicine is the overall 
surface charge and size of the nanoparticle. Adsorption of proteins on the nanoparticle 
is aided by several forces such as Van der Waals force, hydrogen bonds, charge/polarity 
interaction, hydrophobic/hydrophilic interaction etc. The overall surface charge of NPs 
depends upon the combination of NPs charge and adsorbed proteins. The surface charge 
of NPs heavily affects NP diffusion, sedimentation and aggregation determining the fate 
of NPs in colloidal solution, a concept is known as pharmacokinetics (Teeguarden et al., 
2007). Here, the complement components, properdin, TSR4+5 module and rfhSP-D, 
may have altered the surface charge and overall size of the NPs, moulding them to 
behave differently in terms of their uptake and immunomodulation. So, the study of 
overall surface charge and size is necessary in this case. Zeta potential analysis can be 
carried out to measure the surface charge of NPs and their protein-coated version in 
solutions. Moreover, charge modifications of NPs prolongthe half-life of a drug in 
systemic circulation,enhancing the possibility of their interaction with target cells. 
Recent reports demonstrate that rfhSP-D induces apoptosis in prostate cancer 
cell lines (PC3) and primary prostate cancer cells via mitochondrial intrinsic pathway 
and P53 mediated apoptosis  (Thakur et al., 2017) and in pancreatic cancer cells via 
Fas-mediated pathway (Kaur et al., 2018). Similarly, the CRD region of rfhSP-D has 
shown to induce apoptosis in eosinophil leukemic cell line (Mahajan et al., 2013). This 
indicates that rfhSP-D could potentially be developed as an anti-cancer therapeutic. To 
study the anti-cancer effect of rfhSP-D-CNTs, rfhSP-D can be linked to CNTs via its 
collagen region to functionalised CNTs with a linker such as EDC and 
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BS3 [(Bis (sulfocyccinimidyl) suberate] thus freeing the CRD region to actively 
participate in recognition of different moieties on cancer cells. Covalently linking 
rfhSP-D to CNTs would be an interesting idea to analyse whether CNT bound rfhSP-D 
would have a more inhibitory effect on cancer cells than rfhSP-D alone and could 
potentially be tested in vivo. 
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